


Covid-19 Literature Update



A CURATED SELECTION AND OVERVIEW OF COVID-19 PUBLICATIONS

Update January 18 - January 24, 2021,

Dr. Peter J. Lansberg MD, PhD

Weekly COVID-19 Literature Update

will keep you up-to-date with all recent PubMed publications
categorized by relevant topics

COVID-19 publications - Week 03 2021 854 Publications

PubMed based Covid-19 weekly literature update

For those interested in receiving weekly updates
click [here](#)

For questions and requests for topics to add send an e-mail
lansberg@gmail.com

Reliable on-line resources for Covid 19

[WHO](#)

[Daily dashboard](#)

[Country Guidance](#)

[Travel restriction](#)

[Covid Counter](#)

[Covid forecasts](#)

[CDC](#)

[AHA](#)

[ESC](#)

[EMA](#)

[Evidence EPPI](#)

[Wikipedia](#)

[Cardionerds - COVID-19](#)

[Genomic epidemiology](#)

[Oxygenation Ventilation toolkit](#)

[Cochrane](#)

[BMJ](#)

[The Lancet](#)

[New England Journal of Medicine](#)

[JAMA](#)

[Cell](#)

[Science](#)

[Oxford University Press](#)

[Cambridge University Press](#)

[Springer Nature](#)

[Elsevier](#)

[Wiley](#)

[PLOS](#)

[LitCovid NIH-NLM](#)

[SSRN \(Pre-prints\)](#)

[German \(ICU\) bed capacity](#)

[COVID-19 Projections tracker](#)

[AAN - Neurology resources](#)

[COVID-19 resources \(Harvard\)](#)

[COVID-19 resources \(McMasters\)](#)

[COVID-19 resources \(NHLBI\)](#)

[COVID-19 resources \(MEDSCAPE\)](#)

[COVID-19 Diabetes \(JDRF\)](#)

[COVID-19 TELEMEDICINE \(BMJ\)](#)

[Global Causes of death \(Johns Hopkins\)](#)

[COVID-19 calculators \(Medscape\)](#)

[COVID reference \(Steinhauser Verlag\)](#)

[Retracted papers](#)

[COVID-19 risk tools - Apps](#)

[Web app for SARS-CoV2 mutations](#)

Guidelines

[NICE Guidelines Covid-19](#)

[Korean CDC Covid-19 guidelines](#)

[Flattening the curve - Korea](#)

[IDSA COVID-19 Guidelines](#)

[Airway Management Clinical Practice Guidelines \(SIAARTI/EAMS, 2020\)](#)

[ESICM Ventilation Guidelines](#)

[Performing Procedures on Patients With Known or Suspected COVID-19 \(ASA, 2020\)](#)

[OSHA Guidance on Preparing the Workplace for COVID-19 \(2020\)](#)

[Policy for Sterilizers, Disinfectant Devices, and Air Purifiers \(FDA, 2020\)](#)

[Breast Cancer Patient Triage Guidelines \(CPBCC, 2020\)](#)

[clinical guidance for adult Belgian patients with suspected or confirmed COVID-19](#)

[National Covid-19 Testing Action Plan \(Rockefeller Foundation\)](#)

[ASE issues Echo-cardiography guidance](#)

Trials & Registries

[CAPACITY European registry COVID 19 patients](#)

[WHO launches global megatrial](#)

[FDA launches Convalescent plasma trial](#)

[Lets Beat Covid-19 Survey to help plan hospital services](#)

[COVID IBD registry](#)

[Google mobility reports per country COVID 19](#)

[World's largest trial of potential coronavirus treatments rolled out across the UK](#)

[Pregnancy Registry \(US\)](#)

[ICNARC report on COVID-19 in critical care - NHS April 24](#)

[COVID-19 Human Genetics - Biobanks](#)

[COVID19 settings of transmission database](#)

[COVID-19 prevention network](#)

[Covid-Plex trial - \(plasma exchange & convalescent plasma trial\)](#)

**Re: Plasma exchange and convalescent plasma in COVID-19 patients with
multi-organ failure –
The COVID-19 PLEX + Convalescent Plasma trial –
Enrollment initiated**

The Covid-Plex trial is an investigator initiated, multicenter, parallel-group, open-label randomized clinical trial aiming to randomize patients with severe COVID-19 to standard care or standard care plus plasmapheresis and convalescent plasma.

If you are interested to participate Please contact Wladimir Szpirt, Nicholas Carlson Anders, or Perner Bo Feldt-Rasmussen. Depts. Of Intensive Care Therapy and Nephrology, Copenhagen University Hospital Rigshospitalet, Denmark

Covid-Plex trial

Mainstream Media

New York Times - Corona update

Vaccine Shortages Hit E.U. in a Setback for Its Immunization Race
Britain Will Make Citizens Quarantine at Hotels at Their Own Expense
What to Know About the California Variant
Israel's Early Vaccine Data Offers Hope
As Virus Grows Stealthier, Vaccine Makers Reconsider Battle Plans
In Crises, Vaccines Can Be Stretched, but Not Easily
Do Curfews Slow the Coronavirus?
Drug Prevents Coronavirus Infection in Nursing Homes, Maker Claims
Coronavirus Vaccine Tracker
Coronavirus Drug and Treatment Tracker

Washington Post - Corona update

E.U. feuds with AstraZeneca - facility locked down over suspicious package
Philadelphia let 'college kids' distribute vaccines. The result was a 'disaster.'
China rolls out anal swab coronavirus test, saying it's more accurate
The battle over reopening schools
As variants spread, countries pursue new round of travel restrictions
What you need to know about the coronavirus variants
Everyone should be wearing N95 masks now
Dubai seemed to have the coronavirus licked. Then it flung open its doors.
We still don't know how many people are infected with covid. We can find out.

Guardian - Corona update

All countries should pursue a Covid-19 elimination strategy.
Cough and sore throat more common with UK Covid variant – study
Hospital incursions by Covid deniers putting lives at risk, say health leaders
Most poor nations 'will take until 2024 to achieve mass Covid-19 immunisation
AstraZeneca vaccine may not go to older people, EU medicines chief suggests

1. **Most notable 100 articles of COVID-19: an Altmetric study based on bibliometric analysis.** Ir. J. Med. Sci. 2021; Borku Uysal B, Islamoglu MS, Koc S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459942>
The COVID-19 pandemic has fuelled a tsunami of scientific output in peer-reviewed journals. This review analyzes the bibliometric features of the 100 most cited articles ((January – September 2020). All articles were English language articles, and the average citations index was 320 ± 344.3 (143–2676); the average Altmetric (impact on Social Media) score 3246 ± 3795 (85–16,548). “Clinical Characteristics of Coronavirus Disease 2019 in China” is the most cited article, published in April 2020, and received 2676 citations in 5 months. The first three articles with >1000 citations were studies conducted in China, published in March–April. The article with the highest Altmetric score is “Covid-19-Navigating the Uncharted” by Fauci *et al.* with 16,548. Of the top 100 articles., 78 addressed the epidemiological, viral, clinical, and treatment features of COVID-19

2. **Effect of antiplatelet treatments on patients with COVID-19 infection: A systematic review and meta-analysis.** Am J Emerg Med 2021; 43:27-30 Wang Y, Ao G, Nasr B, Qi X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485124>
Platelet activation is associated with thrombin generation triggering disseminated intravascular coagulation and inducing vascular inflammation and extracellular matrix degradation. Early antiplatelet therapy could inhibit platelet adhesion, aggregation, and activation. In this meta-analysis, based on 9 articles and 5970 patients showed no increase in risk for severe COVID-19 complications; OR:0.98 (0.64-1.50; P=0.94; I²=65%) or mortality; OR:0.65 (0.40-1.06, P=0.498; I²=0%).

3. **COVID-19 discharge and follow-up recommendations.** Proc. (Bayl. Univ. Med. Cent.) 2020; 34:73-75 Abdelnabi M, Leelaviwat N, Eshak N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456149>
The management of discharged COVID-19 patients is insufficiently addressed and warrants proper recommendations and guidelines. This concise review presents current understanding and proposals for discharge criteria, treatments, and follow-up visits. Core issues addressed are thromboprophylaxis, corticosteroids, oxygen use, adjuvant therapies such as vitamin D, C, zinc, and follow-up schedules, including monitoring late sequelae of organ related complications, psychological support, and laboratory tests.

4. **Myocardial Inflammation and Dysfunction in COVID-19-Associated Myocardial Injury.** Circ. Cardiovasc. Imaging 2021:Circimaging120011713 Weckbach LT, Curta A, Bieber S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33463366>

5. **Building Experience and Evidence: COVID-19 and Myocardial Injury.** Circ. Cardiovasc. Imaging 2021:Circimaging120012220 Verma AK, Vader JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461305>

6. **Impact of high dose prophylactic anticoagulation in critically ill patients with COVID-19 pneumonia.** Chest 2021; Tacquard C, Mansour A, Godon A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465342>

7. **Short-term cardiac outcome in survivors of COVID-19: a systematic study after hospital discharge.** Clin Res Cardiol 2021;1-10Sechi LA, Colussi G, Bulfone L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481096>

8. **SARS-CoV-2 viral load in nasopharyngeal swabs in the ED does not predict COVID-19 severity and mortality.** Acad Emerg Med 2021; Le Borgne P, Solis M, Severac F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481307>

9. **Antibody tests for COVID-19.** Proc. (Bayl. Univ. Med. Cent.) 2020; 34:63-72Kopel J, Goyal H, Perisetti A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456148>

10. **A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for current COVID-19 (SARS-CoV-2) pandemic.** J Med Virol 2021; Kheirabadi D, Haddad F, Mousavi-Roknabadi RS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33463727>

11. **Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis: JACC Review Topic of the Week.** J Am Coll Cardiol 2021; 77:314-325Kawakami R, Sakamoto A, Kawai K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478655>

12. **Is there a correlation between viral load and olfactory & taste dysfunction in COVID-19 patients?** Am. J. Otolaryngol. 2021; 42:102911Jain A, Pandey AK, Kaur J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476975>

13. **Autopsy findings after long-term treatment of COVID-19 patients with microbiological correlation.** Virchows Arch. 2021;1-12Evert K, Dienemann T, Brochhausen C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33471172>

14. **SARS-CoV-2 vaccines in advanced clinical trials: where do we stand.** Adv Drug Deliv Rev 2021; Chakraborty S, Mallajosyula V, Tato CM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482248>

15. **When Does the Cytokine Storm Begin in COVID-19 Patients? A Quick Score to Recognize It.** J Clin Med 2021; 10Cappanera S, Palumbo M, Kwan SH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467466>

1. **In silico docking analysis revealed the potential of phytochemicals present in *Phyllanthus amarus* and *Andrographis paniculata*, used in Ayurveda medicine in inhibiting SARS-CoV-2.** 3 Biotech 2021; 11:44 Hiremath S, Kumar HDV, Nandan M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457171>
2. **Designing a next generation multi-epitope based peptide vaccine candidate against SARS-CoV-2 using computational approaches.** 3 Biotech 2021; 11:47 Saha R, Ghosh P, Burra V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457172>
3. **Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered via Lipid Nanoparticles.** ACS Nano 2021; Elia U, Ramishetti S, Rosenfeld R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480671>
4. **In silico T cell epitope identification for SARS-CoV-2: Progress and perspectives.** Adv Drug Deliv Rev 2021; Sohail MS, Ahmed SF, Quadeer AA, McKay MR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465451>
5. **Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine.** Angew. Chem. Int. Ed. Engl. 2021; Jangra S, De Vrieze J, Choi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33464672>
6. **Pharmacoinformatics approach based identification of potential Nsp15 endoribonuclease modulators for SARS-CoV-2 inhibition.** Arch. Biochem. Biophys. 2021;108771 Savale RU, Bhowmick S, Osman SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485847>
7. **Biochemical features and mutations of key proteins in SARS-CoV-2 and their impacts on RNA therapeutics.** Biochem. Pharmacol. 2021;114424 Zeng L, Li D, Tong W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482149>
8. **Mechanistic modeling of the SARS-CoV-2 disease map.** BioData Min. 2021; 14:5 Rian K, Esteban-Medina M, Hidalgo MR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478554>
9. **Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury.** Biomed. Pharmacother. 2021; 136:111193 Oz M, Lorke DE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461019>
10. **SARS-CoV infection crosstalk with human host cell noncoding-RNA machinery: An in-silico approach.** Biomed. Pharmacother. 2020; 130:110548 Yousefi H, Poursheikhani A, Bahmanpour Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33475497>
11. **NMR assignments of the macro domain from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).** Biomol NMR Assign 2021; Lin MH, Huang YP, Chang CF, Hsu CH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486617>
12. **(1)H, (13)C and (15)N backbone chemical shift assignments of SARS-CoV-2 nsp3a.** Biomol NMR Assign 2021;1-4 Salvi N, Bessa LM, Guseva S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33475934>
13. **A rapid diagnosis of SARS-CoV-2 using DNA hydrogel formation on microfluidic pores.** Biosens. Bioelectron. 2021; 177:113005 Kim HS, Abbas N, Shin S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486135>
14. **Enhancing the performance of paper-based electrochemical impedance spectroscopy nanobiosensors: An experimental approach.** Biosens.

- [Bioelectron.](https://pubmed.ncbi.nlm.nih.gov/33461849/) 2020:112672Li X, Qin Z, Fu H *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33461849>
15. **Generation of enzymatically competent SARS-CoV-2 decoy receptor ACE2-Fc in glycoengineered *Nicotiana benthamiana*.** [Biotechnol. J.](https://pubmed.ncbi.nlm.nih.gov/33481336/) 2021:e2000566Castilho A, Schwestka J, Kienzl NF *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33481336>
 16. **An integrated approach to determine the abundance, mutation rate and phylogeny of the SARS-CoV-2 genome.** [Brief. Bioinform.](https://pubmed.ncbi.nlm.nih.gov/33479725/) 2021; Desai S, Rashmi S, Rane A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33479725>
 17. **Bioinformatics and system biology approach to identify the influences of COVID-19 on cardiovascular and hypertensive comorbidities.** [Brief. Bioinform.](https://pubmed.ncbi.nlm.nih.gov/33458761/) 2021; Nashiry A, Sarmin Sumi S, Islam S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33458761>
 18. **Ligand-based approach for predicting drug targets and for virtual screening against COVID-19.** [Brief. Bioinform.](https://pubmed.ncbi.nlm.nih.gov/33461215/) 2021; Yang Y, Zhu Z, Wang X *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33461215>
 19. **Significance of NETs Formation in COVID-19.** [Cells](https://pubmed.ncbi.nlm.nih.gov/33466589/) 2021; 10Janiuk K, Jabłońska E, Garley M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466589>
 20. **Synthetic Siglec-9 Agonists Inhibit Neutrophil Activation Associated with COVID-19.** [ChemRxiv](https://pubmed.ncbi.nlm.nih.gov/33469569/) 2020; Delaveris C, Wilk A, Riley N *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33469569>
 21. **Principal Component Analysis Applications in COVID-19 Genome Sequence Studies.** [Cognit. Comput.](https://pubmed.ncbi.nlm.nih.gov/33456620/) 2021:1-12Wang B, Jiang L.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33456620>
 22. **Decoding Covid-19 with the SARS-CoV-2 Genome.** [Curr Genet Med Rep](https://pubmed.ncbi.nlm.nih.gov/33457109/) 2021:1-12Ellis P, Somogyvári F, Virok DP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457109>
 23. **Nanotechnology Enabled Solutions to Combat Covid-19: Prevention, Treatment and Diagnosis.** [Curr. Pharm. Biotechnol.](https://pubmed.ncbi.nlm.nih.gov/33480338/) 2021; Musyuni P, Nagpal M, Singh M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480338>
 24. **An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery.** [Curr. Top. Med. Chem.](https://pubmed.ncbi.nlm.nih.gov/33463470/) 2021; Sabbah DA, Hajjo R, Bardaweel SK, Zhong HA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33463470>
 25. **Two-step strategy for the identification of SARS-CoV-2 variant of concern 202012/01 and other variants with spike deletion H69-V70, France, August to December 2020.** [Euro Surveill](https://pubmed.ncbi.nlm.nih.gov/33478625/) 2021; 26Bal A, Destras G, Gaymard A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33478625>
 26. **The European tiered approach for virucidal efficacy testing - rationale for rapidly selecting disinfectants against emerging and re-emerging viral diseases.** [Euro Surveill](https://pubmed.ncbi.nlm.nih.gov/33478622/) 2021; 26Eggers M, Schwebke I, Suchomel M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33478622>
 27. **Inter-proteomic posttranslational modifications of the SARS-CoV-2 and the host proteins - A new frontier.** [Exp. Biol. Med.](https://pubmed.ncbi.nlm.nih.gov/33467896/) (Maywood). 2021:1535370220986785Mishra S, Bassi G, Nyomba BG.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33467896>
 28. **SARS-CoV-2 RNA dependent RNA polymerase as a therapeutic target for COVID-19.** [Expert Opin. Ther. Pat.](https://pubmed.ncbi.nlm.nih.gov/33475441/) 2021; Vicenti I, Zazzi M, Saladini F.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33475441>

29. **Fortifying the diagnostic-frontiers with nanoscale technology amidst the COVID-19 catastrophe.** Expert Rev Mol Diagn 2021; Konwarh R, Cho WC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33470125>
30. **SARS-CoV-2 meta-interactome suggests disease-specific, autoimmune pathophysiology and therapeutic targets.** F1000Res 2020; 9:992Bellucci G, Ballerini C, Mechelli R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456761>
31. **Nitric Oxide Releasing Hydrogel Nanoparticles Decreases Epithelial Cell Injuries Associated With Airway Reopening.** Front Bioeng Biotechnol 2020; 8:579788Shurbaji S, El-Sherbiny IM, Alser M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469529>
32. **Elucidating Interactions Between SARS-CoV-2 Trimeric Spike Protein and ACE2 Using Homology Modeling and Molecular Dynamics Simulations.** Front Chem 2020; 8:622632Sakkiah S, Guo W, Pan B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469527>
33. **Single-Cell RNA Sequencing of Tocilizumab-Treated Peripheral Blood Mononuclear Cells as an in vitro Model of Inflammation.** Front Genet 2020; 11:610682Zarinsefat A, Hartoularos G, Rychkov D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469465>
34. **The potential association between PARP14 and the SARS-CoV-2 infection (COVID-19).** Future Med. Chem. 2021; Tauber AL, Schweiker SS, Levonis SM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467912>
35. **Transcriptome network analyses in human coronavirus infections suggest a rational use of immunomodulatory drugs for COVID19 therapy.** Genomics 2021; Wong HS, Guo CL, Lin GH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482326>
36. **Clade GR and clade GH isolates of SARS-CoV-2 in Asia show highest amount of SNPs.** Infect Genet Evol 2021:104724Sengupta A, Hassan SS, Choudhury PP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476804>
37. **Partial N Gene Sequencing for SARS-CoV-2 Verification and Pathway Tracing.** Int Med Case Rep J 2021; 14:1-10Lee SH, McGrath J, Connolly SP, Lambert J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469388>
38. **SARS-CoV-2 infects cells following viral entry via clathrin-mediated endocytosis.** J Biol Chem 2021:100306Bayati A, Kumar R, Francis V, McPherson PS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476648>
39. **An in silico analysis of Ibuprofen enantiomers in high concentrations of sodium chloride with SARS-CoV-2 main protease.** J Biomol Struct Dyn 2021:1-12Clemente CM, Freiburger MI, Ravetti S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459192>
40. **In silico study indicates antimalarials as direct inhibitors of SARS-CoV-2-RNA dependent RNA polymerase.** J Biomol Struct Dyn 2021:1-18Doharey PK, Singh V, Gedda MR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33475021>
41. **In silico evaluation of lapachol derivatives binding to the Nsp9 of SARS-CoV-2.** J Biomol Struct Dyn 2021:1-15Junior NN, Santos IA, Meireles BA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478342>
42. **Real Time PCR and Culture-Based Virus Isolation Test in Clinically Recovered Patients: Is the Subject Still Infectious for SARS-CoV2?** J Clin Med 2021; 10Manzulli V, Scioscia G, Giganti G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467628>

43. **Genome-wide DNA methylation profiling of peripheral blood reveals an epigenetic signature associated with severe COVID-19.** *J. Leukoc. Biol.* 2021; Corley MJ, Pang APS, Dody K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33464637>
44. **A U-shaped association between baseline neutrophil count and COVID-19-related mortality: a retrospective cohort study.** *J Med Virol* 2021; Fu W, Chen C, Chen XL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33463721>
45. **Proteomic Approaches to Study SARS-CoV-2 Biology and COVID-19 Pathology.** *J. Proteome Res.* 2021; Haas P, Muralidharan M, Krogan NJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33464917>
46. **ACE-2-Derived Biomimetic Peptides for the Inhibition of Spike Protein of SARS-CoV-2.** *J. Proteome Res.* 2021; Panda SK, Sen Gupta PS, Biswal S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472369>
47. **Mitochondrial Functionality in Inflammatory Pathology-Modulatory Role of Physical Activity.** *Life (Basel)* 2021; 11Casuso RA, Huertas JR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467642>
48. **SARS-CoV-2 Genomic Variation in Space and Time in Hospitalized Patients in Philadelphia.** *mBio* 2021; 12Everett J, Hokama P, Roche AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468702>
49. **Engineering a Reliable and Convenient SARS-CoV-2 Replicon System for Analysis of Viral RNA Synthesis and Screening of Antiviral Inhibitors.** *mBio* 2021; 12Luo Y, Yu F, Zhou M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468688>
50. **Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses In Vitro.** *mBio* 2021; 12Stone NE, Jaramillo SA, Jones AN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468703>
51. **Feasibility of using alternative swabs and storage solutions for paired SARS-CoV-2 detection and microbiome analysis in the hospital environment.** *Microbiome* 2021; 9:25Minich JJ, Ali F, Marotz C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482920>
52. **Topography, Spike Dynamics, and Nanomechanics of Individual Native SARS-CoV-2 Virions.** *Nano Lett* 2021; Kiss B, Kis Z, Pályi B, Kellermayer MSZ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33474931>
53. **Neurobiology of SARS-CoV-2 interactions with the peripheral nervous system: implications for COVID-19 and pain.** *Pain Rep* 2021; 6:e885McFarland AJ, Yousuf MS, Shiers S, Price TJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458558>
54. **SARS-CoV-2/human interactome reveals ACE2 locus crosstalk with the immune regulatory network in the host.** *Pathog Dis* 2021; Lite C, Ahmed S, Juliet MJ, Freddy AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469663>
55. **Major alterations in the mononuclear phagocyte landscape associated with COVID-19 severity.** *Proc Natl Acad Sci U S A* 2021; 118Kvedaraite E, Hertwig L, Sinha I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33479167>
56. **Epigenetic Underpinnings of Inflammation: Connecting the dots between Pulmonary Diseases, Lung Cancer and COVID-19.** *Semin. Cancer Biol.* 2021; Ahmad S, Manzoor S, Siddiqui S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484868>
57. **MSC-NTF (NurOwn®) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS model.** *Stem Cell. Res. Ther.* 2021; 12:72Kaspi H, Semo J,

- Abramov N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468250>
58. **Immuno-informatics approach for B-cell and T-cell epitope based peptide vaccine design against novel COVID-19 virus.** *Vaccine* 2021; Singh J, Malik D, Raina A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478787>
 59. **Nucleocapsid and Spike Proteins of the Coronavirus SARS-CoV-2 Induce IL6 in Monocytes and Macrophages-Potential Implications for Cytokine Storm Syndrome.** *Vaccines (Basel)* 2021; 9Karwaciak I, Sałkowska A, Karaś K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467724>
 60. **Expression of SARS-CoV-2 Host Cell Entry Factors in Immune System Components of Healthy Individuals and Its Relevance for COVID-19 Immunopathology.** *Viral Immunol* 2021; Kumar A, Kumar S, Narayan RK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481684>
 61. **Structural Mapping of Mutations in Spike, RdRp and Orf3a Genes of SARS-CoV-2 in Influenza Like Illness (ILI) Patients.** *Viruses* 2021; 13Alosaimi B, Naeem A, Alghoribi MF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477951>
 62. **Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies.** *Viruses* 2021; 13Finkelstein MT, Mermelstein AG, Parker Miller E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477902>
 63. **MicroRNAs for Virus Pathogenicity and Host Responses, Identified in SARS-CoV-2 Genomes, May Play Roles in Viral-Host Co-Evolution in Putative Zoonotic Host Species.** *Viruses* 2021; 13Lange S, Arisan ED, Grant GH, Uysal-Onganer P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467206>
 64. **Domains and Functions of Spike Protein in Sars-Cov-2 in the Context of Vaccine Design.** *Viruses* 2021; 13Xia X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466921>
 65. **Third update on possible animal sources for human COVID-19.** *Xenotransplantation* 2021:e12671Opriessnig T, Huang YW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476071>

Biomarkers - Genetics (99 articles)

1. **Smart technologies driven approaches to tackle COVID-19 pandemic: a review.** *3 Biotech* 2021; 11:50Khan H, Kushwah KK, Singh S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457174>
2. **SARS-CoV-2 viral load in nasopharyngeal swabs in the ED does not predict COVID-19 severity and mortality.** *Acad Emerg Med* 2021; Le Borgne P, Solis M, Severac F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481307>
3. **In silico T cell epitope identification for SARS-CoV-2: Progress and perspectives.** *Adv Drug Deliv Rev* 2021; Sohail MS, Ahmed SF, Quadeer AA, McKay MR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465451>
4. **COVID-19 testing in English care homes and implications for staff and residents.** *Age Ageing* 2021; Micocci M, Gordon AL, Allen AJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481986>
5. **Elastase and Exacerbation of Neutrophil Innate Immunity are Involved in Multi-Visceral Manifestations of COVID-19.** *Allergy* 2021; Guéant JL, Guéant-Rodriguez RM, Fromonot J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484168>
6. **COVID-19 testing for providers: Leading by example.** *Am J Emerg Med* 2021; Greenky D, Wiltrakis S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468390>

7. **Is there a correlation between viral load and olfactory & taste dysfunction in COVID-19 patients?** Am. J. Otolaryngol. 2021; 42:102911Jain A, Pandey AK, Kaur J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476975>
8. **A critical review of point-of-care diagnostic technologies to combat viral pandemics.** Anal. Chim. Acta 2021; 1146:184-199Everitt ML, Tillery A, David MG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461715>
9. **[SARS-CoV-2 Detection in cerebrospinal fluid in a pediatric patient. Case report].** Arch. Argent. Pediatr. 2021; 119:e58-e60Franco P, Bellesi Y, Nocent E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458993>
10. **Detection-based prioritisation: Framework of multi-laboratory characteristics for asymptomatic COVID-19 carriers based on integrated Entropy-TOPSIS methods.** Artif. Intell. Med. 2021; 111:101983Albahri AS, Hamid RA, Albahri OS, Zaidan AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461683>
11. **COVID-TRACK: world and USA SARS-COV-2 testing and COVID-19 tracking.** BioData Min. 2021; 14:4Zohner YE, Morris JS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472672>
12. **Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury.** Biomed. Pharmacother. 2021; 136:111193Oz M, Lorke DE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461019>
13. **Enhancing the performance of paper-based electrochemical impedance spectroscopy nanobiosensors: An experimental approach.** Biosens. Bioelectron. 2020:112672Li X, Qin Z, Fu H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461849>
14. **Hospital-wide SARS-CoV-2 antibody screening of staff in a university psychiatric centre in Belgium.** BJPsych Open 2021; 7:e40El Abdellati K, Coppens V, Goossens J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468277>
15. **Dynamic changes in lymphocyte subsets and parallel cytokine levels in patients with severe and critical COVID-19.** BMC Infect. Dis. 2021; 21:79Liu Y, Tan W, Chen H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461503>
16. **Predictive value of the neutrophil to lymphocyte ratio for disease deterioration and serious adverse outcomes in patients with COVID-19: a prospective cohort study.** BMC Infect. Dis. 2021; 21:80Zeng ZY, Feng SD, Chen GP, Wu JN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461497>
17. **Combined oropharyngeal/nasal swab is equivalent to nasopharyngeal sampling for SARS-CoV-2 diagnostic PCR.** BMC Microbiol. 2021; 21:31Desmet T, Paepe P, Boelens J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482729>
18. **Gestation and COVID-19: clinical and microbiological observational study (Gesta-COVID19).** BMC Pregnancy Childbirth 2021; 21:78Suy A, Garcia-Ruiz I, Carbonell M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482757>
19. **Public's understanding of swab test results for SARS-CoV-2: an online behavioural experiment during the April 2020 lockdown.** BMJ Open 2021; 11:e043925Pighin S, Tentori K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33455939>
20. **Infographic. COVID-19 RT-PCR testing for elite athletes.** Br. J. Sports Med. 2021; Rankin A, Massey A, Falvey É C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33455908>
21. **Pre-hospital lowest recorded oxygen saturation independently predicts death in patients with COVID-19.** Br Paramed J 2020; 5:59-65Dillon K, Hook C,

- Coupland Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456398>
22. **GM1 Ganglioside Antibody and COVID-19 related Guillain Barre Syndrome - a Case Report, Systemic Review and Implication for Vaccine Development.** Brain Behav Immun Health 2021; 12:100203Dufour C, Co TK, Liu A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33462567>
 23. **An integrated approach to determine the abundance, mutation rate and phylogeny of the SARS-CoV-2 genome.** Brief. Bioinform. 2021; Desai S, Rashmi S, Rane A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33479725>
 24. **Bioinformatics and system biology approach to identify the influences of COVID-19 on cardiovascular and hypertensive comorbidities.** Brief. Bioinform. 2021; Nashiry A, Sarmin Sumi S, Islam S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458761>
 25. **Significance of NETs Formation in COVID-19.** Cells 2021; 10Janiuk K, Jabłońska E, Garley M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466589>
 26. **ICU Admission Levels of Endothelial Biomarkers as Predictors of Mortality in Critically Ill COVID-19 Patients.** Cells 2021; 10Vassiliou AG, Keskinidou C, Jahaj E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477776>
 27. **Building Experience and Evidence: COVID-19 and Myocardial Injury.** Circ. Cardiovasc. Imaging 2021:Circimaging120012220Verma AK, Vader JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461305>
 28. **Myocardial Inflammation and Dysfunction in COVID-19-Associated Myocardial Injury.** Circ. Cardiovasc. Imaging 2021:Circimaging120011713Weckbach LT, Curta A, Bieber S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33463366>
 29. **rRT-PCR for SARS-CoV-2: analytical considerations.** Clin Chim Acta 2021; Rahbari R, Moradi N, Abdi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485902>
 30. **Defining the role of asymptomatic and pre-symptomatic SARS-CoV-2 transmission - a living systematic review.** Clin Microbiol Infect 2021; Qiu X, Nergiz AI, Maraolo AE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484843>
 31. **Should ct be used for the diagnosis of RT-PCR negative suspected COVID-19 patients?** Clin. Respir. J. 2021; Rona G, Arifoğlu M, Voyvoda N, Batirel A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484085>
 32. **Development of SARS-CoV-2 Rapid Antibody Detection Kit and Study on Dynamic Changes in Antibodies in Infected Patients.** Clin. Respir. J. 2021; Wang H, Li X, Li T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484220>
 33. **Predictors of clinical deterioration in non-severe patients with COVID-19: a retrospective cohort study.** Curr. Med. Res. Opin. 2021:1Zhang Y, Chen M, Zhou L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459077>
 34. **An Australian diagnostic microbiology surge response to the COVID-19 pandemic.** Diagn. Microbiol. Infect. Dis. 2021; 100:115309Sparks R, Balgahom R, Janto C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486387>
 35. **Estimating the minimum number of SARS-CoV-2 infected cases needed to detect viral RNA in wastewater: To what extent of the outbreak can surveillance of wastewater tell us?** Environ. Res. 2021:110748Hong PY, Rachmadi AT, Mantilla-Calderon D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465345>
 36. **Persistently high SARS-CoV-2 positivity rate and incidence for Hispanic/Latinos during state reopening in an urban setting: a retrospective cohort study.** Epidemiol Infect 2021; 149:e25Weng CH, Saal A, McGuire DC, Chan PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33455608>

37. **Two-step strategy for the identification of SARS-CoV-2 variant of concern 202012/01 and other variants with spike deletion H69-V70, France, August to December 2020.** Euro Surveill 2021; 26Bal A, Destras G, Gaymard A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33478625>
38. **Complement activation and coagulopathy - an ominous duo in COVID19.** Expert Rev. Hematol. 2021:1-19Tomo S, Kumar KP, Roy D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33480807>
39. **SARS-CoV-2 meta-interactome suggests disease-specific, autoimmune pathophysiologies and therapeutic targets.** F1000Res 2020; 9:992Bellucci G, Ballerini C, Mechelli R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456761>
40. **Do Ocular Fluids Represent a Transmission Route of SARS-CoV-2 Infection?** Front Med (Lausanne) 2020; 7:620412Petronio Petronio G, Di Marco R, Costagliola C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469546>
41. **Distribution of the ACE1 D Allele in the Bosnian-Herzegovinian Population and its Possible Role in the Regional Epidemiological Picture of COVID-19.** Genet. Test. Mol. Biomarkers 2021; 25:55-58Cenanovic M, Dogan S, Asic A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33470888>
42. **Age-associated difference in circulating ACE2, the gateway for SARS-COV-2, in humans: results from the InCHIANTI study.** Geroscience 2021:1-9AlGhatrif M, Tanaka T, Moore AZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33462706>
43. **Level of the SARS-CoV-2 receptor ACE2 activity is highly elevated in old-aged patients with aortic stenosis: implications for ACE2 as a biomarker for the severity of COVID-19.** Geroscience 2021:1-11Fagyas M, Kertész A, Siket IM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33469835>
44. **Clade GR and clade GH isolates of SARS-CoV-2 in Asia show highest amount of SNPs.** Infect Genet Evol 2021:104724Sengupta A, Hassan SS, Choudhury PP.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33476804>
45. **In silico exploration of novel protease inhibitors against coronavirus 2019 (COVID-19).** Inform Med Unlocked 2021; 23:100516Aghaee E, Ghodrati M, Ghasemi JB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457495>
46. **The assessment of high sensitivity cardiac troponin in patients with COVID-19: a multicenter study.** Int J Cardiol Heart Vasc 2021; 32:100715Alfonso Perrone M, Spolaore F, Ammirabile M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457490>
47. **The assessment of high sensitivity cardiac troponin in patients with COVID-19: A multicenter study.** Int J Cardiol Heart Vasc 2021; 32:100715Perrone MA, Spolaore F, Ammirabile M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457490>
48. **D-dimer levels is associated with severe COVID-19 infections: A meta-analysis.** Int J Clin Pract 2021:e14031Wu ZH, Cheng Q.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33474792>
49. **Seroprevalence of antibodies to SARS-CoV-2 among blood donors in the early month of the pandemic in Saudi Arabia.** Int J Infect Dis 2021; Banjar A, Al-Tawfiq JA, Alruwaily A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465488>
50. **SARS-CoV-2 seroconversion among 4040 Egyptian healthcare workers in 12 resource-limited healthcare facilities: A prospective cohort study.** Int J Infect Dis 2021; Mostafa A, Kandil S, El-Sayed MH *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33484863>

51. **Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalized COVID-19 patients.** Int J Infect Dis 2021; Serre-Miranda C, Nobrega C, Roque S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484862>
52. **Partial N Gene Sequencing for SARS-CoV-2 Verification and Pathway Tracing.** Int Med Case Rep J 2021; 14:1-10 Lee SH, McGrath J, Connolly SP, Lambert J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469388>
53. **Electrolyte imbalance in COVID-19 patients admitted to the Emergency Department: a case-control study.** Intern Emerg Med 2021:1-6 De Carvalho H, Richard MC, Chouihed T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484453>
54. **Procalcitonin Has Good Accuracy for Prognosis of Critical Condition and Mortality in COVID-19: A Diagnostic Test Accuracy Systematic Review and Meta-analysis.** Iran. J. Allergy Asthma Immunol. 2020; 19:557-569 Zare ME, Wang Y, Nasir Kansestani A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33463126>
55. **Broader Insights into Understanding Tumor Necrosis Factor and Neurodegenerative Disease Pathogenesis Infer New Therapeutic Approaches.** J. Alzheimers Dis. 2021; Clark IA, Vissel B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459706>
56. **Microfluidic detection of human diseases: From liquid biopsy to COVID-19 diagnosis.** J. Biomech. 2021; 117:110235 Jiang K, Jokhun DS, Lim CT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486262>
57. **Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19.** J. Clin. Immunol. 2021; Azmy V, Kaman K, Tang D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459964>
58. **Prognostic Implications of Chronic Heart Failure and Utility of NT-proBNP Levels in Heart Failure Patients with SARS-CoV-2 Infection.** J Clin Med 2021; 10 Belarte-Tornero LC, Valdivielso-Moré S, Vicente Elcano M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477268>
59. **When Does the Cytokine Storm Begin in COVID-19 Patients? A Quick Score to Recognize It.** J Clin Med 2021; 10 Cappanera S, Palumbo M, Kwan SH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467466>
60. **Real Time PCR and Culture-Based Virus Isolation Test in Clinically Recovered Patients: Is the Subject Still Infectious for SARS-CoV2?** J Clin Med 2021; 10 Manzulli V, Scioscia G, Giganti G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467628>
61. **The Prognostic Value of Eosinophil Recovery in COVID-19: A Multicentre, Retrospective Cohort Study on Patients Hospitalised in Spanish Hospitals.** J Clin Med 2021; 10 Mateos González M, Sierra Gonzalo E, Casado Lopez I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467585>
62. **Self-Collection of Saliva Specimens as a Suitable Alternative to Nasopharyngeal Swabs for the Diagnosis of SARS-CoV-2 by RT-qPCR.** J Clin Med 2021; 10 Trobajo-Sanmartín C, Adelantado M, Navascués A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467501>
63. **Red Blood Cell Distribution Width, Disease Severity, and Mortality in Hospitalized Patients with SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis.** J Clin Med 2021; 10 Zinellu A, Mangoni AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466770>
64. **A cross-sectional seroprevalence for COVID-19 among healthcare workers in a tertiary care hospital in Taiwan.** J Formos Med Assoc 2021; Pan SC, Huang YS,

- Hsieh SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461841>
65. **Evaluation of procalcitonin as a contribution to antimicrobial stewardship in SARS-CoV-2 infection: a retrospective cohort study.** *J Hosp Infect* 2021; Williams EJ, Mair L, de Silva TI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484783>
 66. **Immune profiling reveals early disease trajectories associated with COVID-19 mortality: a sub-study from the ACTT-1 trial.** *J Infect Dis* 2021; Thiede JM, Gress AR, Libby SD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476387>
 67. **Eosinopenia <100/ μ L as a marker of active COVID-19: An observational prospective study.** *J Microbiol Immunol Infect* 2021; Outh R, Boutin C, Gueudet P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468435>
 68. **Proteinuria in COVID-19: prevalence, characterization and prognostic role.** *J Nephrol* 2021;1-10Huart J, Bouquegneau A, Lutteri L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484426>
 69. **Commentary: Should all cancer patients be tested for COVID-19 before each chemotherapy cycle?** *J. Oncol. Pharm. Pract.* 2021;1078155220988753Yekedüz E, Utkan G, Ürün Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33470163>
 70. **Diagnostic Accuracy of the Panbio SARS-CoV-2 Antigen Rapid Test Compared with Rt-Pcr Testing of Nasopharyngeal Samples in the Pediatric Population.** *J. Pediatr.* 2021; Villaverde S, Domínguez-Rodríguez S, Sabrido G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484697>
 71. **SARS-CoV-2 Pneumonia Affects Male Reproductive Hormone Levels: A Prospective, Cohort Study.** *J. Sex. Med.* 2020; Kadihasanoglu M, Aktas S, Yardimci E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468445>
 72. **Seroprevalence and seroconversions for SARS-CoV-2 infections in workers at Bogota Airport, Colombia 2020.** *J Travel Med* 2021; Malagón-Rojas JN, Rubio V, Parra-Barrera E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480402>
 73. **Analytical performances of five SARS-CoV-2 whole-blood finger-stick IgG-IgM combined antibody rapid tests.** *J. Virol. Methods* 2021;114067Péré H, Bouassa RM, Tonen-Wolyec S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476707>
 74. **SARS-CoV-2 Genomic Variation in Space and Time in Hospitalized Patients in Philadelphia.** *mBio* 2021; 12Everett J, Hokama P, Roche AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468702>
 75. **Feasibility of using alternative swabs and storage solutions for paired SARS-CoV-2 detection and microbiome analysis in the hospital environment.** *Microbiome* 2021; 9:25Minich JJ, Ali F, Marotz C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482920>
 76. **The cardiovascular disorders and prognostic cardiac biomarkers in COVID-19.** *Mol. Biol. Rep.* 2021; Shi X, Chen M, Zhang Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33483864>
 77. **Prospects of biotechnological production and adoption of COVID-19 serological assays in Nigeria.** *Pan Afr. Med. J.* 2020; 37:31Abdullahi IN, Umar K, Omosigho PO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456655>
 78. **Clinical and laboratory characteristics of COVID-19 among adult patients admitted to the isolation centre at Abubakar Tafawa Balewa Teaching Hospital Bauchi, Northeast Nigeria.** *Pan Afr. Med. J.* 2020; 37:27Jibrin YB, Okwong OK, Maigari IM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456651>
 79. **SARS-CoV-2/human interactome reveals ACE2 locus crosstalk with the immune regulatory network in the host.** *Pathog Dis* 2021; Lite C, Ahmed S, Juliet

- MJ, Freddy AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469663>
80. **Limits and Opportunities of SARS-CoV-2 Antigen Rapid Tests: An Experienced-Based Perspective.** Pathogens 2021; 10Schildgen V, Demuth S, Lüsebrink J, Schildgen O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466537>
 81. **Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposure to adults with COVID-19: preliminary findings.** Pediatr Pulmonol 2021; Buonsenso D, Valentini P, De Rose C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33470561>
 82. **Antibody tests for COVID-19.** Proc. (Bayl. Univ. Med. Cent.) 2020; 34:63-72Kopel J, Goyal H, Perisetti A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456148>
 83. **Major alterations in the mononuclear phagocyte landscape associated with COVID-19 severity.** Proc Natl Acad Sci U S A 2021; 118Kvedaraite E, Hertwig L, Sinha I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33479167>
 84. **Deep vein thrombosis in COVID-19 patients in general wards: prevalence and association with clinical and laboratory variables.** Radiol Med 2021;1-7Ierardi AM, Gaibazzi N, Tuttolomondo D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469817>
 85. **Loop-mediated isothermal amplification (LAMP): An effective molecular point-of-care technique for the rapid diagnosis of coronavirus SARS-CoV-2.** Rev Med Virol 2021:e2215Chaouch M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476080>
 86. **Diagnostic Performance of a Blood Urea Nitrogen to Creatinine Ratio-based Nomogram for Predicting In-hospital Mortality in COVID-19 Patients.** Risk Manag. Healthc. Policy 2021; 14:117-128Liu Q, Wang Y, Zhao X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469395>
 87. **The assessment of serum ACE activity in COVID-19 and its association with clinical features and severity of the disease.** Scand. J. Clin. Lab. Invest. 2021:1-6Avanoglu Guler A, Tombul N, Aysert Yıldız P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33474994>
 88. **An increase in CD62L(dim) neutrophils precedes the development of pulmonary embolisms in COVID-19 patients.** Scand. J. Immunol. 2021:e13023Spijkerman R, Jorritsma NK, Bongers SH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482019>
 89. **Duration of SARS-CoV-2 viral shedding in faeces as a parameter for wastewater-based epidemiology: Re-analysis of patient data using a shedding dynamics model.** Sci Total Environ 2021; 769:144549Miura F, Kitajima M, Omori R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477053>
 90. **Epigenetic Underpinnings of Inflammation: Connecting the dots between Pulmonary Diseases, Lung Cancer and COVID-19.** Semin. Cancer Biol. 2021; Ahmad S, Manzoor S, Siddiqui S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484868>
 91. **Utility of D-dimer in predicting venous thromboembolism in non-mechanically ventilated COVID-19 survivors.** Thromb Res 2020; 199:82-84Nauka PC, Baron SW, Assa A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476901>
 92. **Analysis of blood donors' characteristics and deferrals related to COVID-19 in Iran.** Transfus. Apher. Sci. 2021:103049Rafiee MH, Kafiabad SA, Maghsudlu M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468406>
 93. **Anti-HLA and anti-SARS-CoV2 Antibodies in Kidney Transplant Recipient with COVID-19.** Transpl Int 2021; Gandolfini I, Zanelli P, Palmisano A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481306>

94. **Altered Cholesterol and Lipid Synthesis Mediates Hyperinflammation in COVID-19.** Trends Endocrinol. Metab. 2021; Sohrabi Y, Reinecke H, Godfrey R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33455862>
95. **Nucleocapsid and Spike Proteins of the Coronavirus SARS-CoV-2 Induce IL6 in Monocytes and Macrophages-Potential Implications for Cytokine Storm Syndrome.** Vaccines (Basel) 2021; 9Karwaciak I, Sałkowska A, Karaś K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467724>
96. **Structural Mapping of Mutations in Spike, RdRp and Orf3a Genes of SARS-CoV-2 in Influenza Like Illness (ILI) Patients.** Viruses 2021; 13Alosaimi B, Naeem A, Alghoribi MF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477951>
97. **Waste disposal characteristics and data variability in a mid-sized Canadian city during COVID-19.** Waste Manag. 2021; 122:49-54Richter A, Ng KTW, Vu HL, Kabir G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485254>
98. **Stigma, Trust, and Procedural Integrity: Covid-19 Testing in Malawi.** World Dev 2021; 105351Ferree K, Harris A, Dulani B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456104>
99. **Stigma, Trust, and procedural integrity: Covid-19 testing in Malawi.** World Dev 2021; 141:105351Ferree KE, Harris AS, Dulani B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456104>

Children (25 articles)

1. **Impact of the COVID-19 pandemic on children with and without risk for neurodevelopmental impairments.** Acta Paediatr 2021; Ehrler M, Werninger I, Schnider B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486835>
2. **[SARS-CoV-2 Detection in cerebrospinal fluid in a pediatric patient. Case report].** Arch. Argent. Pediatr. 2021; 119:e58-e60Franco P, Bellesi Y, Nocent E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458993>
3. **Multisystem inflammatory syndrome in children related to COVID-19: An update regarding the presentation of two critically ill patients.** Arch. Argent. Pediatr. 2021; 119:e26-e35Taffarel P, Jorro Barón F, Rodríguez AP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458987>
4. **Post-traumatic growth during the COVID-19 pandemic in carers of children in Portugal and the UK: cross-sectional online survey.** BJPsych Open 2021; 7:e37Stallard P, Pereira AI, Barros L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468270>
5. **The different manifestations of COVID-19 in adults and children: a cohort study in an intensive care unit.** BMC Infect. Dis. 2021; 21:87Girona-Alarcon M, Bobillo-Perez S, Sole-Ribalta A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472588>
6. **REACT study protocol: resilience after the COVID-19 threat (REACT) in adolescents.** BMJ Open 2021; 11:e042824Smith AJ, Moreno-López L, Davidson E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472787>
7. **ESCAP CovCAP survey of heads of academic departments to assess the perceived initial (April/May 2020) impact of the COVID-19 pandemic on child and adolescent psychiatry services.** Eur. Child Adolesc. Psychiatry 2021; 1-10Revet A, Hebebrand J, Anagnostopoulos D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33474653>

8. **Resurgence of combined intravenous Ketamine and regional anesthesia in pediatric ocular surgery in COVID-19 pandemic.** Indian J Ophthalmol 2021; 69:395-399 Rajput VK, Tuvar S, Bhalsing S, Bhalsing S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33463598>
9. **Physical Activity and Daily Routine among Children Aged 0-12 during the COVID-19 Pandemic in Spain.** Int J Environ Res Public Health 2021; 18 Cachón-Zagalaz J, Zagalaz-Sánchez M^a L, Arufe-Giráldez V *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33467514>
10. **A hidden side of the COVID-19 pandemic in children: the double burden of undernutrition and overnutrition.** Int J Equity Health 2021; 20:44 Zemrani B, Gehri M, Masserey E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482829>
11. **Epidemiology, characteristics, and outcomes of hospitalized children with COVID-19 in Oman: A multicenter cohort study.** Int J Infect Dis 2021; Al Yazidi LS, Al Hinai Z, Al Waili B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476759>
12. **Loss of smell and taste in COVID-19 infection in adolescents.** Int J Pediatr Otorhinolaryngol 2021; 142:110626 Kumar L, Kahlon N, Jain A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33477014>
13. **Typologies of coping in young adults in the context of the COVID-19 pandemic.** J. Gen. Psychol. 2021:1-34 Shigeto A, Laxman DJ, Landy JF, Scheier LM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33475048>
14. **Pediatric urology amidst SARS-CoV-2 pandemic: Building the future with current knowledge.** J. Pediatr. Surg. 2021; Lombardo AM, Andolfi C, Deshpande AP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33483106>
15. **Pediatric surgical wait priority score (pSWAPS): Modifying a health system's adult-based elective surgery prioritization system for children's surgery during the COVID-19 pandemic.** J. Pediatr. Surg. 2021; Slater BJ, Cappello MT, Butterly MM, Sherman J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33483104>
16. **Clinical presentations and management of COVID-19 infected children seen in a district health facility in Kambia, northern Sierra Leone.** Pan Afr. Med. J. 2020; 37:28 Adetola HH, Ishola D, Afolabi MO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456652>
17. **[Differential clinic in children infected by SARS-CoV-2, traceability of contacts and cost-effectiveness of diagnostic tests: Cross-sectional observational study].** An Pediatr (Barc) 2020; Fiel-Ozores A, González-Durán ML, Novoa-Carballal R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485824>
18. **Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposure to adults with COVID-19: preliminary findings.** Pediatr Pulmonol 2021; Buonsenso D, Valentini P, De Rose C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33470561>
19. **Autism, Therapy and COVID-19.** Pediatr. Rep. 2021; 13:35-44 Sergi L, Mingione E, Ricci MC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466265>
20. **Pediatric chest X-rays during the COVID-19 pandemic.** Radiologia (Roma) 2021; Aguirre Pascual E, Coca Robinot D, Gallego Herrero C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33483143>
21. **While quarantined: An online parent education and training model for families of children with autism in China.** Res. Dev. Disabil. 2021; 109:103851 McDevitt SE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465589>

22. **Parental well-being in times of Covid-19 in Germany.** Rev Econ Househ 2021;1-32 Huebener M, Waights S, Spiess CK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469413>
23. **Strategic management of pediatric intensive care unit in a tertiary children's hospital in southwest China during the COVID-19 pandemic.** Transl Pediatr 2020; 9:849-862 Zeng P, Luo X, Zeng W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457308>
24. **The Prospective of Autism in the Next Generation; The Need for Pay Attention to the COVID-19 Pandemic.** World J. Biol. Psychiatry 2021;1-4 Mohammadi MR, Zandifar A, Badrfam R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33475040>
25. **Differences between radiological findings of COVID-19 and non-COVID-19 infections in pediatric patients.** World J Pediatr 2021; Kuzan BN, Aslan B, Kuzan TY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33460024>

Clinical Features (49 articles)

1. **The impact of SARS-CoV-2 on skeletal muscles.** Acta Myol. 2020; 39:307-312 De Giorgio MR, Di Noia S, Morciano C, Conte D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458586>
2. **Is there a correlation between viral load and olfactory & taste dysfunction in COVID-19 patients?** Am. J. Otolaryngol. 2021; 42:102911 Jain A, Pandey AK, Kaur J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476975>
3. **Case reports in the COVID-19 pandemic: first responders to an emergency in evidence-based medicine.** Anaesth Rep 2021; 9:e12088 Kearsley R, Daly Guris R, Miles LF, Shelton CL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458676>
4. **[SARS-CoV-2 Detection in cerebrospinal fluid in a pediatric patient. Case report].** Arch. Argent. Pediatr. 2021; 119:e58-e60 Franco P, Bellesi Y, Nocent E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458993>
5. **The different manifestations of COVID-19 in adults and children: a cohort study in an intensive care unit.** BMC Infect. Dis. 2021; 21:87 Girona-Alarcon M, Bobillo-Perez S, Sole-Ribalta A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472588>
6. **Clinical characteristics of 14 COVID-19 deaths in Tianmen, China: a single-center retrospective study.** BMC Infect. Dis. 2021; 21:88 Hu J, Zhang Y, Wang W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472591>
7. **Dynamic changes in lymphocyte subsets and parallel cytokine levels in patients with severe and critical COVID-19.** BMC Infect. Dis. 2021; 21:79 Liu Y, Tan W, Chen H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461503>
8. **Gestation and COVID-19: clinical and microbiological observational study (Gesta-COVID19).** BMC Pregnancy Childbirth 2021; 21:78 Suy A, Garcia-Ruiz I, Carbonell M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482757>
9. **Temporal changes of haematological and radiological findings of the COVID-19 infection-a review of literature.** BMC Pulm. Med. 2021; 21:37 Lim AYH, Goh JL, Chua MCW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482780>
10. **Olfactory function and viral recovery in COVID-19.** Brain Behav 2021:e02006 Mazzoli M, Molinari MA, Tondelli M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465295>
11. **Clinical Features of Venous Thromboembolism in Patients With Coronavirus Disease 2019 (COVID-19) in Japan - A Case Series Study.** Circ. J. 2021;

- Yamashita Y, Hara N, Obana M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33473096>
12. **Epidemiology and pathobiology of SARS-CoV-2 (COVID-19) in comparison with SARS, MERS: An updated overview of current knowledge and future perspectives.** *Clin Epidemiol Glob Health* 2021; 10:100694 Ganesh B, Rajakumar T, Malathi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33462564>
 13. **Re: 'High prevalence of heterotopic ossification in critically ill patients with severe COVID-19' by Stoiria et al.** *Clin Microbiol Infect* 2021; de l'Escalopier N, Mathieu L, Duret C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33460830>
 14. **Defining the role of asymptomatic and pre-symptomatic SARS-CoV-2 transmission - a living systematic review.** *Clin Microbiol Infect* 2021; Qiu X, Nergiz AI, Maraolo AE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484843>
 15. **Clinical Characteristics of 47 Death Cases With COVID-19: A Retrospective Study at a Tertiary Center in Lahore.** *Cureus* 2020; 12:e12039 Ussaid A, Riaz B, Rafai W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457138>
 16. **Predictors of clinical deterioration in non-severe patients with COVID-19: a retrospective cohort study.** *Curr. Med. Res. Opin.* 2021:1 Zhang Y, Chen M, Zhou L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459077>
 17. **Maculopapular skin eruptions associated with Covid-19: a systematic review.** *Dermatol Ther* 2021:e14788 Shams S, Rathore SS, Anvekar P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481314>
 18. **Tinnitus in COVID-19 Pandemic.** *Ear Nose Throat J* 2021:145561320988364 Narozny W, Tretiakow D, Skorek A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33470830>
 19. **Impact of the smell loss on the quality of life and adopted coping strategies in COVID-19 patients.** *Eur Arch Otorhinolaryngol* 2021:1-8 Elkholi SMA, Abdelwahab MK, Abdelhafeez M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33464401>
 20. **Objective gustatory and olfactory dysfunction in COVID-19 patients: a prospective cross-sectional study.** *Eur Arch Otorhinolaryngol* 2021:1-8 Singer-Cornelius T, Cornelius J, Oberle M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33471170>
 21. **Is Persistent Thick Copious Mucus a Long-Term Symptom of COVID-19?** *Eur J Case Rep Intern Med* 2020; 7:002145 Manckoundia P, Franon E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457378>
 22. **Association Between Clinical Characteristics and Short-Term Outcomes in Adult Male COVID-19 Patients With Mild Clinical Symptoms: A Single-Center Observational Study.** *Front Med (Lausanne)* 2020; 7:571396 Yan B, Song L, Guo J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469542>
 23. **Mucor in a Viral Land: A Tale of Two Pathogens.** *Indian J Ophthalmol* 2021; 69:244-252 Sen M, Lahane S, Lahane TP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33463566>
 24. **Clinical Characteristics of Patients with Severe and Critical COVID-19 in Wuhan: A Single-Center, Retrospective Study.** *Infect Dis Ther* 2021:1-18 Chen Z, Hu J, Liu L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481202>
 25. **Hiccups and psychosis: two atypical presentations of COVID-19.** *Int. J. Emerg. Med.* 2021; 14:8 Alvarez-Cisneros T, Lara-Reyes A, Sansón-Tinoco S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472577>
 26. **Epidemiology, characteristics, and outcomes of hospitalized children with COVID-19 in Oman: A multicenter cohort study.** *Int J Infect Dis* 2021; Al Yazidi

- LS, Al Hinai Z, Al Waili B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476759>
27. **Viral arthralgia a new manifestation of COVID-19 infection? A cohort study of COVID-19-associated musculoskeletal symptoms.** *Int J Infect Dis* 2021; Hoong CWS, Amin M, Tan TC, Lee JE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476761>
 28. **Loss of smell and taste in COVID-19 infection in adolescents.** *Int J Pediatr Otorhinolaryngol* 2021; 142:110626Kumar L, Kahlon N, Jain A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477014>
 29. **Unusual cause of acute sinusitis and orbital abscess in COVID-19 positive patient: Case report.** *Int. J. Surg. Case Rep.* 2021; 79:164-168Shires CB, Klug T, Dryden S, Ford J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477076>
 30. **Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies.** *J Allergy Clin Immunol* 2021; Patrick MT, Zhang H, Wasikowski R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485957>
 31. **The clinical spectrum of COVID-19-associated cutaneous manifestations: an Italian multicentre study of 200 adult patients.** *J Am Acad Dermatol* 2021; Marzano AV, Genovese G, Moltrasio C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476725>
 32. **Outcomes of COVID-19 Positive Acute Coronary Syndrome Patients; a multisource Electronic Healthcare Records Study from England.** *J Intern Med* 2021; Rashid M, Wu J, Timmis A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33462815>
 33. **High frequency of smell and taste dysfunctions in allergy health care professionals suffering from COVID-19.** *J. Investig. Allergol. Clin. Immunol.* 2021:0Antolín-Amérigo D, Cubero JL, Colás C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465033>
 34. **Proteinuria in COVID-19: prevalence, characterization and prognostic role.** *J Nephrol* 2021:1-10Huart J, Bouquegneau A, Lutteri L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484426>
 35. **Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19).** *J. Neurol.* 2021; Harapan BN, Yoo HJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486564>
 36. **Skin manifestations of COVID-19: A worldwide review.** *JAAD Int* 2021; 2:119-133Tan SW, Tam YC, Oh CC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33479703>
 37. **[Clinical characteristics of coronavirus disease 2019 in a single center of Argentina. Retrospective cohort].** *Medicina (B. Aires)* 2020; 80 Suppl 6:35-43Castro HM, Canale HL, Ferreyro BL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481731>
 38. **[Analysis of the first 100 patients with COVID-19 admitted to internal medicine wards at the Hospital de Clínicas José de San Martín, Buenos Aires University].** *Medicina (B. Aires)* 2020; 80 Suppl 6:48-55Ludueña MG, Labato M, Chiaradia V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481733>
 39. **Ischaemic stroke as an initial presentation in patients with COVID-19: evaluation of a case series in an emergency in Brazil.** *Neuroradiol. J.* 2021:1971400920987357Oliveira IB, Pessoa MS, Lima CF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33455541>

40. **Viral pathogenesis of SARS-CoV-2 infection and male reproductive health.** Open Biol 2021; 11:200347Roychoudhury S, Das A, Jha NK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465325>
41. **Clinical presentations and management of COVID-19 infected children seen in a district health facility in Kambia, northern Sierra Leone.** Pan Afr. Med. J. 2020; 37:28Adetola HH, Ishola D, Afolabi MO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456652>
42. **Clinical and laboratory characteristics of COVID-19 among adult patients admitted to the isolation centre at Abubakar Tafawa Balewa Teaching Hospital Bauchi, Northeast Nigeria.** Pan Afr. Med. J. 2020; 37:27Jibrin YB, Okwong OK, Maigari IM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456651>
43. **Deep vein thrombosis in COVID-19 patients in general wards: prevalence and association with clinical and laboratory variables.** Radiol Med 2021;1-7Ierardi AM, Gaibazzi N, Tuttolomondo D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469817>
44. **Characteristics of COVID-19 patients admitted into two hospitals in sapporo, Japan: Analyses and insights from two outbreak waves.** Respir Investig 2021; Hattori T, Saito A, Chiba H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461939>
45. **Epidemiological Characteristics of 64 Covid-19 Patients in Errachidia Province (Darâa-Tafilalet region), Morocco: A Retrospective Analysis.** Rev. Recent Clin. Trials 2021; Akdad M, Algharrass Y, Talha H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459245>
46. **The assessment of serum ACE activity in COVID-19 and its association with clinical features and severity of the disease.** Scand. J. Clin. Lab. Invest. 2021;1-6Avanoglu Guler A, Tombul N, Aysert Yıldız P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33474994>
47. **People with dyssomnia showed increased vulnerability to CoVID-19 pandemic: a questionnaire-based study exploring the patterns and predictors of sleep quality using the latent class analysis technique in Indian population.** Sleep Med. 2021; 79:29-39Radhakrishnan A, Govindaraj R, Sasidharan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485259>
48. **Robust Detection of COVID-19 in Cough Sounds: Using Recurrence Dynamics and Variable Markov Model.** SN Comput Sci 2021; 2:34Mouawad P, Dubnov T, Dubnov S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458700>
49. **[Olfactory dysfunction and COVID-19 - current state of the problem].** Vestn. Otorinolaringol. 2020; 85:100-104Karapetyan LS, Svistushkin VM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33474926>

CNS (22 articles)

1. **SARS-CoV-2: its potential neurological manifestations and plausible mechanism: a review article.** Acta Neurol. Belg. 2021;1-9Taher T, Sheikh AB, Anwar F, Khosa F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33464546>
2. **Impact of the COVID-19 pandemic on children with and without risk for neurodevelopmental impairments.** Acta Paediatr 2021; Ehrler M, Werninger I, Schnider B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486835>
3. **[SARS-CoV-2 Detection in cerebrospinal fluid in a pediatric patient. Case report].** Arch. Argent. Pediatr. 2021; 119:e58-e60Franco P, Bellesi Y, Nocent E *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458993>
4. **GM1 Ganglioside Antibody and COVID-19 related Guillain Barre Syndrome - a Case Report, Systemic Review and Implication for Vaccine Development.** Brain Behav Immun Health 2021; 12:100203Dufour C, Co TK, Liu A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33462567>
 5. **The neuropathological impact of COVID-19: a review.** Bull Natl Res Cent 2021; 45:19Ibrahim Fouad G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456304>
 6. **Tinnitus in COVID-19 Pandemic.** Ear Nose Throat J 2021;145561320988364Narozny W, Tretiakow D, Skorek A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33470830>
 7. **Objective gustatory and olfactory dysfunction in COVID-19 patients: a prospective cross-sectional study.** Eur Arch Otorhinolaryngol 2021:1-8Singer-Cornelius T, Cornelius J, Oberle M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33471170>
 8. **Neurological complications of COVID-19 in hospitalized patients: The registry of a neurology department in the first wave of the pandemic.** Eur. J. Neurol. 2021; Portela-Sánchez S, Sánchez-Soblechero A, Melgarejo Ojalora PJ *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33474816>
 9. **COVID 19 and dementia: experience from six European countries.** Int. J. Geriatr. Psychiatry 2021; Burns A, Lobo A, Olde Rikkert M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33462849>
 10. **Loss of smell and taste in COVID-19 infection in adolescents.** Int J Pediatr Otorhinolaryngol 2021; 142:110626Kumar L, Kahlon N, Jain A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33477014>
 11. **Evidence of Coronavirus (CoV) Pathogenesis and Emerging Pathogen SARS-CoV-2 in the Nervous System: A Review on Neurological Impairments and Manifestations.** J. Mol. Neurosci. 2021:1-18Jha NK, Ojha S, Jha SK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33464535>
 12. **Purinergic Signaling of ATP in COVID-19 Associated Guillain-Barré Syndrome.** J. Neuroimmune Pharmacol. 2021:1-11Simões JLB, Bagatini MD.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33462776>
 13. **Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19).** J. Neurol. 2021; Harapan BN, Yoo HJ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33486564>
 14. **COVID-19 in spinal cord injury patients at a veterans administration hospital: A case series.** J. Spinal Cord Med. 2021:1-13Galea MD, Gelman MA, Galea VP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465012>
 15. **COVID-19 in ocrelizumab-treated people with multiple sclerosis.** Mult Scler Relat Disord 2020; 49:102725Hughes R, Whitley L, Fitovski K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33482590>
 16. **SARS-CoV-2-induced encephalopathy.** Nervenheilkunde 2020; 39:844-845Abdelnaby R, Elsayed M, Abele-Haupts F *et al.*
 17. **Favorable outcome of COVID-19 infection in a patient with congenital myasthenic syndrome.** Neurol Sci 2021:1-2Bonanno S, Maggi L.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33483883>
 18. **Neuropathologic findings of patients with COVID-19: a systematic review.** Neurol Sci 2021; Pajo AT, Espiritu AI, Apor A, Jamora RDG.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33483885>

19. **Neurobiology of SARS-CoV-2 interactions with the peripheral nervous system: implications for COVID-19 and pain.** *Pain Rep* 2021; 6:e885McFarland AJ, Yousuf MS, Shiers S, Price TJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458558>
20. **People with dyssomnia showed increased vulnerability to CoVID-19 pandemic: a questionnaire-based study exploring the patterns and predictors of sleep quality using the latent class analysis technique in Indian population.** *Sleep Med.* 2021; 79:29-39Radhakrishnan A, Govindaraj R, Sasidharan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485259>
21. **Meningoencephalitis Associated with SARS-Coronavirus-2.** *Transl Med UniSa* 2020; 23:42-47Iaconetta G, De Luca P, Scarpa A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457322>
22. **Neuroinvasion and Encephalitis Following Intranasal Inoculation of SARS-CoV-2 in K18-hACE2 Mice.** *Viruses* 2021; 13Kumari P, Rothan HA, Natekar JP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477869>

Coagulation (20 articles)

1. **Effect of antiplatelet treatments on patients with COVID-19 infection: A systematic review and meta-analysis.** *Am J Emerg Med* 2021; 43:27-30Wang Y, Ao G, Nasr B, Qi X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485124>
2. **Anatomical and Pathological Observation and Analysis of SARS and COVID-19: Microthrombosis Is the Main Cause of Death.** *Biol. Proced. Online* 2021; 23:4Chen W, Pan JY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472576>
3. **Impact of high dose prophylactic anticoagulation in critically ill patients with COVID-19 pneumonia.** *Chest* 2021; Tacquard C, Mansour A, Godon A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465342>
4. **Clinical Features of Venous Thromboembolism in Patients With Coronavirus Disease 2019 (COVID-19) in Japan - A Case Series Study.** *Circ. J.* 2021; Yamashita Y, Hara N, Obana M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33473096>
5. **Aorto-iliac/right leg arterial thrombosis necessitating limb amputation, pulmonary arterial, intracardiac, and ilio-caval venous thrombosis in a 40-year-old with COVID-19.** *Clin Imaging* 2021; 75:1-4Madani MH, Leung ANC, Becker HC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477081>
6. **Coagulation Inhibitors in COVID-19 Leading to Compressive Airway Hematoma.** *Cureus* 2021; 13:e12580Mohamed A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457144>
7. **Critical Care COVID-19 Patient with a Picture of Thrombotic Thrombocytopenic Purpura.** *Eur J Case Rep Intern Med* 2020; 7:002143Al-Ansari RY, Bakkar M, Abdalla L, Sewify K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457377>
8. **Combined hormonal contraception and COVID-19.** *Eur. J. Contracept. Reprod. Health Care* 2021:1-9Lete I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33475429>
9. **Complement activation and coagulopathy - an ominous duo in COVID19.** *Expert Rev. Hematol.* 2021:1-19Tomo S, Kumar KP, Roy D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480807>
10. **D-dimer levels is associated with severe COVID-19 infections: A meta-analysis.** *Int J Clin Pract* 2021:e14031Wu ZH, Cheng Q. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33474792>

11. **Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?** Int. J. Hematol. 2021;1-7Iba T, Connors JM, Spyropoulos AC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33471294>
12. **A Unique Tale of COVID-19 Induced Concomitant Overt DIC and Acute Bilateral Pulmonary Embolism.** Int J Infect Dis 2021; Siddiqui SN, Jayasekhar R, Tshering S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486013>
13. **A considerable asymptomatic proportion and thromboembolism risk of pregnant women with COVID-19 infection in Wuhan, China.** J. Perinat. Med. 2020; Wang Y, Liang X, Wang H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33470960>
14. **Intracranial Hemorrhage in COVID-19 Patients.** J. Stroke Cerebrovasc. Dis. 2021; 30:105603Mishra S, Choueka M, Wang Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484980>
15. **Subacute stent thrombosis in a patient with COVID-19 pneumonia.** Proc. (Bayl. Univ. Med. Cent.) 2020; 34:175-177Ayan M, Kovelamudi S, Al-Hawwas M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456191>
16. **Ascending aortic thrombus with multiple emboli associated with COVID-19.** Proc. (Bayl. Univ. Med. Cent.) 2020; 34:178-179Schmidt P, Vasquez J, Gagliano B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456192>
17. **Deep vein thrombosis in COVID-19 patients in general wards: prevalence and association with clinical and laboratory variables.** Radiol Med 2021;1-7Ierardi AM, Gaibazzi N, Tuttolomondo D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469817>
18. **An increase in CD62L(dim) neutrophils precedes the development of pulmonary embolisms in COVID-19 patients.** Scand. J. Immunol. 2021:e13023Spijkerman R, Jorritsma NK, Bongers SH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482019>
19. **Utility of D-dimer in predicting venous thromboembolism in non-mechanically ventilated COVID-19 survivors.** Thromb Res 2020; 199:82-84Nauka PC, Baron SW, Assa A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476901>
20. **Effect of government interventions to contain the COVID-19 pandemic on incidence of pulmonary embolism - A Danish nationwide register-based cohort study.** Thromb Res 2021; 199:97-100Sindet-Pedersen C, Olesen JB, Blanche P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485095>

Complications (70 articles)

1. **Awake proning in COVID-19 - does CPAP make a difference?** Adv Respir Med 2021; Mittal S, Pb S, Madan K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33471353>
2. **Effect of antiplatelet treatments on patients with COVID-19 infection: A systematic review and meta-analysis.** Am J Emerg Med 2021; 43:27-30Wang Y, Ao G, Nasr B, Qi X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485124>
3. **Occurrence of Invasive Pulmonary Fungal Infections in Severe COVID-19 Patients Admitted to the ICU.** Am J Respir Crit Care Med 2020; Fekkar A, Lampros A, Mayaux J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480831>
4. **An Evolving Clinical Need: Discordant Oxygenation Measurements of Intubated COVID-19 Patients.** Ann. Biomed. Eng. 2021:1-5Rubano JA, Maloney LM, Simon J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469819>

5. **Multidrug-Resistant Bacterial Infections in Geriatric Hospitalized Patients before and after the COVID-19 Outbreak: Results from a Retrospective Observational Study in Two Geriatric Wards.** Antibiotics (Basel) 2021; 10:Gasperini B, Cherubini A, Lucarelli M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478088>
6. **Anatomical and Pathological Observation and Analysis of SARS and COVID-19: Microthrombosis Is the Main Cause of Death.** Biol. Proced. Online 2021; 23:4Chen W, Pan JY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472576>
7. **Association of Overlapped and Un-overlapped Comorbidities with COVID-19 Severity and Treatment Outcomes: A Retrospective Cohort Study from Nine Provinces in China.** Biomed. Environ. Sci. 2020; 33:893-905Ma Y, Zhu DS, Chen RB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472729>
8. **Clinical course and challenging management of early COVID-19 infection after heart transplantation: case report of two patients.** BMC Infect. Dis. 2021; 21:89Tchana-Sato V, Ancion A, Tridetti J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472599>
9. **The use of electrical impedance tomography for individualized ventilation strategy in COVID-19: a case report.** BMC Pulm. Med. 2021; 21:38Zhao Z, Zhang JS, Chen YT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482796>
10. **Late onset of Guillain-Barré syndrome following SARS-CoV-2 infection: part of 'long COVID-19 syndrome'?** BMJ Case Rep. 2021; 14Raahimi MM, Kane A, Moore CE, Alareed AW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33462068>
11. **Autoimmune haemolytic anaemia and a marked rise in the lymphocyte count associated with COVID-19 in a patient with treatment-naïve chronic lymphocytic leukaemia: a case report.** Br. J. Haematol. 2020; 190:e326-e328Nesr G, Koshy R, Foldes D, Kagdi H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33460041>
12. **Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients.** Cancer Cell 2021; Abdul-Jawad S, Baù L, Alaguthurai T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476581>
13. **Clinical Features of Venous Thromboembolism in Patients With Coronavirus Disease 2019 (COVID-19) in Japan - A Case Series Study.** Circ. J. 2021; Yamashita Y, Hara N, Obana M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33473096>
14. **Microthrombi As A Major Cause of Cardiac Injury in COVID-19: A Pathologic Study.** Circulation 2021; Pellegrini D, Kawakami R, Guagliumi G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480806>
15. **Aorto-iliac/right leg arterial thrombosis necessitating limb amputation, pulmonary arterial, intracardiac, and ilio-caval venous thrombosis in a 40-year-old with COVID-19.** Clin Imaging 2021; 75:1-4Madani MH, Leung ANC, Becker HC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477081>
16. **Lesson of the month: Severe granulomatosis with polyangiitis (GPA): a diagnostic challenge during the COVID-19 pandemic.** Clin Med (Lond) 2021; 21:79-80Qurratulain Q, Ahmed A, Jones Q. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33479073>
17. **A Review of Venous Thromboembolism in COVID-19: In a Clinical Perspective.** Clin. Respir. J. 2021; Ozsu S, Gunay E, Konstantinides SV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484090>

18. **Coagulation Inhibitors in COVID-19 Leading to Compressive Airway Hematoma.** Cureus 2021; 13:e12580Mohamed A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33457144>
19. **The development of dermatologic diseases in patients recovered from COVID-19.** Dermatol Ther 2021; Temiz SA, Kutlu Ö. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484016>
20. **80-year-old patient with jaundice after a severe Covid-19 infection.** Deutsche Medizinische Wochenschrift 2021; 146:13-14Muehlenberg K, Tannapfel A, Pech O.
21. **Prevalence of Clostridioides difficile and Other Gastrointestinal Pathogens in Patients with COVID-19.** Dig. Dis. Sci. 2021:1-8Laszkowska M, Kim J, Faye AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33479861>
22. **Thyroid complications of SARS and coronavirus disease 2019 (COVID-19).** Endocr. J. 2021; Speer G, Somogyi P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33473054>
23. **Critical Care COVID-19 Patient with a Picture of Thrombotic Thrombocytopenic Purpura.** Eur J Case Rep Intern Med 2020; 7:002143Al-Ansari RY, Bakkar M, Abdalla L, Sewify K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457377>
24. **Dengue Fever and COVID-19 Co-Infection at the Emergency Department of a Tertiary Care Hospital in Jeddah, Saudi Arabia.** Eur J Case Rep Intern Med 2020; 7:002167Khalil A, Badr B, Wright H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457380>
25. **Pulmonary Hypertension in COVID-19 Pneumoniae: It Is Not Always as It Seems.** Eur J Case Rep Intern Med 2020; 7:002160Pasqualetto MC, Sorbo MD, Vitiello M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457379>
26. **Neurological complications of COVID-19 in hospitalized patients: The registry of a neurology department in the first wave of the pandemic.** Eur. J. Neurol. 2021; Portela-Sánchez S, Sánchez-Soblechero A, Melgarejo Ojalora PJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33474816>
27. **Complement activation and coagulopathy - an ominous duo in COVID19.** Expert Rev. Hematol. 2021:1-19Tomo S, Kumar KP, Roy D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480807>
28. **Incidence and Clinical Impacts of COVID-19 Infection in Patients with Hemodialysis: Systematic Review and Meta-Analysis of 396,062 Hemodialysis Patients.** Healthcare (Basel) 2021; 9Chen CY, Shao SC, Chen YT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466527>
29. **The measles outbreak in Israel in 2018-19: lessons for COVID-19 pandemic.** Hum Vaccin Immunother 2021:1-5Stein-Zamir C, Levine H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481632>
30. **Exuberant bullous vasculitis associated with SARS-CoV-2 infection.** IDCases 2021:e01047da Cruz Gouveia PA, Cipriano IC, de Melo MAZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457205>
31. **Exuberant bullous vasculitis associated with SARS-CoV-2 infection.** IDCases 2021; 23:e01047Gouveia P, Cipriano IC, de Melo MAZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457205>
32. **Tracheostomy in the COVID19 Patients: Our Experience in 12 Cases.** Indian J Otolaryngol Head Neck Surg 2021:1-5Pradhan P, Mishra AK, Mittal Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457312>

33. **Clinical Characteristics of Patients with Severe and Critical COVID-19 in Wuhan: A Single-Center, Retrospective Study.** Infect Dis Ther 2021:1-18Chen Z, Hu J, Liu L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481202>
34. **Extracorporeal membrane oxygenation versus mechanical ventilation alone in adults with severe acute respiratory distress syndrome: a systematic review and meta-analysis.** Int J Clin Pract 2021:e14046Zhu Y, Zhang M, Zhang R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486824>
35. **Hiccups and psychosis: two atypical presentations of COVID-19.** Int. J. Emerg. Med. 2021; 14:8Alvarez-Cisneros T, Lara-Reyes A, Sansón-Tinoco S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472577>
36. **Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?** Int. J. Hematol. 2021:1-7Iba T, Connors JM, Spyropoulos AC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33471294>
37. **A Unique Tale of COVID-19 Induced Concomitant Overt DIC and Acute Bilateral Pulmonary Embolism.** Int J Infect Dis 2021; Siddiqui SN, Jayasekhar R, Tshering S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486013>
38. **Risk factors for illness severity in patients with COVID-19 pneumonia: a prospective cohort study.** Int. J. Med. Sci. 2021; 18:921-928Zhang N, Zhang H, Tang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456349>
39. **COVID-19 and related symptoms in patients under disulfiram for alcohol use disorder.** Intern Emerg Med 2021:1-3Tamburin S, Mantovani E, De Bernardis E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33464469>
40. **Hemoptysis and a Newly Formed Lung Bulla in a Case of Convalescent COVID-19 Pneumonia.** Intern Med 2021; Sato L, Kinoshita N, Nakamoto T, Ohmagari N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456035>
41. **Community-acquired and hospital-acquired respiratory tract infection and bloodstream infection in patients hospitalized with COVID-19 pneumonia.** J Intensive Care 2021; 9:10Søgaard KK, Baettig V, Osthoff M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461613>
42. **Co-Infection of Influenza A Virus and SARS-CoV-2: A Retrospective Cohort Study.** J Med Virol 2021; Cheng Y, Ma J, Wang H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33475159>
43. **COVID-19 pandemic and its consequences disrupt epidemiology of enterovirus meningitis, South-East France.** J Med Virol 2021; Luciani L, Ninove L, Zandotti C, Nougairède A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482046>
44. **Purinergic Signaling of ATP in COVID-19 Associated Guillain-Barré Syndrome.** J. Neuroimmune Pharmacol. 2021:1-11Simões JLB, Bagatini MD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33462776>
45. **Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19).** J. Neurol. 2021; Harapan BN, Yoo HJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486564>
46. **An environmental study of tracheostomy on eight COVID-19 patients.** J. Otolaryngol. Head Neck Surg. 2021; 50:3Xu K, Zhang XH, Long XB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461626>
47. **Clinical Outcomes of Critically Ill Patients with COVID-19 by Race.** J Racial Ethn Health Disparities 2021:1-5Marmarchi F, Liu M, Rangaraju S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469873>

48. **SARS-CoV-2 Pneumonia Affects Male Reproductive Hormone Levels: A Prospective, Cohort Study.** J. Sex. Med. 2020; Kadihasanoglu M, Aktas S, Yardimci E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468445>
49. **COVID-19 in spinal cord injury patients at a veterans administration hospital: A case series.** J. Spinal Cord Med. 2021;1-13Galea MD, Gelman MA, Galea VP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465012>
50. **Intracranial Hemorrhage in COVID-19 Patients.** J. Stroke Cerebrovasc. Dis. 2021; 30:105603Mishra S, Choueka M, Wang Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484980>
51. **Two episodes of SARS-CoV-2 infection in a patient on chronic hemodialysis. A note of caution.** Kidney Int 2021; Torreggiani M, Ebikili B, Bianchi S, Piccoli GB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485912>
52. **Early prone positioning therapy for patients with mild COVID-19 disease.** Med Clin (Barc) 2020; Liu X, Liu H, Lan Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478810>
53. **Diabetic foot and COVID-19. Medical consultation and severity of lesions compared to 2019.** Medicina (B. Aires) 2020; 80 Suppl 6:30-34Carro GV, Carlucci EM, Torterola I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481730>
54. **[Dengue and SARS-CoV-2 coinfection in an HIV positive patient].** Medicina (B. Aires) 2020; 80 Suppl 6:94-96Salvo CP, Di Lella N, Solveyra López F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481738>
55. **[Tuberculosis and COVID-19 coinfection].** Medicina (B. Aires) 2020; 80 Suppl 6:100-103Vanzetti CP, Salvo CP, Kushner P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481740>
56. **[Preliminary results of a non-invasive ventilatory support unit in SARS-COVID-2].** Medicina (B. Aires) 2020; 80 Suppl 6:1-8Vega ML, Montiel G, Colaianni N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481726>
57. **SARS-COV-2 infection and lung tumor microenvironment.** Mol. Biol. Rep. 2021; Malkani N, Rashid MU. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486674>
58. **Spinal cord infarction in a 41-year-old male patient with COVID-19.** Neuroradiol. J. 2021;1971400921988925Eissa M, Abdelhady M, Alqatami H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480310>
59. **Ischaemic stroke as an initial presentation in patients with COVID-19: evaluation of a case series in an emergency in Brazil.** Neuroradiol. J. 2021;1971400920987357Oliveira IB, Pessoa MS, Lima CF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33455541>
60. **SARS-CoV-2 and Obesity: "CoVesity"-a Pandemic Within a Pandemic.** Obes. Surg. 2021;1-10Zakka K, Chidambaram S, Mansour S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33479921>
61. **Surgical Tracheostomy Outcomes in COVID-19-Positive Patients.** OTO Open 2021; 5:2473974x20984998Courtney A, Lignos L, Ward PA, Vizcaychipi MP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33474524>
62. **Severe COVID-19 infection in a patient with a blastic transformation of a chronic myeloid leukemia and severe treatment-induced immunosuppression: a case report.** Pan Afr. Med. J. 2020; 37:34Mounir L, Mehdi S, Kawtar F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456658>
63. **Subacute stent thrombosis in a patient with COVID-19 pneumonia.** Proc. (Bayl. Univ. Med. Cent.) 2020; 34:175-177Ayan M, Kovelamudi S, Al-Hawwas M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456191>

64. **Ascending aortic thrombus with multiple emboli associated with COVID-19.** Proc. (Bayl. Univ. Med. Cent.) 2020; 34:178-179 Schmidt P, Vasquez J, Gagliano B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456192>
65. **Deep vein thrombosis in COVID-19 patients in general wards: prevalence and association with clinical and laboratory variables.** Radiol Med 2021:1-7 Ierardi AM, Gaibazzi N, Tuttolomondo D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469817>
66. **Factors associated with hospitalization, invasive mechanical ventilation treatment and death among all confirmed COVID-19 cases in Norway: Prospective cohort study.** Scand J Public Health 2021:1403494820985172 Telle KE, Grøslund M, Helgeland J, Håberg SE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461404>
67. **Effect of government interventions to contain the COVID-19 pandemic on incidence of pulmonary embolism - A Danish nationwide register-based cohort study.** Thromb Res 2021; 199:97-100 Sindet-Pedersen C, Olesen JB, Blanche P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485095>
68. **Meningoencephalitis Associated with SARS-Coronavirus-2.** Transl Med UniSa 2020; 23:42-47 Iaconetta G, De Luca P, Scarpa A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457322>
69. **Neuroinvasion and Encephalitis Following Intranasal Inoculation of SARS-CoV-2 in K18-hACE2 Mice.** Viruses 2021; 13 Kumari P, Rothan HA, Natekar JP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477869>
70. **Prevalence of Co-Infections with Respiratory Viruses in Individuals Investigated for SARS-CoV-2 in Ontario, Canada.** Viruses 2021; 13 Peci A, Tran V, Guthrie JL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477649>

Cured – Recovered (11 articles)

1. **An Evolving Clinical Need: Discordant Oxygenation Measurements of Intubated COVID-19 Patients.** Ann. Biomed. Eng. 2021:1-5 Rubano JA, Maloney LM, Simon J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469819>
2. **Late onset of Guillain-Barré syndrome following SARS-CoV-2 infection: part of 'long COVID-19 syndrome'?** BMJ Case Rep. 2021; 14 Raahimi MM, Kane A, Moore CE, Alareed AW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33462068>
3. **Developing services for long COVID: lessons from a study of wounded healers.** Clin Med (Lond) 2021; 21:59-65 Ladds E, Rushforth A, Wieringa S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33479069>
4. **The development of dermatologic diseases in patients recovered from COVID-19.** Dermatol Ther 2021; Temiz SA, Kutlu Ö. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484016>
5. **Real Time PCR and Culture-Based Virus Isolation Test in Clinically Recovered Patients: Is the Subject Still Infectious for SARS-CoV2?** J Clin Med 2021; 10 Manzulli V, Scioscia G, Giganti G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467628>
6. **The Prognostic Value of Eosinophil Recovery in COVID-19: A Multicentre, Retrospective Cohort Study on Patients Hospitalised in Spanish Hospitals.** J Clin Med 2021; 10 Mateos González M, Sierra Gonzalo E, Casado Lopez I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467585>

7. **Long-term recovery from COVID-19 anosmia: promising findings and unanswered questions.** J Intern Med 2021; Giovanni LL, Gallo O.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33462906>
8. **[Telerehabilitation: from the virtual world to reality-Medicine in the twenty-first century : Video-assisted treatment in times of COVID-19].** Nervenarzt 2021; Meyding-Lamadé U, Bassa B, Tibitanzl P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33459797>
9. **Views and experiences of discharged COVID-19 patients in Kano, Nigeria: a qualitative study.** Pan Afr. Med. J. 2020; 37:38Mukhtar NB, Abdullahi A, Abba MA, Mohammed J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456662>
10. **COVID-19 discharge and follow-up recommendations.** Proc. (Bayl. Univ. Med. Cent.) 2020; 34:73-75Abdelnabi M, Leelaviwat N, Eshak N *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33456149>
11. **Post-COVID syndrome and suicide risk.** QJM 2021; Sher L.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33486531>

Cardiovascular disease (46 articles)

1. **Electrocardiographic markers of increased risk of sudden cardiac death in patients with COVID-19 pneumonia.** Ann. Noninvasive Electrocardiol. 2021:e12824Alareedh M, Nafakhi H, Shaghee F, Nafakhi A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33463863>
2. **Clinical course and challenging management of early COVID-19 infection after heart transplantation: case report of two patients.** BMC Infect. Dis. 2021; 21:89Tchana-Sato V, Ancion A, Tridetti J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33472599>
3. **Bioinformatics and system biology approach to identify the influences of COVID-19 on cardiovascular and hypertensive comorbidities.** Brief. Bioinform. 2021; Nashiry A, Sarmin Sumi S, Islam S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33458761>
4. **Building Experience and Evidence: COVID-19 and Myocardial Injury.** Circ. Cardiovasc. Imaging 2021:Circimaging120012220Verma AK, Vader JM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33461305>
5. **Myocardial Inflammation and Dysfunction in COVID-19-Associated Myocardial Injury.** Circ. Cardiovasc. Imaging 2021:Circimaging120011713Weckbach LT, Curta A, Bieber S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33463366>
6. **Why Automated E-Counseling for Chronic Heart Failure Matters in the COVID-19 Pandemic Era.** Circ Heart Fail 2021; 14:e008071Reid KRY.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33464946>
7. **Microthrombi As A Major Cause of Cardiac Injury in COVID-19: A Pathologic Study.** Circulation 2021; Pellegrini D, Kawakami R, Guagliumi G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33480806>
8. **Short-term cardiac outcome in survivors of COVID-19: a systematic study after hospital discharge.** Clin Res Cardiol 2021:1-10Sechi LA, Colussi G, Bulfone L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481096>
9. **COVID-19, Angiotensin-Converting Enzyme 2 and Renin-Angiotensin System Inhibition: Implications for Practice.** Curr. Hypertens. Rev. 2021; Katsi V, Pavlidis G, Charalambous G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33475077>

10. **Atrial arrhythmia and its association with COVID-19 outcome: a pooled analysis.** Diagnosis (Berl) 2021; Mulia EPB, Maghfirah I, Rachmi DA, Julario R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33470951>
11. **Cardiac MRI and Myocardial Injury in COVID-19: Diagnosis, Risk Stratification and Prognosis.** Diagnostics (Basel) 2021; 11Sanghvi SK, Schwarzman LS, Nazir NT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467705>
12. **The impact of COVID-19 on the management of heart failure: a United Kingdom patient questionnaire study.** ESC Heart Fail 2021; Sankaranarayanan R, Hartshorne-Evans N, Redmond-Lyon S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33463044>
13. **Pulmonary Hypertension in COVID-19 Pneumoniae: It Is Not Always as It Seems.** Eur J Case Rep Intern Med 2020; 7:002160Pasqualetto MC, Sorbo MD, Vitiello M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457379>
14. **Delivering telemedicine consultations for patients with Transient Ischemic Attack during the COVID-19 pandemic in a comprehensive tertiary stroke centre in the United Kingdom.** Eur. J. Neurol. 2021; D'Anna L, Ellis N, Bentley P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476421>
15. **Association between regional distributions of SARS-CoV-2 seroconversion and out-of-hospital sudden death during the first epidemic outbreak in New York.** Heart Rhythm 2021; Coleman KM, Saleh M, Mountantonakis SE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472765>
16. **Exuberant bullous vasculitis associated with SARS-CoV-2 infection.** IDCases 2021:e01047da Cruz Gouveia PA, Cipriano IC, de Melo MAZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457205>
17. **Exuberant bullous vasculitis associated with SARS-CoV-2 infection.** IDCases 2021; 23:e01047Gouveia P, Cipriano IC, de Melo MAZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457205>
18. **The assessment of high sensitivity cardiac troponin in patients with COVID-19: a multicenter study.** Int J Cardiol Heart Vasc 2021; 32:100715Alfonso Perrone M, Spolaore F, Ammirabile M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457490>
19. **Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?** Int. J. Hematol. 2021:1-7Iba T, Connors JM, Spyropoulos AC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33471294>
20. **A Unique Tale of COVID-19 Induced Concomitant Overt DIC and Acute Bilateral Pulmonary Embolism.** Int J Infect Dis 2021; Siddiqui SN, Jayasekhar R, Tshering S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486013>
21. **EXPRESS: Global Impact of the COVID-19 Pandemic on Stroke Hospitalizations and Mechanical Thrombectomy Volumes.** Int. J. Stroke 2021:1747493021991652Nogueira R, Abdalkader M, Qureshi MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459583>
22. **Myocarditis in COVID-19 patients: current problems.** Intern Emerg Med 2021:1-7Mele D, Flamigni F, Rapezzi C, Ferrari R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484452>
23. **Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis: JACC Review Topic of the Week.** J Am Coll Cardiol 2021; 77:314-325Kawakami R, Sakamoto A, Kawai K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478655>

24. **First clinical use of real-time remote programming in cardiac implantable electronic devices.** J Cardiovasc Electrophysiol 2020; 31:2759-2761 Okabe T, Afzal MR, Hummel JD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33462860>
25. **The Impact of COVID-19 on In-Hospital Outcomes of ST-Segment Elevation Myocardial Infarction Patients.** J Clin Med 2021; 10 Ayad S, Shenouda R, Henein M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466588>
26. **Prognostic Implications of Chronic Heart Failure and Utility of NT-proBNP Levels in Heart Failure Patients with SARS-CoV-2 Infection.** J Clin Med 2021; 10 Belarte-Tornero LC, Valdivielso-Moré S, Vicente Elcano M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477268>
27. **Advanced echocardiographic phenotyping of critically ill patients with coronavirus-19 sepsis: a prospective cohort study.** J Intensive Care 2021; 9:12 Bagate F, Masi P, d'Humières T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472693>
28. **Outpatient initiation of dofetilide: insights from the complexities of atrial fibrillation management during the COVID-19 lockdown.** J. Interv. Card. Electrophysiol. 2021; 1-8 Mascarenhas DAN, Mudumbi PC, Kantharia BK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484394>
29. **Intracranial Hemorrhage in COVID-19 Patients.** J. Stroke Cerebrovasc. Dis. 2021; 30:105603 Mishra S, Choueka M, Wang Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484980>
30. **Cardiac Arrests During the COVID-19 Pandemic: The Perfect Storm.** JACC Clin Electrophysiol 2021; 7:12-15 Mitrani RD, Goldberger JJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478703>
31. **Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19.** JACC Clin Electrophysiol 2021; 7:16-25 O'Connell TF, Bradley CJ, Abbas AE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478708>
32. **Out-of-Hospital Cardiac Arrest Response and Outcomes During the COVID-19 Pandemic.** JACC Clin Electrophysiol 2021; 7:6-11 Uy-Evanado A, Chugh HS, Sargsyan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478713>
33. **Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19.** Med. Hypotheses 2021; 147:110486 Vitiello A, La Porta R, Ferrara F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33460992>
34. **[Acute myocardial infarction in patients recovering from COVID-19 pneumonia].** Medicina (B. Aires) 2020; 80 Suppl 6:97-99 Trivi M, Lalor N, Spaletta P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481739>
35. **The cardiovascular disorders and prognostic cardiac biomarkers in COVID-19.** Mol. Biol. Rep. 2021; Shi X, Chen M, Zhang Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33483864>
36. **Ischaemic stroke as an initial presentation in patients with COVID-19: evaluation of a case series in an emergency in Brazil.** Neuroradiol. J. 2021; 1971400920987357 Oliveira IB, Pessoa MS, Lima CF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33455541>
37. **Lockdown-related factors associated with the worsening of cardiovascular risk and anxiety or depression during the COVID-19 pandemic.** Prev Med Rep 2021; 21:101300 Bérard E, Huo Yung Kai S, Coley N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457196>

38. **Subacute stent thrombosis in a patient with COVID-19 pneumonia.** Proc. (Bayl. Univ. Med. Cent.) 2020; 34:175-177 Ayan M, Kovelamudi S, Al-Hawwas M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33456191>
39. **Ascending aortic thrombus with multiple emboli associated with COVID-19.** Proc. (Bayl. Univ. Med. Cent.) 2020; 34:178-179 Schmidt P, Vasquez J, Gagliano B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456192>
40. **The effect of the COVID-19 pandemic on acute coronary syndrome hospitalizations and out-of-hospital cardiac arrest in Greece.** Public Health 2020; 191:17-19 Kapelios CJ, Siafarikas C, Bonou M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33472127>
41. **Impact of the COVID-19 Pandemic on Hospitalizations for Acute Coronary Syndromes: a Multinational Study.** QJM 2021; Araiza-Garaygordobil D, Montalto C, Martinez-Amezcu P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486512>
42. **Public defibrillator accessibility and mobility trends during the COVID-19 pandemic in Canada.** Resuscitation 2021; Leung KHB, Alam R, Brooks SC, Chan TCY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482269>
43. **An increase in CD62L(dim) neutrophils precedes the development of pulmonary embolisms in COVID-19 patients.** Scand. J. Immunol. 2021:e13023 Spijkerman R, Jorritsma NK, Bongers SH *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33482019>
44. **Takotsubo Syndrome a Rare Entity in COVID-19: a Systemic Review-Focus on Biomarkers, Imaging, Treatment, and Outcome.** SN Compr Clin Med 2021:1-11 Sharma K, Desai HD, Patoliya JV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458567>
45. **Utility of D-dimer in predicting venous thromboembolism in non-mechanically ventilated COVID-19 survivors.** Thromb Res 2020; 199:82-84 Nauka PC, Baron SW, Assa A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476901>
46. **Altered Cholesterol and Lipid Synthesis Mediates Hyperinflammation in COVID-19.** Trends Endocrinol. Metab. 2021; Sohrabi Y, Reinecke H, Godfrey R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33455862>

Diagnosis (13 articles)

1. **A rapid diagnosis of SARS-CoV-2 using DNA hydrogel formation on microfluidic pores.** Biosens. Bioelectron. 2021; 177:113005 Kim HS, Abbas N, Shin S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486135>
2. **Should ct be used for the diagnosis of RT-PCR negative suspected COVID-19 patients?** Clin. Respir. J. 2021; Rona G, Arifoğlu M, Voyvoda N, Batirel A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484085>
3. **Cardiac MRI and Myocardial Injury in COVID-19: Diagnosis, Risk Stratification and Prognosis.** Diagnostics (Basel) 2021; 11:113005 Sanghvi SK, Schwarzman LS, Nazir NT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467705>
4. **Medical Students and COVID-19: Knowledge, Preventive Behaviors, and Risk Perception.** Int J Environ Res Public Health 2021; 18:18181 Alsoghair M, Almazyad M, Alburaykan T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478172>
5. **Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis: JACC Review Topic of the Week.** J Am Coll Cardiol 2021; 77:314-325 Kawakami R, Sakamoto A, Kawai K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478655>

6. **Accurate detection of Covid-19 patients based on Feature Correlated Naïve Bayes (FCNB) classification strategy.** *J Ambient Intell Humaniz Comput* 2021;1-33Mansour NA, Saleh AI, Badawy M, Ali HA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469467>
7. **COVID-19 diagnosis from chest X-ray images using transfer learning: Enhanced performance by debiasing dataloader.** *J Xray Sci Technol* 2021; Polat Ç, Karaman O, Karaman C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459685>
8. **[Analysis of the first 100 patients with COVID-19 admitted to internal medicine wards at the Hospital de Clínicas José de San Martín, Buenos Aires University].** *Medicina (B. Aires)* 2020; 80 Suppl 6:48-55Ludueña MG, Labato M, Chiaradia V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481733>
9. **[Sorting and detection of COVID-19 by low-dose thoracic CT scan in patients consulting the radiology department of Fann hospital (Dakar-Senegal)].** *Pan Afr. Med. J.* 2020; 37:22Niang I, Diallo I, Diouf JCN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456646>
10. **[Differential clinic in children infected by SARS-CoV-2, traceability of contacts and cost-effectiveness of diagnostic tests: Cross-sectional observational study].** *An Pediatr (Barc)* 2020; Fiel-Ozores A, González-Durán ML, Novoa-Carballal R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485824>
11. **Robust Detection of COVID-19 in Cough Sounds: Using Recurrence Dynamics and Variable Markov Model.** *SN Comput Sci* 2021; 2:34Mouawad P, Dubnov T, Dubnov S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458700>
12. **The Many Faces of Covid-19: Organizing Pneumonia (OP) Pattern HRCT Features.** *Transl Med UniSa* 2020; 23:16-18Rea G, Valente T, Lieto R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457315>
13. **Differences between radiological findings of COVID-19 and non-COVID-19 infections in pediatric patients.** *World J Pediatr* 2021; Kuzan BN, Aslan B, Kuzan TY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33460024>

DM-MS-Obesity (11 articles)

1. **Eating in the lockdown during the Covid 19 pandemic; self-reported changes in eating behaviour, and associations with BMI, eating style, coping and health anxiety.** *Appetite* 2021:105082Coulthard H, Sharps M, Cunliffe L, van den Tol A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476651>
2. **A Case of Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes Mellitus and COVID-19.** *Cureus* 2020; 12:e12029Morrison N, Barnett K, Tantum J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457131>
3. **Good is not good enough: Why diabetes care at hospitals are so important precisely in times of corona.** *Diabetes Aktuell* 2020; 18:310-311.
4. **Practical recommendations of the German Diabetes Society for the management of diabetes in patients with COVID-19.** *Diabetologe* 2021; Bornstein SR, Gallwitz B, Kellerer M *et al.*
5. **Diabetes Might Augment the Severity of COVID-19: A Current Prospects.** *Front Cardiovasc Med* 2020; 7:613255Sur J, Sharma J, Sharma D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469551>
6. **In silico evaluation of lapachol derivatives binding to the Nsp9 of SARS-CoV-2.** *J Biomol Struct Dyn* 2021:1-15Junior NN, Santos IA, Meireles BA *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478342>
7. **Predictors of Mortality in a Multi-Racial Urban Cohort of Persons with Type 2 Diabetes and Novel Coronavirus 19.** J. Diabetes 2021; Myers AK, Kim TS, Zhu X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486896>
 8. **How to Best Protect People With Diabetes From the Impact of SARS-CoV-2: Report of the International COVID-19 and Diabetes Summit.** J. Diabetes Sci. Technol. 2021:1932296820978399Zhang JY, Shang T, Ahn D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476193>
 9. **Obesity surgery and COVID-19 pandemic: What is the suitable attitude to adopt?** J Visc Surg 2020; Sterkers A, Blanchet MC, Genser L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461888>
 10. **Diabetic foot and COVID-19. Medical consultation and severity of lesions compared to 2019.** Medicina (B. Aires) 2020; 80 Suppl 6:30-34Carro GV, Carlucci EM, Torterola I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481730>
 11. **SARS-CoV-2 and Obesity: "CoVesity"-a Pandemic Within a Pandemic.** Obes. Surg. 2021:1-10Zakka K, Chidambaram S, Mansour S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33479921>

Education and training and science (38 articles)

1. **Adaptive strategies to conduct participant-centric structured virtual group discussions for postgraduate students in the wake of the COVID-19 pandemic.** Adv. Physiol. Educ. 2021; 45:37-43Kaur S, Bir M, Chandran DS, Deepak KK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33464190>
2. **Androgens, Kidney and COVID-19: An Opportunity for Translational Research.** Am J Physiol Renal Physiol 2021; Yanes Cardozo LL, Rezq S, Pruett JE, Romero DG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33464168>
3. **Communications in the time of a pandemic: the readability of documents for public consumption.** Aust. N. Z. J. Public Health 2021; Ferguson C, Merga M, Winn S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33460234>
4. **Nonlinear adaptive control of COVID-19 with media campaigns and treatment.** Biochem. Biophys. Res. Commun. 2021; Cao B, Kang T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461738>
5. **A protocol for adding knowledge to Wikidata: aligning resources on human coronaviruses.** BMC Biol. 2021; 19:12Waagmeester A, Willighagen EL, Su AI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482803>
6. **Quality and readability of web-based Arabic health information on COVID-19: an infodemiological study.** BMC Public Health 2021; 21:151Halboub E, Al-Ak'hali MS, Al-Mekhlafi HM, Alhajj MN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461516>
7. **Research Evaluation Alongside Clinical Treatment in COVID-19 (REACT COVID-19): an observational and biobanking study.** BMJ Open 2021; 11:e043012Burke H, Freeman A, Dushianthan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33483446>
8. **Factors associated with adherence to COVID-19 prevention measures in the Democratic Republic of the Congo (DRC): results of an online survey.** BMJ Open 2021; 11:e043356Ditekemena JD, Nkamba DM, Muhindo HM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33462101>

9. **COVID-19 Pandemic 101: An Epidemiology and Public Health Primer for Oncology Nurses.** Clin. J. Oncol. Nurs. 2021; 25:33-40Yackzan S, Mahon SM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480886>
10. **Health Behaviors of Higher Education Students from 7 Countries: Poorer Sleep Quality during the COVID-19 Pandemic Predicts Higher Dietary Risk.** Clocks Sleep 2021; 3:12-30Du C, Zan MCH, Cho MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467418>
11. **The Association between Future Anxiety, Health Literacy and the Perception of the COVID-19 Pandemic: A Cross-Sectional Study.** Healthcare (Basel) 2021; 9Duplaga M, Grysztar M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466487>
12. **Developing the eMedical Student (eMS)-A Pilot Project Integrating Medical Students into the Tele-ICU during the COVID-19 Pandemic and beyond.** Healthcare (Basel) 2021; 9Ho J, Susser P, Christian C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466781>
13. **Determinants of Behavioral Changes Since COVID-19 among Middle School Students.** Healthcare (Basel) 2021; 9Lee J, Allen J, Lim H, Choi G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466851>
14. **COVID 19: A Cause for Pause in Undergraduate Medical Education and Catalyst for Innovation.** HEC Forum 2021:1-18Southworth E, Gleason SH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481144>
15. **Essentials of setting up a wet lab for ophthalmic surgical training in COVID-19 pandemic.** Indian J Ophthalmol 2021; 69:410-416Mishra D, Bhatia K, Verma L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33463600>
16. **Medical Students and COVID-19: Knowledge, Preventive Behaviors, and Risk Perception.** Int J Environ Res Public Health 2021; 18Alsoghair M, Almazyad M, Alburaykan T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478172>
17. **Medical Studies during the COVID-19 Pandemic: The Impact of Digital Learning on Medical Students' Burnout and Mental Health.** Int J Environ Res Public Health 2021; 18Zis P, Artemiadis A, Bargiotas P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466459>
18. **Knowledge, Practice, and Attitude Toward COVID-19 Among Physicians in Jordan and Palestine: Cross-Sectional Study.** Int. J. Gen. Med. 2021; 14:77-87Al Demour S, Ababneh MA, Al-Taher RN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469347>
19. **Most notable 100 articles of COVID-19: an Altmetric study based on bibliometric analysis.** Ir. J. Med. Sci. 2021; Borku Uysal B, Islamoglu MS, Koc S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459942>
20. **Deep Learning applications for COVID-19.** J Big Data 2021; 8:18Shorten C, Khoshgoftaar TM, Furht B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457181>
21. **Repurposing Biomedical Informaticians for COVID-19.** J. Biomed. Inform. 2021:103673Sosa DN, Chen B, Kaushal A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486067>
22. **A study of community knowledge, attitudes, practices, and health in Pakistan during the COVID-19 pandemic.** J. Community Psychol. 2021; Nadeem M, Khaliq N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465247>
23. **Healthcare Workers' Knowledge, Attitude, Practice and Perceived Health Facility Preparedness Regarding COVID-19 in Sierra Leone.** J Multidiscip Healthc 2021; 14:67-80Kanu S, James PB, Bah AJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469299>

24. **COVID-19 Vaccination: An Overview and Education Tool for Nuclear Medical Technologists.** *J. Nucl. Med. Technol.* 2021; Barnswell LH, 3rd, Crosthwaite MH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33483330>
25. **Providing Compassionate Care: The Role of Medical Students and Videoconference Technology in the COVID-19 Pandemic.** *J Patient Exp* 2020; 7:1002-1006 Suresh D, Flatley K, McDonough M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457538>
26. **Where Do We Go From Here? Assessing Medical Students' Surgery Clerkship Preparedness During COVID-19.** *J Surg Educ* 2021; Nnamani Silva ON, Hernandez S, Kim AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485827>
27. **Disrupting the Fellowship Match: COVID-19 and the Applicant Arms Race.** *J Surg Educ* 2020; Swendiman RA, Jones RE, Blinman TA, Krummel T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468442>
28. **COVID-19-Related Knowledge and Practices Among Health Care Workers in Saudi Arabia: Cross-sectional Questionnaire Study.** *JMIR Form Res* 2021; 5:e21220 Shaikhain TA, Al-Husayni FA, Alhejaili EA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33460390>
29. **Online Obstetrics and Gynecology Medical Students Clerkship During the Covid-19 Pandemic: a Pilot Study.** *Med Sci Educ* 2021:1-5 Armon S, Benyamini Y, Grisaru-Granovsky S, Avitan T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457067>
30. **Transition in learning during COVID-19: Student nurse anxiety, stress, and resource support.** *Nurs. Forum* 2021; Fitzgerald A, Konrad S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484171>
31. **Promotion of unproved and potential dangerous measures in fighting COVID-19 pandemic: urgent need for vigilant appropriate public communication and generation of scientific evidence.** *Pan Afr. Med. J.* 2020; 37:29 Kalabamu FS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456653>
32. **Opportunities to improve COVID-19 provider communication resources: A systematic review.** *Patient Educ. Couns.* 2021; Wittenberg E, Goldsmith JV, Chen C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33455825>
33. **Deep vein thrombosis in COVID-19 patients in general wards: prevalence and association with clinical and laboratory variables.** *Radiol Med* 2021:1-7 Ierardi AM, Gaibazzi N, Tuttolomondo D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469817>
34. **While quarantined: An online parent education and training model for families of children with autism in China.** *Res. Dev. Disabil.* 2021; 109:103851 McDevitt SE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465589>
35. **COVID-19 and Clinical Trials: Current Challenges and Future Directions.** *Rev. Recent Clin. Trials* 2021; Singh V, Garg S, Klimek M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480349>
36. **Letter to Article: COVID 19 SCIENTIFIC PUBLICATIONS FROM TURKEY.** *Turk J Med Sci* 2021; Uyaroğlu OA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486916>
37. **Virtual skills-training in urology: Teaching at the Technical University of Munich during the COVID-19-pandemic.** *Urologe* 2021; Kidess M, Schmid SC, Pollak S *et al.*
38. **Identifying factors that influenced wellbeing and learning effectiveness during the sudden transition into eLearning due to the COVID-19 lockdown.** *Work*

Elderly (12 articles)

1. **"We have become prisoners of our own age": From a continuing care retirement community to a total institution in the midst of the COVID-19 outbreak.** *Age Ageing* 2021; Ayalon L, Avidor S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481987>
2. **COVID-19 testing in English care homes and implications for staff and residents.** *Age Ageing* 2021; Micocci M, Gordon AL, Allen AJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481986>
3. **"Getting back to normality seems as big of a step as going into lockdown": The Impact of the COVID-19 Pandemic on People with Early-Middle Stage Dementia.** *Age Ageing* 2021; Talbot CV, Briggs P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481988>
4. **Predictors for development of critical illness amongst older adults with COVID-19: Beyond age to age-associated factors.** *Arch. Gerontol. Geriatr.* 2020; 94:104331 Lim JP, Low KYH, Lin NJJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476755>
5. **COVID-19-related social support service closures and mental well-being in older adults and those affected by dementia: a UK longitudinal survey.** *BMJ Open* 2021; 11:e045889 Giebel C, Pulford D, Cooper C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33455941>
6. **Age-associated difference in circulating ACE2, the gateway for SARS-COV-2, in humans: results from the InCHIANTI study.** *Geroscience* 2021:1-9 AlGhatrif M, Tanaka T, Moore AZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33462706>
7. **Level of the SARS-CoV-2 receptor ACE2 activity is highly elevated in old-aged patients with aortic stenosis: implications for ACE2 as a biomarker for the severity of COVID-19.** *Geroscience* 2021:1-11 Fagyas M, Kertész A, Siket IM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469835>
8. **D-dimer levels is associated with severe COVID-19 infections: A meta-analysis.** *Int J Clin Pract* 2021:e14031 Wu ZH, Cheng Q. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33474792>
9. **A Commentary on Blue Zones®: A Critical Review of Age-Friendly Environments in the 21st Century and Beyond.** *Int J Environ Res Public Health* 2021; 18 Marston HR, Niles-Yokum K, Silva PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478140>
10. **Severe COVID-19 Lung Infection in Older People and Periodontitis.** *J Clin Med* 2021; 10 Aquino-Martinez R, Hernández-Vigueras S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466585>
11. **Physical and Mental Health of Older People while Cocooning during the COVID-19 Pandemic.** *QJM* 2021; Bailey L, Ward M, DiCosimo A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33471128>
12. **Impact of the COVID-19 pandemic on the mortality of the elderly patient with a hip fracture.** *Rev. Esp. Anesthesiol. Reanim.* 2020; Biarnés-Suñé A, Solà-Enríquez B, González Posada M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461768>

Epidemiology (72 articles)

1. **COVID-19 testing in English care homes and implications for staff and residents.** *Age Ageing* 2021; Micocci M, Gordon AL, Allen AJ *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33481986>
2. **SARS-CoV-2 pandemic in the Brazilian community of rare diseases: A patient reported survey.** *Am. J. Med. Genet. C Semin. Med. Genet.* 2021; Schwartz IVD, Randon DN, Monsorres N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33474836>
3. **COVID-TRACK: world and USA SARS-COV-2 testing and COVID-19 tracking.** *BioData Min.* 2021; 14:4Zohner YE, Morris JS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33472672>
4. **Using Baidu search values to monitor and predict the confirmed cases of COVID-19 in China: - evidence from Baidu index.** *BMC Infect. Dis.* 2021; 21:98Tu B, Wei L, Jia Y, Qian J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478425>
5. **Evaluation and improvement of the National Early Warning Score (NEWS2) for COVID-19: a multi-hospital study.** *BMC Med* 2021; 19:23Carr E, Bendayan R, Bean D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472631>
6. **Efficient SARS-CoV-2 surveillance strategies to prevent deadly outbreaks in vulnerable populations.** *BMC Med* 2021; 19:25Toth DJA, Khader K.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33478447>
7. **Navigating inequities: a roadmap out of the pandemic.** *BMJ Glob Health* 2021; 6Ismail SJ, Tunis MC, Zhao L, Quach C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33479019>
8. **Factors associated with adherence to COVID-19 prevention measures in the Democratic Republic of the Congo (DRC): results of an online survey.** *BMJ Open* 2021; 11:e043356Ditekemena JD, Nkamba DM, Muhindo HM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33462101>
9. **Socio-demographic, social, cognitive, and emotional correlates of adherence to physical distancing during the COVID-19 pandemic: a cross-sectional study.** *Can. J. Public Health.* 2021:1-12Gouin JP, MacNeil S, Switzer A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33464556>
10. **Spatiotemporal variability of COVID-19 pandemic in relation to air pollution, climate and socioeconomic factors in Pakistan.** *Chemosphere* 2021; 271:129584Mehmood K, Bao Y, Abrar MM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33482526>
11. **Population-based Estimates of COVID-19-like Illness, COVID-19 Illness, and Rates of Case Ascertainment, Hospitalizations, and Deaths - Non-Institutionalized New York City Residents, March-April 2020.** *Clin Infect Dis* 2021; Alroy KA, Crossa A, Dominianni C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33458740>
12. **Evaluation of SARS-CoV-2 transmission mitigation strategies on a university campus using an agent-based network model.** *Clin Infect Dis* 2021; Goyal R, Hotchkiss J, Schooley RT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33462589>
13. **Reopening Schools and the Dynamics of SARS-CoV-2 Infections in Israel: A Nationwide Study.** *Clin Infect Dis* 2021; Somekh I, Shohat T, Boker LK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33460434>
14. **COVID-19 Pandemic 101: An Epidemiology and Public Health Primer for Oncology Nurses.** *Clin. J. Oncol. Nurs.* 2021; 25:33-40Yackzan S, Mahon SM.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33480886>

15. **Awareness, acceptance, and adoption of the national digital contact tracing tool post COVID-19 lockdown among visitors of a public hospital in Singapore.** Clin Microbiol Infect 2021; Huang Z, Guo H, YeeFen Lim H, Chow A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482353>
16. **Reopening schools safely in the face of COVID-19: Can cluster randomized trials help?** Clin. Trials 2021:1740774520984860Weijer C, Hemming K, Phillips Hey S, Fernandez Lynch H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472432>
17. **COVID-19 Australia: Epidemiology Report 32: Four-week reporting period ending 3 January 2021.** Commun Dis Intell (2018) 2021; 45. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33460555>
18. **SARS-CoV-2 in Mexico: Beyond Detection Methods, Scope and Limitations.** Diagnostics (Basel) 2021; 11Martinez-Liu C, Martínez-Acuña N, Arellanos-Soto D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466884>
19. **Observations on the Occurrence, Transmission and Management of the COVID-19 Pandemic Derived from Physics.** Diseases 2021; 9Ingersoll JG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467041>
20. **Examining geographical disparities in the incubation period of the COVID-19 infected cases in Shenzhen and Hefei, China.** Environ. Health Prev. Med. 2021; 26:10Xiao Z, Guo W, Luo Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461491>
21. **Spatiotemporal mapping and assessment of daily ground NO₂ concentrations in China using high-resolution TROPOMI retrievals.** Environ Pollut 2021; 273:116456Wu S, Huang B, Wang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477063>
22. **Estimating the minimum number of SARS-CoV-2 infected cases needed to detect viral RNA in wastewater: To what extent of the outbreak can surveillance of wastewater tell us?** Environ. Res. 2021:110748Hong PY, Rachmadi AT, Mantilla-Calderon D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465345>
23. **Persistently high SARS-CoV-2 positivity rate and incidence for Hispanic/Latinos during state reopening in an urban setting: a retrospective cohort study.** Epidemiol Infect 2021; 149:e25Weng CH, Saal A, McGuire DC, Chan PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33455608>
24. **Confronting COVID-19 in under-resourced, African American neighborhoods: a qualitative study examining community member and stakeholders' perceptions.** Ethn. Health 2021:1-19Bateman LB, Schoenberger YM, Hansen B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472411>
25. **Demographic predictors of hospitalization and mortality in US children with COVID-19.** Eur. J. Pediatr. 2021:1-5Moreira A, Chorath K, Rajasekaran K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33474580>
26. **Health Inequalities and Ethnic Vulnerabilities During COVID-19 in the UK: A Reflection on the PHE Reports.** Fem Leg Stud 2021:1-12Keys C, Nanayakkara G, Onyejekwe C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469247>
27. **Distribution of the ACE1 D Allele in the Bosnian-Herzegovinian Population and its Possible Role in the Regional Epidemiological Picture of COVID-19.** Genet. Test. Mol. Biomarkers 2021; 25:55-58Cenanovic M, Dogan S, Asic A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33470888>
28. **COVID-19 in Rural Nigeria: Diminishing Social Support for Older People in Nigeria.** Gerontol Geriatr Med 2020; 6:2333721420986301Ekoh PC, Agbawodikeizu

- PU, Ejimkararonye C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457460>
29. **COVID-19 in Germany and China: mitigation versus elimination strategy.** Glob Health Action 2021; 14:1875601 Lu G, Razum O, Jahn A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472568>
30. **Lockdowns and low- and middle-income countries: building a feasible, effective, and ethical COVID-19 response strategy.** Global Health 2021; 17:13 Eyawo O, Viens AM, Ugoji UC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472638>
31. **Estimation of COVID-19 epidemic curves using genetic programming algorithm.** Health Informatics J 2021; 27:1460458220976728 Andelić N, Baressi Šegota S, Lorencin I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459107>
32. **China health technology and stringency containment measures during COVID-19 pandemic: A discussion of first and second wave of COVID-19.** Health Technol (Berl) 2021; 1-6 Abbas HSM, Xu X, Sun C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33462559>
33. **A Case Series: Successfully Preventing COVID-19 Outbreak in a Residential Community Setting at a Drug and Alcohol Addiction Treatment Center.** Healthcare (Basel) 2021; 9 Hanton K, McHugh D, Boris G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477319>
34. **COVID-19 in China: Responses, Challenges and Implications for the Health System.** Healthcare (Basel) 2021; 9 Xing C, Zhang R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466996>
35. **A primer on using mathematics to understand COVID-19 dynamics: Modeling, analysis and simulations.** Infect Dis Model 2021; 6:148-168 Gumel AB, Iboi EA, Ngonghala CN, Elbasha EH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33474518>
36. **Analysis of the Spread of COVID-19 in the USA with a Spatio-Temporal Multivariate Time Series Model.** Int J Environ Res Public Health 2021; 18 Rui R, Tian M, Tang ML *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477576>
37. **Epidemiology, characteristics, and outcomes of hospitalized children with COVID-19 in Oman: A multicenter cohort study.** Int J Infect Dis 2021; Al Yazidi LS, Al Hinai Z, Al Waili B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476759>
38. **Seroprevalence of antibodies to SARS-CoV-2 among blood donors in the early month of the pandemic in Saudi Arabia.** Int J Infect Dis 2021; Banjar A, Al-Tawfiq JA, Alruwaily A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465488>
39. **COVID-19 within a large prison with high number of vulnerable adults in the UK, March to June 2020: an outbreak investigation and screening event.** Int J Infect Dis 2021; Wilburn J, Blakey E, Trindall A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465486>
40. **A quantitative exploration of symptoms in COVID-19 patients: an observational cohort study.** Int. J. Med. Sci. 2021; 18:1082-1095 Qu G, Chen J, Huang G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456367>
41. **Accurate detection of Covid-19 patients based on Feature Correlated Naïve Bayes (FCNB) classification strategy.** J Ambient Intell Humaniz Comput 2021; 1-33 Mansour NA, Saleh AI, Badawy M, Ali HA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469467>
42. **A mathematical model for COVID-19 pandemic-SIIR model: Effects of asymptomatic individuals.** J Gen Fam Med 2021; 22:5-14 Tomochi M, Kono M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457150>

43. **Impact of a Long-Term Air Pollution Exposure on the Case Fatality Rate of COVID-19 Patients - A Multi-City Study.** *J Med Virol* 2021; Hou CK, Qin YF, Wang G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33470428>
44. **The effectiveness of active surveillance measures for COVID-19 cases in Pudong New Area Shanghai, China, 2020.** *J Med Virol* 2021; Liu H, Ye C, Wang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33463732>
45. **"Ten years of war! You expect people to fear a 'germ'?" : A qualitative study of initial perceptions and responses to the COVID-19 pandemic among displaced communities in opposition-controlled northwest Syria.** *J Migr Health* 2020; 1-2:100021 Douedari Y, Alhaffar M, Al-Twaish M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458715>
46. **Socio-demographic factors associated with self-protecting behavior during the Covid-19 pandemic.** *J Popul Econ* 2021:1-48 Papageorge NW, Zahn MV, Belot M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33462529>
47. **Spread of COVID-19 in urban neighbourhoods and slums of the developing world.** *J R Soc Interface* 2021; 18:20200599 Sahasranaman A, Jensen HJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468021>
48. **Understanding How Race, Ethnicity, and Gender Shape Mask-Wearing Adherence During the COVID-19 Pandemic: Evidence from the COVID Impact Survey.** *J Racial Ethn Health Disparities* 2021:1-8 Hearne BN, Niño MD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469866>
49. **Seroprevalence and seroconversions for SARS-CoV-2 infections in workers at Bogota Airport, Colombia 2020.** *J Travel Med* 2021; Malagón-Rojas JN, Rubio V, Parra-Barrera E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480402>
50. **Digital Contact Tracing Based on a Graph Database Algorithm for Emergency Management During the COVID-19 Epidemic: Case Study.** *JMIR Mhealth Uhealth* 2021; 9:e26836 Mao Z, Yao H, Zou Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33460389>
51. **Optimal control of the SIR model in the presence of transmission and treatment uncertainty.** *Math. Biosci.* 2021:108539 Gatto NM, Schellhorn H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33460674>
52. **Numerical simulation of the force of infection and the typical times of SARS-CoV-2 disease for different location countries.** *Model Earth Syst Environ* 2021:1-6 Al-Raei M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457496>
53. **The calculated responses against COVID-19 in Namibia.** *Pan Afr. Med. J.* 2020; 37:25 Amesho JN, Ahmadi A, Lucero-Prisno Iii DE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456649>
54. **COVID-19 pandemic response fatigue in Africa: causes, consequences, and counter-measures.** *Pan Afr. Med. J.* 2020; 37:37 Ilesanmi OS, Bello AE, Afolabi AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456661>
55. **Shortfalls in home quarantine for COVID-19 prevention: a case report.** *Pan Afr. Med. J.* 2020; 37:39 Mbenge CC, Tiale L, Ntoni L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456663>
56. **A descriptive study of the trends of COVID-19 in Zimbabwe from March-June 2020: policy and strategy implications.** *Pan Afr. Med. J.* 2020; 37:33 Murewanhema G, Burukai T, Mazingi D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456657>
57. **Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposure to adults with COVID-19: preliminary findings.** *Pediatr Pulmonol* 2021;

- Buonsenso D, Valentini P, De Rose C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33470561>
58. **Time series forecasting of COVID-19 transmission in Asia Pacific countries using deep neural networks.** *Pers Ubiquitous Comput* 2021;1-18Rauf HT, Lali MIU, Khan MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456433>
 59. **The evolution of COVID-19: A discontinuous approach.** *Physica A* 2021; 568:125752Doménech-Carbó A, Doménech-Casasús C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456130>
 60. **Early relaxation of community mitigation policies and risk of COVID-19 resurgence in the United States.** *Prev. Med.* 2021;106435Hatef E, Kitchen C, Chang HY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486000>
 61. **The evolution of health care in the Texas correctional system and the impact of COVID-19.** *Proc. (Bayl. Univ. Med. Cent.)* 2020; 34:76-80Rao S, Ali K, Berdine G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456150>
 62. **Forecasting of COVID-19 cases using Deep learning models: Is it reliable and practically significant?** *Results Phys* 2021;103817Devaraj J, Madurai Elavarasan R, Pugazhendhi R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33462560>
 63. **The impact of closing schools on working from home during the COVID-19 pandemic: evidence using panel data from Japan.** *Rev Econ Househ* 2021;1-20Yamamura E, Tsustsui Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456424>
 64. **[Role of the information systems and e-health in the COVID-19 pandemic. A call to action.].** *Rev. Esp. Salud Publica* 2021; 95Martín Fernández A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33473100>
 65. **How artificial intelligence may help the Covid-19 pandemic: Pitfalls and lessons for the future.** *Rev Med Virol* 2020:e2205Malik YS, Sircar S, Bhat S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476063>
 66. **Duration of SARS-CoV-2 viral shedding in faeces as a parameter for wastewater-based epidemiology: Re-analysis of patient data using a shedding dynamics model.** *Sci Total Environ* 2021; 769:144549Miura F, Kitajima M, Omori R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477053>
 67. **Optimization using the firefly algorithm of ensemble neural networks with type-2 fuzzy integration for COVID-19 time series prediction.** *Soft comput* 2021;1-38Melin P, Sánchez D, Monica JC, Castillo O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456340>
 68. **Analysis of blood donors' characteristics and deferrals related to COVID-19 in Iran.** *Transfus. Apher. Sci.* 2021;103049Rafiee MH, Kafiabad SA, Maghsudlu M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468406>
 69. **A big-data driven approach to analyzing and modeling human mobility trend under non-pharmaceutical interventions during COVID-19 pandemic.** *Transp Res Part C Emerg Technol* 2021; 124:102955Hu S, Xiong C, Yang M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456212>
 70. **Maximum incubation period for COVID-19 infection: do we need to rethink the 14-day quarantine policy?** *Travel Med Infect Dis* 2021; 40:101976Bikbov B, Bikbov A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476809>
 71. **Waste disposal characteristics and data variability in a mid-sized Canadian city during COVID-19.** *Waste Manag* 2021; 122:49-54Richter A, Ng KTW, Vu HL, Kabir G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485254>
 72. **Stigma, Trust, and Procedural Integrity: Covid-19 Testing in Malawi.** *World Dev* 2021;105351Ferree K, Harris A, Dulani B *et al.*

Gastro-enterology (18 articles)

1. **Elastase and Exacerbation of Neutrophil Innate Immunity are Involved in Multi-Visceral Manifestations of COVID-19.** Allergy 2021; Guéant JL, Guéant-Rodriguez RM, Fromonot J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484168>
2. **80-year-old patient with jaundice after a severe Covid-19 infection.** Deutsche Medizinische Wochenschrift 2021; 146:13-14 Muehlenberg K, Tannapfel A, Pech O.
3. **Prevalence of Clostridioides difficile and Other Gastrointestinal Pathogens in Patients with COVID-19.** Dig. Dis. Sci. 2021:1-8 Laszkowska M, Kim J, Faye AS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33479861>
4. **Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population.** Dig. Liver Dis. 2020; Maconi G, Bosetti C, De Monti A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33483259>
5. **Reply: Dysbiosis in SARS-CoV-2 infected patients.** Gastroenterology 2021; Xu Z, Chan FK, Ng SC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484691>
6. **SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.** Gut 2021; Siegel CA, Melmed GY, McGovern DP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472895>
7. **Estimation of COVID-19 epidemic curves using genetic programming algorithm.** Health Informatics J 2021; 27:1460458220976728 Anđelić N, Baressi Šegota S, Lorencin I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459107>
8. **Acute appendicitis management during the COVID-19 pandemic: A prospective cohort study from a LARGE UK centre.** Int J Surg 2021; Antakia R, Xanthis A, Georgiades F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465496>
9. **More Severe Presentations of Acute Appendicitis During COVID-19.** J Gastrointest Surg 2021:1-3 Angeramo CA, Dreifuss NH, Schlottmann F, Rotholtz NA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469887>
10. **Vascular liver injury mimicking an intrahepatic cholangiocarcinoma in a COVID-19 patient.** J Med Virol 2021; Ugolotti MC, Pedrazzini M, Silini EM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458846>
11. **Panendoscopy and COVID-19: Positioning could reduce risk of contamination.** Laryngo- Rhino- Otologie 2021; 100:6-7 Walther LE.
12. **Absolute targets for HCV elimination and national health policy paradigms: Foreseeing future requirements.** Liver Int 2021; Kondili LA, Craxi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486885>
13. **[Impact of COVID-19 pandemic in liver transplantation in Argentina. Other collateral damage].** Medicina (B. Aires) 2020; 80 Suppl 6:71-82 Gondolesi GE, Reyes-Toso ML, Bisigniano L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481736>
14. **Successful non-directed living liver donor transplant for an infant with biliary atresia during the COVID-19 pandemic.** Pediatr. Transplant. 2020; 24:e13816 Feldman AG, Adams MA, Wachs ME *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33460202>
15. **A narrative review of the challenges and countermeasures in hepatoblastoma management during COVID-19 epidemic.** Transl Pediatr 2020; 9:840-848 Xu H, Zhou Y, Sun R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457307>

16. **COVID-19 after liver transplant: Mortality is comparable with other patient groups.** Z. Gastroenterol. 2020; 58:1162-1164 Franke K.
17. **Challenge of corona pandemic: Experiences from practice.** Z. Gastroenterol. 2020; 58:1289 Heil FJ.
18. **Management of acute severe ulcerative colitis during the COVID-19 pandemic.** Z. Gastroenterol. 2020; 58:1170 Hofmann-Aßmus M.

Guidelines (10 articles)

1. **Developing statewide remdesivir use criteria.** Am. J. Health Syst. Pharm. 2021; Fox ER, Shah M, Vinik R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33483744>
2. **New S2k guidelines for the inpatient treatment of COVID-19 patients published.** Atemwegs- und Lungenkrankheiten 2020; 46:739-740.
3. **The NICE COVID-19 rapid guideline on haematopoietic stem cell transplantation: development, implementation and impact.** Br. J. Haematol. 2021; Orchard K, Dignan FL, Lee J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33474730>
4. **COVID-19 Infection in Former Living Kidney Donors.** Clin. Transplant. 2021:e14230 Doshi MD, Tsapepas D, Prashar R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484065>
5. **Practical recommendations of the German Diabetes Society for the management of diabetes in patients with COVID-19.** Diabetologe 2021; Bornstein SR, Gallwitz B, Kellner M *et al.*
6. **DGGG and other professional societies - Update October 2020: Recommendations on SARS-CoV-2/COVID-19 in pregnancy, childbirth and puerperium.** Geburtshilfe Frauenheilkd. 2020; 80:1182-1190 Hagenbeck C, Hecher K, Pecks U *et al.*
7. **Personal protective equipment (PPE) guidance during a global pandemic: A statistical analysis of National perceived confidence, knowledge and educational deficits amongst UK-based doctors.** Int J Clin Pract 2021:e14029 Al-Hity S, Bhamra N, Kumar R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465833>
8. **An Evidence-Based Guide to SARS-CoV-2 Vaccination of Patients on Immunotherapies in Dermatology.** J Am Acad Dermatol 2021; Gresham LM, Marzario B, Dutz J, Kirchhof MG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482251>
9. **Expert Consensus on Clinical Practice of Burn Units in Shanghai during the COVID-19 Epidemic.** J Burn Care Res 2021; Ma B, Fan X, Kong W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484264>
10. **How to Best Protect People With Diabetes From the Impact of SARS-CoV-2: Report of the International COVID-19 and Diabetes Summit.** J. Diabetes Sci. Technol. 2021:1932296820978399 Zhang JY, Shang T, Ahn D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476193>

Imaging (26 articles)

1. **Enabling Your Radiology Business to Thrive Strategic Lessons Learned During the Initial and Subsequent Surges of the Covid-19 Pandemic.** Acad

- Radiol 2021; Kruskal JB, Rosen MP, Hara AK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33455861>
2. **Multi-Radiologist User Study for Artificial Intelligence-Guided Grading of COVID-19 Lung Disease Severity on Chest Radiographs.** Acad Radiol 2021; Li MD, Little BP, Alkasab TK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485773>
 3. **Temporal changes of haematological and radiological findings of the COVID-19 infection-a review of literature.** BMC Pulm. Med. 2021; 21:37Lim AYH, Goh JL, Chua MCW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482780>
 4. **Utility of visual coronary artery calcification on non-cardiac gated thoracic CT in predicting clinical severity and outcome in COVID-19.** Clin Imaging 2021; 74:123-130Nair AV, Kumar D, Yadav SK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485116>
 5. **The prognostic value of chest X-ray in patients with COVID-19 on admission and when starting CPAP.** Clin Med (Lond) 2021; 21:e14-e19Sargent W, Ali S, Kukran S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33479078>
 6. **Should ct be used for the diagnosis of RT-PCR negative suspected COVID-19 patients?** Clin. Respir. J. 2021; Rona G, Arifoğlu M, Voyvoda N, Batirel A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484085>
 7. **Cardiac MRI and Myocardial Injury in COVID-19: Diagnosis, Risk Stratification and Prognosis.** Diagnostics (Basel) 2021; 11Sanghvi SK, Schwarzman LS, Nazir NT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467705>
 8. **Automated processing of social media content for radiologists: applied deep learning to radiological content on twitter during COVID-19 pandemic.** Emerg Radiol 2021; Khurana S, Chopra R, Khurana B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459907>
 9. **Association of AI quantified COVID-19 chest CT and patient outcome.** Int. J. Comput. Assist. Radiol. Surg. 2021; Fang X, Kruger U, Homayounieh F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484428>
 10. **Deep Learning applications for COVID-19.** J Big Data 2021; 8:18Shorten C, Khoshgoftaar TM, Furht B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457181>
 11. **ADOPT: automatic deep learning and optimization-based approach for detection of novel coronavirus COVID-19 disease using X-ray images.** J Biomol Struct Dyn 2021:1-13Dhiman G, Chang V, Kant Singh K, Shankar A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33475019>
 12. **Advanced echocardiographic phenotyping of critically ill patients with coronavirus-19 sepsis: a prospective cohort study.** J Intensive Care 2021; 9:12Bagate F, Masi P, d'Humières T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472693>
 13. **COVID-19 detection and heatmap generation in chest x-ray images.** J Med Imaging (Bellingham) 2021; 8:014001Kusakunniran W, Karnjanapreechakorn S, Siriapisith T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457446>
 14. **Magnetic resonance imaging features of COVID-19-related cranial nerve lesions.** J. Neurovirol. 2021; Corrêa DG, Hygino da Cruz LC, Jr., Lopes FCR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33460014>
 15. **Perfusion patterns of peripheral pulmonary lesions in COVID-19 patients using contrast-enhanced ultrasound (CEUS): A case series.** J Ultrasound Med 2021; Safai Zadeh E, Beutel B, Dietrich CF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459393>

16. **COVID-19 diagnosis from chest X-ray images using transfer learning: Enhanced performance by debiasing dataloader.** J Xray Sci Technol 2021; Polat Ç, Karaman O, Karaman C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459685>
17. **Effect of Wearing a Face Mask on fMRI BOLD Contrast.** Neuroimage 2021;117752Law CSW, Lan PS, Glover GH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33460795>
18. **Impact of the COVID-19 pandemic on neuroimaging scan volumes at a teaching hospital.** Neuroradiol. J. 2021;1971400920988664Ginat DT, Kenniff J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472535>
19. **[Sorting and detection of COVID-19 by low-dose thoracic CT scan in patients consulting the radiology department of Fann hospital (Dakar-Senegal)].** Pan Afr. Med. J. 2020; 37:22Niang I, Diallo I, Diouf JCN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456646>
20. **Thermodynamic imaging calculation model on COVID-19 transmission and epidemic cities risk level assessment-data from Hubei in China.** Pers Ubiquitous Comput 2021;1-17Pang S, Wu J, Lu Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456432>
21. **Pediatric chest X-rays during the COVID-19 pandemic.** Radiologia (Roma) 2021; Aguirre Pascual E, Coca Robinot D, Gallego Herrero C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33483143>
22. **Evolution of chest CT scan manifestations in a patient recovered from COVID-19 severe pneumonia with acute respiratory distress syndrome.** Respir Med Case Rep 2021; 32:101342Maranatha D, Rahardjo P, Lusman R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457203>
23. **Early clinical and CT features of COVID-19 and community-acquired pneumonia from a fever observation ward in Ningbo, China.** Singapore Med J 2021; Qian G, Lin Y, Chen X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472338>
24. **Takotsubo Syndrome a Rare Entity in COVID-19: a Systemic Review-Focus on Biomarkers, Imaging, Treatment, and Outcome.** SN Compr Clin Med 2021;1-11Sharma K, Desai HD, Patoliya JV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458567>
25. **The Many Faces of Covid-19: Organizing Pneumonia (OP) Pattern HRCT Features.** Transl Med UniSa 2020; 23:16-18Rea G, Valente T, Lieto R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457315>
26. **Differences between radiological findings of COVID-19 and non-COVID-19 infections in pediatric patients.** World J Pediatr 2021; Kuzan BN, Aslan B, Kuzan TY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33460024>

Immune response (25 articles)

1. **Elastase and Exacerbation of Neutrophil Innate Immunity are Involved in Multi-Visceral Manifestations of COVID-19.** Allergy 2021; Guéant JL, Guéant-Rodriguez RM, Fromonot J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484168>
2. **Multisystem inflammatory syndrome in children related to COVID-19: An update regarding the presentation of two critically ill patients.** Arch. Argent. Pediatr. 2021; 119:e26-e35Taffarel P, Jorro Barón F, Rodríguez AP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458987>

3. **Hospital-wide SARS-CoV-2 antibody screening of staff in a university psychiatric centre in Belgium.** *BJPsych Open* 2021; 7:e40El Abdellati K, Coppens V, Goossens J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468277>
4. **Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients.** *Cancer Cell* 2021; Abdul-Jawad S, Baù L, Alaguthurai T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476581>
5. **Anti-SARS-CoV-2 IgM improves clinical sensitivity early in disease course.** *Clin. Biochem.* 2021; Higgins V, Fabros A, Wang XY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476578>
6. **Prevalence and socio-demographic factors of SARS-CoV-2 antibody in multi-ethnic healthcare workers.** *Clin Med (Lond)* 2021; 21:e5-e8Patel M, Nair M, Pirozzoli E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33479076>
7. **Development of SARS-CoV-2 Rapid Antibody Detection Kit and Study on Dynamic Changes in Antibodies in Infected Patients.** *Clin. Respir. J.* 2021; Wang H, Li X, Li T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484220>
8. **Anti-phospholipids antibodies and immune complexes in COVID-19 patients: a putative role in disease course for anti-annexin-V antibodies.** *Clin Rheumatol* 2021:1-7Cristiano A, Fortunati V, Cherubini F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33464429>
9. **Lack of Antibodies to SARS-CoV-2 among Blood Donors during COVID-19 Lockdown: A Study from Saudi Arabia.** *Healthcare (Basel)* 2021; 9Alandijany TA, El-Kafrawy SA, Al-Ghamdi AA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466554>
10. **Immunology, immunopathogenesis and immunotherapeutics of COVID-19; an overview.** *Int Immunopharmacol* 2021; 93:107364Mohamed Khosroshahi L, Rokni M, Mokhtari T, Noorbakhsh F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486333>
11. **Value of Immunizations during the COVID-19 Emergency.** *Int J Environ Res Public Health* 2021; 18Stefanati A, d'Anchera E, De Motoli F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477591>
12. **SARS-CoV-2 seroconversion among 4040 Egyptian healthcare workers in 12 resource-limited healthcare facilities: A prospective cohort study.** *Int J Infect Dis* 2021; Mostafa A, Kandil S, El-Sayed MH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484863>
13. **Clocks, Viruses, and Immunity: Lessons for the COVID-19 Pandemic.** *J. Biol. Rhythms* 2021:748730420987669Sengupta S, Ince L, Sartor F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480287>
14. **Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19.** *J. Clin. Immunol.* 2021; Azmy V, Kaman K, Tang D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459964>
15. **When Does the Cytokine Storm Begin in COVID-19 Patients? A Quick Score to Recognize It.** *J Clin Med* 2021; 10Cappanera S, Palumbo M, Kwan SH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467466>
16. **A cross-sectional seroprevalence for COVID-19 among healthcare workers in a tertiary care hospital in Taiwan.** *J Formos Med Assoc* 2021; Pan SC, Huang YS, Hsieh SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461841>
17. **Analytical performances of five SARS-CoV-2 whole-blood finger-stick IgG-IgM combined antibody rapid tests.** *J. Virol. Methods* 2021:114067Péré H, Bouassa RM, Tonen-Wolyec S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476707>

18. **Effective virus-neutralizing activities in antisera from the first wave of severe COVID-19 survivors.** JCI Insight 2021; Han Y, Liu P, Qiu Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33476301>
19. **Treatment of Severe COVID-19 with Convalescent Plasma in Bronx, NYC.** JCI Insight 2021; Yoon HA, Bartash R, Gendlina I *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33476300>
20. **SARS-CoV-2/human interactome reveals ACE2 locus crosstalk with the immune regulatory network in the host.** Pathog Dis 2021; Lite C, Ahmed S, Juliet MJ, Freddy AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469663>
21. **Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposure to adults with COVID-19: preliminary findings.** Pediatr Pulmonol 2021; Buonsenso D, Valentini P, De Rose C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33470561>
22. **Takotsubo Syndrome a Rare Entity in COVID-19: a Systemic Review-Focus on Biomarkers, Imaging, Treatment, and Outcome.** SN Compr Clin Med 2021:1-11 Sharma K, Desai HD, Patoliya JV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458567>
23. **Can we Turn off the "Covid-Biting-Tail" Inflammation?** Transl Med UniSa 2020; 23:39-41 Giudice V, Filippelli A, Selleri C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457321>
24. **Anti-HLA and anti-SARS-CoV2 Antibodies in Kidney Transplant Recipient with COVID-19.** Transpl Int 2021; Gandolfini I, Zanelli P, Palmisano A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33481306>
25. **Immuno-informatics approach for B-cell and T-cell epitope based peptide vaccine design against novel COVID-19 virus.** Vaccine 2021; Singh J, Malik D, Raina A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478787>

Management miscellaneous diseases (76 articles)

1. **SARS-CoV-2 and Cancer: Beyond Immunosuppression.** Acta Med Port 2021; Mendes Pedro D, Mendes Pedro MM, Valadas E, Hanscheid T.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33480839>
2. **Follow-up services for delirium after COVID-19-where now?** Age Ageing 2021; Rahman S, Byatt K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481990>
3. **Screening and brief intervention for substance use disorders in times of COVID-19: potential opportunities, adaptations, and challenges.** Am. J. Drug Alcohol Abuse 2021:1-6 Ghosh A, Sharma K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481639>
4. **Adapting ambulatory care learning environments in response to the COVID-19 pandemic.** Am. J. Health Syst. Pharm. 2021; Anderson SL, Bianco J, DeRemer CE.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33483738>
5. **Advancing ambulatory pharmacy practice through a crisis: Objectives and strategies used in an ambulatory care action team's response to the COVID-19 pandemic.** Am. J. Health Syst. Pharm. 2021; Do T, Luon S, Boothe K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33483755>
6. **Alteration of Auto-CPAP requirements in obstructive sleep apnea patients with COVID-19 history.** Am. J. Otolaryngol. 2021; 42:102919 Fidan V, Koyuncu H, Akin O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476971>

7. **The effect of national public health interventions for COVID-19 on emergency general surgery in Northland, New Zealand.** ANZ J Surg 2021; McGuinness MJ, Harmston C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33475217>
8. **Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes.** Best Pract. Res. Clin. Rheumatol. 2020;101657Grainger R, Machado PM, Robinson PC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468418>
9. **Impact of a pandemic on surgical neuro-oncology-maintaining functionality in the early phase of crisis.** BMC Surg. 2021; 21:40Hameed NUF, Ma Y, Zhen Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461509>
10. **Impact on health and provision of healthcare services during the COVID-19 lockdown in India: a multicentre cross-sectional study.** BMJ Open 2021; 11:e043590Raman R, Rajalakshmi R, Surya J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468529>
11. **The economic and psychological impact of cancellations of elective spinal surgeries in the COVID-19 era.** Br. J. Neurosurg. 2021:1-5Kaiser R, Svoboda N, Waldauf P, Netuka D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459075>
12. **Impact of COVID-19 Pandemic on Ovarian Cancer Management: Adjusting to the New Normal.** Cancer Manag. Res. 2021; 13:359-366Jacome LS, Deshmukh SK, Thulasiraman P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469377>
13. **Patients' Responses to the Sudden Interruption of Chemotherapy During the Outbreak of the Novel Coronavirus: A Cross-Sectional Study.** Cancer Manag. Res. 2021; 13:351-358Zhang H, Yin J, Wang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469376>
14. **Triple-Negative Breast Cancer and the COVID-19 Pandemic: Clinical Management Perspectives and Potential Consequences of Infection.** Cancers (Basel) 2021; 13Brown JM, Wasson MD, Marcato P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467411>
15. **Ambulatory Oncology: Infrastructure Development in Response to the COVID-19 Pandemic.** Clin. J. Oncol. Nurs. 2021; 25:41-47Yackzan S, Shah M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480885>
16. **The Global Impact of COVID-19 on Craniomaxillofacial Surgeons.** Craniomaxillofac. Trauma Reconstr. 2020; 13:157-167van der Tas J, Dodson T, Buchbinder D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456681>
17. **Implementing Hypertension Management Interventions in Immigrant Communities in the U.S.: a Narrative Review of Recent Developments and Suggestions for Programmatic Efforts.** Curr. Hypertens. Rep. 2021; 23:5Ali SH, Islam NS, Commodore-Mensah Y, Yi SS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33483867>
18. **Evaluation of urticaria patients before and during the period of the COVID-19 pandemic: A retrospective study.** Dermatol Ther 2021:e14800Akca HM, Tuncer Kara K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486861>
19. **Treating Melanoma in Situ During a Pandemic with Telemedicine and a Combination of Imiquimod, 5-Fluorouracil, and Tretinoin.** Dermatol Ther (Heidelb) 2021; Nahm WJ, Gwillim EC, Badiavas EV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458805>
20. **Delayed treatment of bacteremia during the COVID-19 pandemic.** Diagnosis (Berl) 2021; Miyagami T, Uehara Y, Harada T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33470952>

21. **Successful coping with SARS-CoV-2 infection of adult celiac patients assessed by telemedicine.** Dig. Liver Dis. 2021; Galli G, Esposito G, Dilaghi E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468430>
22. **Implementing a Pandemic Roster in a Specialty Emergency Department - Challenges & Benefits.** Emerg. Med. Australas. 2021; Au BWY, Tranquilino R, Apswoude G, Crock C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458933>
23. **The Double Effect of COVID-19 Confinement Measures and Economic Recession on High-Risk Drug Users and Drug Services.** Eur. Addict. Res. 2021:1-3Costa Storti C, Bretteville-Jensen AL, De Grauwe P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477135>
24. **Decreased volume of hip fractures observed during COVID-19 lockdown.** Eur. Geriatr. Med. 2021:1-8Ojeda-Thies C, Cuarental-García J, Ramos-Pascua LR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481186>
25. **Parkinson Patients' needs during COVID-19 pandemic in a red zone: a Framework Analysis of Open-Ended Survey Questions.** Eur. J. Neurol. 2021; Cavallieri F, Sireci F, Fioravanti V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33460507>
26. **Managing emerging challenges of Coronavirus disease 2019 (COVID-19) in dentistry.** Eur Oral Res 2020; 54:101-107Ak G, Gunay AY, Olley RC, Sen N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33474555>
27. **Knowledge, attitude and practice of dentists in Coronavirus disease 2019 pandemic in Turkey.** Eur Oral Res 2020; 54:86-91Tokuc B, Coskunes FM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33474553>
28. **Major Urological Cancer Surgery for Patients is Safe and Surgical Training Should Be Encouraged During the COVID-19 Pandemic: A Multicentre Analysis of 30-day Outcomes.** Eur Urol Open Sci 2021; Tan WS, Arianayagam R, Khetrapal P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458711>
29. **Postponed Dental Visits during the COVID-19 Pandemic and their Correlates. Evidence from the Nationally Representative COVID-19 Snapshot Monitoring in Germany (COSMO).** Healthcare (Basel) 2021; 9Hajek A, De Bock F, Huebl L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466552>
30. **Resurgence of combined intravenous Ketamine and regional anesthesia in pediatric ocular surgery in COVID-19 pandemic.** Indian J Ophthalmol 2021; 69:395-399Rajput VK, Tuvar S, Bhalsing S, Bhalsing S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33463598>
31. **Primary and Secondary Health Impacts of COVID-19 among Minority Individuals in New York State.** Int J Environ Res Public Health 2021; 18Clay LA, Rogus S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466938>
32. **The Impact of the SARS-CoV-2 Outbreak on the Psychological Flexibility and Behaviour of Cancelling Medical Appointments of Italian Patients with Pre-Existing Medical Condition: The "ImpACT-COVID-19 for Patients" Multi-Centre Observational Study.** Int J Environ Res Public Health 2021; 18Deledda G, Riccardi N, Gori S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466374>
33. **Detrimental Health Behaviour Changes among Females Living in Rural Areas during the COVID-19 Pandemic.** Int J Environ Res Public Health 2021; 18Glenister KM, Ervin K, Podubinski T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467693>
34. **Response of L V Prasad Eye Institute to COVID-19 outbreak in India: experience at its tertiary eye care centre and adoption to its Eye Health**

- Pyramid.** *Int J Ophthalmol* 2021; 14:1-9Khanna RC, Garg P, Vaddavalli PK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469477>
35. **Acute appendicitis management during the COVID-19 pandemic: A prospective cohort study from a LARGE UK centre.** *Int J Surg* 2021; Antakia R, Xanthis A, Georgiades F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465496>
 36. **Acute appendicitis management during the COVID-19 pandemic: A prospective cohort study from a large UK centre.** *Int J Surg* 2021; 86:32-37Antakia R, Xanthis A, Georgiades F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465496>
 37. **Intravitreal injections of anti-VEGF agents during COVID-19 pandemic: clinical audit from Tanta University Hospital.** *Int. Ophthalmol.* 2021:1-7Moussa M, Elshorbagy MS, Emarah A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33475906>
 38. **The Magnitude of COVID-19's Effect on the Timely Management of Melanoma and Non-Melanoma Skin Cancers.** *J Am Acad Dermatol* 2021; Marson JW, Maner BS, Harding TP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482258>
 39. **Promoting Healthy Aging During COVID-19.** *J Am Geriatr Soc* 2021; Batsis JA, Daniel K, Eckstrom E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33470421>
 40. **Expert Consensus on Clinical Practice of Burn Units in Shanghai during the COVID-19 Epidemic.** *J Burn Care Res* 2021; Ma B, Fan X, Kong W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484264>
 41. **The impact of COVID-19 on adult burn management in the UK: a regional centre experience.** *J Burn Care Res* 2021; Varma P, Kazzazi D, Anwar MU, Muthayya P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482004>
 42. **SARS-CoV-2 Infection and Oral Health: Therapeutic Opportunities and Challenges.** *J Clin Med* 2021; 10Coke CJ, Davison B, Fields N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466289>
 43. **Impact of the coronavirus disease 2019 pandemic on periodontal practice: a questionnaire survey.** *J. Clin. Periodontol.* 2021; Rocha-Gomes G, Flecha OD, Miranda TS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33474762>
 44. **How to Best Protect People With Diabetes From the Impact of SARS-CoV-2: Report of the International COVID-19 and Diabetes Summit.** *J. Diabetes Sci. Technol.* 2021:1932296820978399Zhang JY, Shang T, Ahn D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476193>
 45. **What was the impact of a global pandemic (COVID-19) lockdown period on experiences within an eating disorder service? A service evaluation of the views of patients, parents/carers and staff.** *J Eat Disord* 2021; 9:14Shaw H, Robertson S, Ranceva N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468242>
 46. **Ambulatory chemotherapy: Past, present, and future.** *J. Oncol. Pharm. Pract.* 2021:1078155220985916Sabbagh Dit Hawasli R, Barton S, Nabhani-Gebara S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461412>
 47. **Commentary: Should all cancer patients be tested for COVID-19 before each chemotherapy cycle?** *J. Oncol. Pharm. Pract.* 2021:1078155220988753Yekedüz E, Utkan G, Ürün Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33470163>
 48. **Outpatient clinical pharmacy practice in the face of COVID-19 at a cancer center in New York City.** *J. Oncol. Pharm. Pract.* 2021:1078155220987625Yerram P, Thackray J, Modelevsky LR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459159>

49. **Transition Planning for Chronic Illnesses in the Time of COVID-19.** J Patient Exp 2020; 7:848-850Hunt WR, Linnemann RW, Middour-Oxler B.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33457510>
50. **Pediatric urology amidst SARS-CoV-2 pandemic: Building the future with current knowledge.** J. Pediatr. Surg. 2021; Lombardo AM, Andolfi C, Deshpande AP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33483106>
51. **Pediatric surgical wait priority score (pSWAPS): Modifying a health system's adult-based elective surgery prioritization system for children's surgery during the COVID-19 pandemic.** J. Pediatr. Surg. 2021; Slater BJ, Cappello MT, Butterly MM, Sherman J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33483104>
52. **Drug supply shortage in Nigeria during COVID-19: efforts and challenges.** J Pharm Policy Pract 2021; 14:17Faiva E, Hashim HT, Ramadhan MA *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33482871>
53. **Drastic times need drastic measures: COVID-19 and widening access to medicine.** J. R. Coll. Physicians Edinb. 2020; 50:431-435Smith KG, Cleland J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33469625>
54. **Impact of COVID-19 on the self-reported physical activity of people with complete thoracic spinal cord injury full-time manual wheelchair users.** J. Spinal Cord Med. 2021:1-5Marco-Ahulló A, Montesinos-Magraner L, González LM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465023>
55. **Lung transplantation during the outbreak of Coronavirus Disease 2019 in China.** J. Thorac. Cardiovasc. Surg. 2020; Wu B, Huang M, Jiao G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33461803>
56. **Impact of COVID-19 on the Society for Vascular Surgery Vascular Quality Initiative Venous Procedure Registries (Varicose Vein and Inferior Vena Cava Filter).** J Vasc Surg Venous Lymphat Disord 2021; Mahenthiran AK, Natarajan JP, Bertges DJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482377>
57. **Obesity surgery and COVID-19 pandemic: What is the suitable attitude to adopt?** J Visc Surg 2020; Sterkers A, Blanchet MC, Genser L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33461888>
58. **Derma-Wochenende 2020: Präsidium, Vorstand sowie Chefärzte und Ordinarien trafen sich zum virtuellen Austausch.** JDDG - Journal of the German Society of Dermatology 2020; 18:1527Arnold D.
59. **COVID-19 epidemiology in rheumatic diseases in Tuscany: a case control study.** Joint Bone Spine 2021:105131Francesconi P, Cantini F, Profili F *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33486110>
60. **Absolute targets for HCV elimination and national health policy paradigms: Foreseeing future requirements.** Liver Int 2021; Kondili LA, Craxì A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33486885>
61. **Treatment of hypothyroidism in special situations.** Medicina (B. Aires) 2020; 80 Suppl 6:83-93Rizzo LFL, Mana DL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481737>
62. **Enhanced Recovery after Surgery (ERAS) for Hip and Knee Replacement-Why and How It Should Be Implemented Following the COVID-19 Pandemic.** Medicina (Kaunas) 2021; 57Wainwright TW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477852>
63. **Implementing trauma resuscitation protocol in COVID 19 Era: Our modifications at the national trauma centre, Abuja, Nigeria.** Niger. J. Clin. Pract. 2021; 24:138-141Okoye OG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33473041>

64. **Ocular Trauma During the COVID-19 Lockdown.** Ophthalmic Epidemiol. 2021;1-3Stedman EN, Jefferis JM, Tan JH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467961>
65. **Az új koronavírus okozta járvány első hullámának jellemzői és esetleges kapcsolata a tuberkulózis elleni oltottsággal.** Orv. Hetil. 2021; 162:123-134Emődy-Kiss B, Pataki Á, Deli G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486464>
66. **Autism, Therapy and COVID-19.** Pediatr. Rep. 2021; 13:35-44Sergi L, Mingione E, Ricci MC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466265>
67. **Successful non-directed living liver donor transplant for an infant with biliary atresia during the COVID-19 pandemic.** Pediatr. Transplant. 2020; 24:e13816Feldman AG, Adams MA, Wachs ME *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33460202>
68. **COVID-19 pandemic reduces the negative perception of oral health-related quality of life in adolescents.** Qual. Life Res. 2021;1-7Knorst JK, Brondani B, Tomazoni F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33475914>
69. **Axial presentation of reactive arthritis secondary to Covid-19 infection.** Rheumatology (Oxford) 2021; Coath FL, Mackay J, Gaffney JK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33471106>
70. **Cancer diagnosis in Brazil in the COVID-19 era.** Semin. Oncol. 2021; Marques NP, Silveira DMM, Marques NCT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478743>
71. **Nurse navigators' telemonitoring for cancer patients with COVID-19: a French case study.** Support. Care Cancer 2021;1-8Ferrua M, Mathivon D, Duflot-Boukobza A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33462724>
72. **"Swords and Shields" against COVID-19 for patients with cancer at "clean" and "pandemic" hospitals: are we ready for the second wave?** Support. Care Cancer 2021;1-7Karacin C, Acar R, Bal O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33479795>
73. **Urology during COVID-19 Pandemic Crisis: A Systematic Review.** Surg J (N Y) 2021; 7:e3-e10Thapa BB, Shrestha D, Bista S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469564>
74. **A narrative review of the challenges and countermeasures in hepatoblastoma management during COVID-19 epidemic.** Transl Pediatr 2020; 9:840-848Xu H, Zhou Y, Sun R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457307>
75. **Impact of the COVID-19 Crisis on Same-Day Discharge After Robotic Urologic Surgery.** Urology 2021; Abaza R, Kogan P, Martinez O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482129>
76. **Short term impact of the COVID-19 pandemic on incidence of vaccine preventable diseases and participation in routine infant vaccinations in the Netherlands in the period March-September 2020.** Vaccine 2021; Middeldorp M, van Lier A, van der Maas N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478793>

Management (44 articles)

1. **Awake prone in COVID-19 - does CPAP make a difference?** Adv Respir Med 2021; Mittal S, Pb S, Madan K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33471353>

2. **COVID-19 preparedness: A Bronx, New York, inner-city hospital's experience with medication management and readiness for a second surge.** Am. J. Health Syst. Pharm. 2021; Kang KS, Huggins C, Diaz-Fuentes G, Schiller L.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33483730>
3. **Lifestyle Medicine During (and After) the COVID-19 Pandemic.** Am. J. Lifestyle Med. 2021; 15:60-67Smirmaul BPC, Chamon RF, de Moraes FM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33456421>
4. **An Evolving Clinical Need: Discordant Oxygenation Measurements of Intubated COVID-19 Patients.** Ann. Biomed. Eng. 2021:1-5Rubano JA, Maloney LM, Simon J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469819>
5. **Australian specialist palliative care's response to COVID-19: an anonymous online survey of service providers.** Ann Palliat Med 2021; Luckett T, Donkor A, Phillips J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33474953>
6. **New S2k guidelines for the inpatient treatment of COVID-19 patients published.** Atemwegs- und Lungenkrankheiten 2020; 46:739-740.
7. **Chemical profiling of selected Ayurveda formulations recommended for COVID-19.** Beni Suef Univ J Basic Appl Sci 2021; 10:2C TS, M D, P RR *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33457430>
8. **Cost-effectiveness of intensive care for hospitalized COVID-19 patients: experience from South Africa.** BMC Health Serv. Res. 2021; 21:82Cleary SM, Wilkinson T, Tamandjou Tchuem CR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482807>
9. **The use of electrical impedance tomography for individualized ventilation strategy in COVID-19: a case report.** BMC Pulm. Med. 2021; 21:38Zhao Z, Zhang JS, Chen YT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482796>
10. **Priority setting during the COVID-19 pandemic: going beyond vaccines.** BMJ Glob Health 2021; 6Williams I, Essue B, Nouvet E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33461979>
11. **Vitamin A in Resistance to and Recovery from Infection: Relevance to SARS-CoV2.** Br. J. Nutr. 2021:1-26Stephensen CB, Lietz G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33468263>
12. **Impact of high dose prophylactic anticoagulation in critically ill patients with COVID-19 pneumonia.** Chest 2021; Tacquard C, Mansour A, Godon A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33465342>
13. **Why Automated E-Counseling for Chronic Heart Failure Matters in the COVID-19 Pandemic Era.** Circ Heart Fail 2021; 14:e008071Reid KRY.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33464946>
14. **COVID-19 Pandemic: What Have We Learned?** Clin. J. Oncol. Nurs. 2021; 25:11-12Carr E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480875>
15. **Interprofessional Communication: Integrating Evidence to Enhance Systems During a Pandemic.** Clin. J. Oncol. Nurs. 2021; 25:56-60Cazeau N.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33480871>
16. **Care Delivery and Treatment Decision Making: Bioethical and Nursing Considerations During and After the COVID-19 Pandemic.** Clin. J. Oncol. Nurs. 2021; 25:61-68Tariman JD, Klugman CM, Webber-Ritchey KJ, Amer K.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33480884>
17. **Home quarantine in COVID-19: A study on 50 consecutive patients in Austria.** Clin Med (Lond) 2021; 21:e9-e13Gietl S, Schönegger CM, Falk M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33479077>

18. **Integrating Metamaterial Antenna Node and LiFi for Privacy Preserving Intelligent COVID-19 Hospital Patient Management.** Cognit. Comput. 2021;1-14 Garhwal A, Bunruangsas M, Arumona AE *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33456619>
19. **Orthopedic Surgery and Telemedicine in Times of COVID-19 and Beyond: a Review.** Curr. Rev. Musculoskelet. Med. 2021; Moisan P, Barimani B, Antoniou J.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33460020>
20. **Good is not good enough: Why diabetes care at hospitals are so important precisely in times of corona.** Diabetes Aktuell 2020; 18:310-311.
21. **Practical recommendations of the German Diabetes Society for the management of diabetes in patients with COVID-19.** Diabetologe 2021; Bornstein SR, Gallwitz B, Kellerer M *et al.*
22. **Critical Care COVID-19 Patient with a Picture of Thrombotic Thrombocytopenic Purpura.** Eur J Case Rep Intern Med 2020; 7:002143 Al-Ansari RY, Bakkar M, Abdalla L, Sewify K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457377>
23. **Compounds of Citrus medica and Zingiber officinale for COVID-19 inhibition: in silico evidence for cues from Ayurveda.** Futur J Pharm Sci 2021; 7:13 Haridas M, Sasidhar V, Nath P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457429>
24. **Tracheostomy in the COVID19 Patients: Our Experience in 12 Cases.** Indian J Otolaryngol Head Neck Surg 2021;1-5 Pradhan P, Mishra AK, Mittal Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33457312>
25. **Extracorporeal membrane oxygenation versus mechanical ventilation alone in adults with severe acute respiratory distress syndrome: a systematic review and meta-analysis.** Int J Clin Pract 2021:e14046 Zhu Y, Zhang M, Zhang R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33486824>
26. **Knowledge, Practice, and Attitude Toward COVID-19 Among Physicians in Jordan and Palestine: Cross-Sectional Study.** Int. J. Gen. Med. 2021; 14:77-87 Al-Demour S, Ababneh MA, Al-Taher RN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469347>
27. **Development and validation of a machine learning model predicting illness trajectory and hospital utilization of COVID-19 patients-a nationwide study.** J Am Med Inform Assoc 2021; Roimi M, Gutman R, Somer J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33479727>
28. **Knowledge, Attitudes and Practices Regarding COVID-19 in N'Djamena, Chad.** J. Community Health 2021;1-8 Takoudjou Dzomo GR, Bernales M, López R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33484402>
29. **The effectiveness of active surveillance measures for COVID-19 cases in Pudong New Area Shanghai, China, 2020.** J Med Virol 2021; Liu H, Ye C, Wang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33463732>
30. **Nurses' experiences of being recruited and transferred to a new sub-intensive care unit devoted to COVID-19 patients.** J. Nurs. Manag. 2021; Danielis M, Peressoni L, Piani T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480143>
31. **Impact of COVID-19 on Acute Isolation Bed Capacity and Nursing Workforce Requirements: A Retrospective Review.** J. Nurs. Manag. 2021; Fan PEM, Nguyen NHL, Ang SY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480121>
32. **An environmental study of tracheostomy on eight COVID-19 patients.** J. Otolaryngol. Head Neck Surg. 2021; 50:3 Xu K, Zhang XH, Long XB *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33461626>

33. **Relationship-Centered Care in a Novel Dual-Visit Model COVID Nursery Follow-Up Clinic.** J Patient Exp 2020; 7:998-1001 Saslaw M, Glassman ME, Keown MK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457537>
34. **Avoiding a Med-Wreck: a structured medication reconciliation framework and standardized auditing tool utilized to optimize patient safety and reallocate hospital resources.** J Pharm Policy Pract 2021; 14:10 Elbeddini A, Almasalkhi S, Prabakaran T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468248>
35. **Early prone positioning therapy for patients with mild COVID-19 disease.** Med Clin (Barc) 2020; Liu X, Liu H, Lan Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478810>
36. **[Preliminary results of a non-invasive ventilatory support unit in SARS-COVID-2].** Medicina (B. Aires) 2020; 80 Suppl 6:1-8 Vega ML, Montiel G, Colaianni N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481726>
37. **Surgical Tracheostomy Outcomes in COVID-19-Positive Patients.** OTO Open 2021; 5:2473974x20984998 Courtney A, Lignos L, Ward PA, Vizcaychipi MP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33474524>
38. **Early relaxation of community mitigation policies and risk of COVID-19 resurgence in the United States.** Prev. Med. 2021:106435 Hatf E, Kitchen C, Chang HY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486000>
39. **[Reinforcement in a COVID resuscitation unit in the Grand-Est region].** Rev. Infirm. 2021; 70:40-41 Michelini C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33455681>
40. **Factors associated with hospitalization, invasive mechanical ventilation treatment and death among all confirmed COVID-19 cases in Norway: Prospective cohort study.** Scand J Public Health 2021:1403494820985172 Telle KE, Grøslund M, Helgeland J, Håberg SE. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461404>
41. **Re-reading ACT, BCG, and Low COVID-19 in Africa.** SN Compr Clin Med 2021:1-5 Kangbai JB, Babawo LS, Kaitibi D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458569>
42. **Saving Limited Resources During Covid-19 Pandemic.** Transl Med UniSa 2020; 23:20-21 Piazza O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457317>
43. **Strategic management of pediatric intensive care unit in a tertiary children's hospital in southwest China during the COVID-19 pandemic.** Transl Pediatr 2020; 9:849-862 Zeng P, Luo X, Zeng W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457308>
44. **Medicinal plants for COVID-19.** Zeitschrift für Phytotherapie 2020; 41:291-294 Uehleke B.

Mental – public health (104 articles)

1. **Mental health status of pregnant and breastfeeding women during the COVID-19 pandemic - a multinational cross-sectional study.** Acta Obstet Gynecol Scand 2021; Ceulemans M, Foulon V, Ngo E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33475148>
2. **"Getting back to normality seems as big of a step as going into lockdown": The Impact of the COVID-19 Pandemic on People with Early-Middle Stage Dementia.** Age Ageing 2021; Talbot CV, Briggs P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481988>

3. **Online lockdown diaries as endurance art.** *AI Soc* 2021;1-10Yang G.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33469246>
4. **Harm Reduction and Adaptations Among PWUD in Rural Oregon During COVID-19.** *AIDS Behav.* 2021;1-9Seaman A, Leichtling G, Stack E *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33471243>
5. **Eating in the lockdown during the Covid 19 pandemic; self-reported changes in eating behaviour, and associations with BMI, eating style, coping and health anxiety.** *Appetite* 2021;105082Coulthard H, Sharps M, Cunliffe L, van den Tol A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33476651>
6. **Different prevalence trend of depression and anxiety among healthcare workers and general public before and after the peak of COVID-19 occurred in China: A meta-analysis.** *Asian J Psychiatr* 2021; 56:102547Deng Y, Chen Y, Zhang B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465749>
7. **COVID-19 and suicides in India: A pilot study of reports in the media and scientific literature.** *Asian J Psychiatr* 2021; 57:102560Panigrahi M, Pattnaik JI, Padhy SK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465521>
8. **Effects of previous exposure to psychotherapeutic strategies on depression and anxiety symptoms during the COVID-19 pandemic.** *BJPsych Open* 2021; 7:e38Gulliver A, Banfield M, Batterham PJ *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33461641>
9. **Post-traumatic growth during the COVID-19 pandemic in carers of children in Portugal and the UK: cross-sectional online survey.** *BJPsych Open* 2021; 7:e37Stallard P, Pereira AI, Barros L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468270>
10. **Efficient SARS-CoV-2 surveillance strategies to prevent deadly outbreaks in vulnerable populations.** *BMC Med* 2021; 19:25Toth DJA, Khader K.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33478447>
11. **Temperament and character of patients with alcohol toxicity during COVID - 19 pandemic.** *BMC Psychiatry* 2021; 21:49Estedlal AR, Mani A, Vardanjani HM *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33472610>
12. **COVID-19 outbreak in Brazil: adherence to national preventive measures and impact on people's lives, an online survey.** *BMC Public Health* 2021; 21:152Faria de Moura Villela E, López RVM, Sato APS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33461508>
13. **Home was not a safe haven: women's experiences of intimate partner violence during the COVID-19 lockdown in Nigeria.** *BMC Womens Health* 2021; 21:32Fawole OI, Okedare OO, Reed E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472627>
14. **Navigating inequities: a roadmap out of the pandemic.** *BMJ Glob Health* 2021; 6Ismail SJ, Tunis MC, Zhao L, Quach C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33479019>
15. **COVID-19-related social support service closures and mental well-being in older adults and those affected by dementia: a UK longitudinal survey.** *BMJ Open* 2021; 11:e045889Giebel C, Pulford D, Cooper C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33455941>
16. **Hedonic and eudaimonic well-being during the COVID-19 lockdown in Italy: The role of stigma and appraisals.** *Br. J. Health Psychol.* 2021; Paleari FG, Pivetti M, Galati D, Fincham FD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33460503>

17. **Emerging New Psychiatric Symptoms and the Worsening of Pre-existing Mental Disorders during the COVID-19 Pandemic: A Canadian Multisite Study: Nouveaux symptômes psychiatriques émergents et détérioration des troubles mentaux préexistants pendant la pandémie de la COVID-19: une étude canadienne multisite.** Can. J. Psychiatry. 2021;706743720986786Robillard R, Daros AR, Phillips JL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33464115>
18. **Socio-demographic, social, cognitive, and emotional correlates of adherence to physical distancing during the COVID-19 pandemic: a cross-sectional study.** Can. J. Public Health. 2021;1-12Gouin JP, MacNeil S, Switzer A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33464556>
19. **A survey of psychological distress among Bangladeshi people during the COVID-19 pandemic.** Clin Epidemiol Glob Health 2021; 10:100693Marzo RR, Singh A, Mukti RF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33462563>
20. Clin. J. Oncol. Nurs. 2021; 25:10. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480887>
21. **Care and Coping During COVID-19: Practice Changes and Innovations in the Oncology Setting.** Clin. J. Oncol. Nurs. 2021; 25:48-55Duncan R, Szabo B, Jackson QL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480874>
22. **Mental Health and COVID-19: The Psychological Implications of a Pandemic for Nurses.** Clin. J. Oncol. Nurs. 2021; 25:69-75Shah M, Roggenkamp M, Ferrer L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480882>
23. **COVID-19: Causes of anxiety and wellbeing support needs of healthcare professionals in the UK: A cross-sectional survey.** Clin Med (Lond) 2021; 21:66-72Siddiqui I, Aurelio M, Gupta A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33479070>
24. **"Making Sure We Are All Okay": Healthcare Workers' Strategies for Emotional Connectedness During the COVID-19 Pandemic.** Clin. Soc. Work J. 2021;1-11Bender AE, Berg KA, Miller EK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456094>
25. **Backing the Blue in the Midst of COVID-19: Simultaneous Shared Trauma and the Effects of Coping in Law Enforcement Couples.** Clin. Soc. Work J. 2021;1-7Collazo J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456093>
26. **Health Behaviors of Higher Education Students from 7 Countries: Poorer Sleep Quality during the COVID-19 Pandemic Predicts Higher Dietary Risk.** Clocks Sleep 2021; 3:12-30Du C, Zan MCH, Cho MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467418>
27. **Psychological reactions to COVID-19: Survey data assessing perceived susceptibility, distress, mindfulness, and preventive health behaviors.** Data Brief 2021; 34:106687O'Brien WH, Wang S, Xu H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457475>
28. **Psycho-social and behavioural impact of COVID 19 on young adults: Qualitative research comprising focused group discussion and in-depth interviews.** Diabetes Metab Syndr 2021; 15:309-312Mazumder A, Bandhu Kalanidhi K, Sarkar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484988>
29. **Changes in anxiety, depression, and stress in one week and one month later after the Wuhan shutdown against the COVID-19 epidemic.** Disaster Med Public Health Prep 2021;1-32Chen Q, Li M, Wang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472726>

30. **Impact of the smell loss on the quality of life and adopted coping strategies in COVID-19 patients.** Eur Arch Otorhinolaryngol 2021;1-8Elkholi SMA, Abdelwahab MK, Abdelhafeez M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33464401>
31. **ESCAP CovCAP survey of heads of academic departments to assess the perceived initial (April/May 2020) impact of the COVID-19 pandemic on child and adolescent psychiatry services.** Eur. Child Adolesc. Psychiatry 2021;1-10Revet A, Hebebrand J, Anagnostopoulos D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33474653>
32. **The emergence of Urban Community Resilience Initiatives During the COVID-19 Pandemic: An International Exploratory Study.** Eur J Dev Res 2021;1-23Fransen J, Peralta DO, Vanelli F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456209>
33. **Attitudes of healthcare workers towards COVID-19 vaccination: a survey in France and French-speaking parts of Belgium and Canada, 2020.** Euro Surveill 2021; 26Verger P, Scronias D, Dauby N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478623>
34. **Psychological burden of the COVID-19 pandemic and its associated factors among frontline doctors of Bangladesh: a cross-sectional study.** F1000Res 2020; 9:1304Barua L, Zaman MS, Omi FR, Faruque M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33447383>
35. **Mental Health Outcomes in Healthcare Workers in COVID-19 and Non-COVID-19 Care Units: A Cross-Sectional Survey in Belgium.** Front. Psychol. 2020; 11:612241Tiete J, Guatteri M, Lachaux A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469439>
36. **Is Fear of COVID-19 Contagious? The Effects of Emotion Contagion and Social Media Use on Anxiety in Response to the Coronavirus Pandemic.** Front. Psychol. 2020; 11:567379Wheaton MG, Prikhidko A, Messner GR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469434>
37. **Primary drivers and psychological manifestations of stress in frontline healthcare workforce during the initial COVID-19 outbreak in the United States.** Gen. Hosp. Psychiatry 2021; 69:20-26Norful AA, Rosenfeld A, Schroeder K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485091>
38. **COVID-19 and healthcare system in China: challenges and progression for a sustainable future.** Global Health 2021; 17:14Sun S, Xie Z, Yu K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478558>
39. **In the name of COVID-19: legitimizing the exclusion of community participation in Ecuador's health policy.** Health Promot. Int. 2021; Torres I, López-Cevallos D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33471084>
40. **What Will Be the Impact of the Covid-19 Quarantine on Psychological Distress? Considerations Based on a Systematic Review of Pandemic Outbreaks.** Healthcare (Basel) 2021; 9Caviccholi M, Ferrucci R, Guidetti M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477981>
41. **Religious Coping, Depression and Anxiety among Healthcare Workers during the COVID-19 Pandemic: A Malaysian Perspective.** Healthcare (Basel) 2021; 9Chow SK, Francis B, Ng YH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467744>
42. **Nurses' Workplace Conditions Impacting Their Mental Health during COVID-19: A Cross-Sectional Survey Study.** Healthcare (Basel) 2021; 9Havaei F, Ma A, Staempfli S, MacPhee M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467080>

43. **Burnout Prevalence and Its Associated Factors among Malaysian Healthcare Workers during COVID-19 Pandemic: An Embedded Mixed-Method Study.** Healthcare (Basel) 2021; 9Roslan NS, Yusoff MSB, Razak AA, Morgan K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477380>
44. **COVID-19 in China: Responses, Challenges and Implications for the Health System.** Healthcare (Basel) 2021; 9Xing C, Zhang R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466996>
45. **Medical Students and COVID-19: Knowledge, Preventive Behaviors, and Risk Perception.** Int J Environ Res Public Health 2021; 18Alsoghair M, Almazyad M, Alburaykan T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478172>
46. **Empathy and COVID-19: Study in Professionals and Students of the Social Health Field in Ecuador.** Int J Environ Res Public Health 2021; 18Cañas-Lerma AJ, Cuartero-Castañer ME, Mascialino G, Hidalgo-Andrade P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466348>
47. **More Is Not Enough: A Deeper Understanding of the COVID-19 Impacts on Healthcare, Energy and Environment Is Crucial.** Int J Environ Res Public Health 2021; 18Jiang P, Klemeš JJ, Fan YV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466940>
48. **COVID-19 Stress and Mental Health of Students in Locked-Down Colleges.** Int J Environ Res Public Health 2021; 18Li X, Fu P, Fan C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477595>
49. **The Role of Coping in the Wellbeing and Work-Related Quality of Life of UK Health and Social Care Workers during COVID-19.** Int J Environ Res Public Health 2021; 18McFadden P, Ross J, Moriarty J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477880>
50. **Secondary Traumatic Stress and Burnout in Healthcare Workers during COVID-19 Outbreak.** Int J Environ Res Public Health 2021; 18Orrù G, Marzetti F, Conversano C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466346>
51. **Depressive Symptoms, Fatigue and Social Relationships Influenced Physical Activity in Frail Older Community-Dwellers during the Spanish Lockdown due to the COVID-19 Pandemic.** Int J Environ Res Public Health 2021; 18Pérez LM, Castellano-Tejedor C, Cesari M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477879>
52. **Psychological Distress and Post-Traumatic Symptomatology Among Dental Healthcare Workers in Russia: Results of a Pilot Study.** Int J Environ Res Public Health 2021; 18Sarapultseva M, Zolotareva A, Kritsky I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467573>
53. **COVID-19 Anxiety-A Longitudinal Survey Study of Psychological and Situational Risks among Finnish Workers.** Int J Environ Res Public Health 2021; 18Savolainen I, Oksa R, Savela N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477756>
54. **The Progressive Public Measures of Saudi Arabia to Tackle Covid-19 and Limit Its Spread.** Int J Environ Res Public Health 2021; 18Sayed AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477645>
55. **Medical Studies during the COVID-19 Pandemic: The Impact of Digital Learning on Medical Students' Burnout and Mental Health.** Int J Environ Res Public Health 2021; 18Zis P, Artemiadis A, Bargiotas P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466459>

56. **COVID 19 and dementia: experience from six European countries.** Int. J. Geriatr. Psychiatry 2021; Burns A, Lobo A, Olde Rikkert M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33462849>
57. **Psychometric Evaluation of the Fear of COVID-19 Scale Among Chinese Population.** Int J Ment Health Addict 2021:1-16 Chi X, Chen S, Chen Y *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33456407>
58. **The Effect of COVID-19 Anxiety on General Health: the Role of COVID-19 Coping.** Int J Ment Health Addict 2021:1-12 Yıldırım M, Akgül Ö, Geçer E.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33456406>
59. **The Effects of Fear and Knowledge of COVID-19 on Preventive Practice Among Pregnant Women Who Attend Antenatal Care in Northwest Ethiopia, 2020: Institution-Based Cross-Sectional Study.** Int J Womens Health 2021; 13:95-100 TG WM, Kassie BA, Asratie MH, Abate AT.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33469387>
60. **Early impact of COVID-19 quarantine on the perceived change of anxiety symptoms in a non-clinical, non-infected Italian sample: Effect of COVID-19 quarantine on anxiety.** J Affect Disord Rep 2021; 4:100078 De Pietri S, Chiorri C.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33469571>
61. **'It's been adapted rather than impacted': A qualitative evaluation of the impact of Covid-19 restrictions on the positive behavioural support of people with an intellectual disability and/or autism.** J Appl Res Intellect Disabil 2021; McKenzie K, Murray GC, Martin R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484052>
62. **Thematic Analysis of Parent-Child Conversations About COVID-19: "Playing It Safe".** J Child Fam Stud 2021:1-13 Tambling RR, Tomkunas AJ, Russell BS *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33456294>
63. **The Impact of COVID-19 Pandemic and Lockdown Measures on Quality of Life among Italian General Population.** J Clin Med 2021; 10 Epifanio MS, Andrei F, Mancini G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466778>
64. **COVID-19 Awareness, Adoption of COVID-19 Preventive Measures, and Effects of COVID-19 Lockdown Among Adolescent Boys and Young Men in Kampala, Uganda.** J. Community Health 2021:1-12 Matovu JKB, Kabwama SN, Ssekamatte T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481156>
65. **What was the impact of a global pandemic (COVID-19) lockdown period on experiences within an eating disorder service? A service evaluation of the views of patients, parents/carers and staff.** J Eat Disord 2021; 9:14 Shaw H, Robertson S, Ranceva N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468242>
66. **COVID-19, anorexia nervosa and obese patients with an eating disorder - some considerations for practitioners and researchers.** J Eat Disord 2021; 9:15 Simeunovic Ostojic M, Maas J, Bodde NMG.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33472682>
67. **Patient's Fear of Being Infected, Another Complication of COVID-19 Outbreak: A Lesson Learned from a Case of Life-Threatening Urolithiasis.** J Endourol Case Rep 2020; 6:402-404 Romantini F, Saldutto P, Maselli G *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33457685>
68. **Typologies of coping in young adults in the context of the COVID-19 pandemic.** J. Gen. Psychol. 2021:1-34 Shigeto A, Laxman DJ, Landy JF, Scheier LM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33475048>
69. **COVID-19, suicide, and femicide: Rapid Research using Google search phrases.** J. Gen. Psychol. 2021:1-22 Standish K.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33480333>

70. **Post-Traumatic Growth and Stress-Related Responses During the COVID-19 Pandemic in a National Representative Sample: The Role of Positive Core Beliefs About the World and Others.** *J Happiness Stud* 2021;1-21 Vazquez C, Valiente C, García FE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456320>
71. **Psychosocial Effects of the COVID-19 Pandemic and Mental Health among LGBTQ+ Young Adults: A Cross-Cultural Comparison across Six Nations.** *J. Homosex.* 2021;1-19 Gato J, Barrientos J, Tasker F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480823>
72. **The Psychological Burden of COVID-19 Stigma: Evaluation of the Mental Health of Isolated Mild Condition COVID-19 Patients.** *J Korean Med Sci* 2021; 36:e33 Kang E, Lee SY, Kim MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33463098>
73. **The experiences of nurses infected with COVID-19 in Wuhan, China: a qualitative study.** *J. Nurs. Manag.* 2021; He J, Liu L, Chen X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480116>
74. **Challenges experienced by ICU nurses throughout the provision of care for COVID-19 patients: A qualitative study.** *J. Nurs. Manag.* 2021; Moradi Y, Baghaei R, Hosseingholipour K, Mollazadeh F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480145>
75. **Anxiety, depression, and cognitive emotion regulation strategies in Chinese nurses during the COVID-19 outbreak.** *J. Nurs. Manag.* 2021; Wang QQ, Fang YY, Huang HL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480056>
76. **Drug supply situation in Rwanda during COVID-19: issues, efforts and challenges.** *J Pharm Policy Pract* 2021; 14:12 Uwizeyimana T, Hashim HT, Kabakambira JD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472702>
77. **The COVID-19 pandemic: unmasking challenges and vulnerability in the HSCT population.** *J. Psychosoc. Oncol.* 2021;1-3 Amonoo HL, Longley RM, El-Jawahri A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468030>
78. **The implications of COVID-19 in the ambient environment and psychological conditions.** *NanoImpact* 2021;100295 Wang Y, Xue Q. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458449>
79. **Editorial for special issue on neglect rehabilitation.** *Neuropsychol. Rehabil.* 2021;1-10 Harvey M, Learmonth G, Rossit S, Chen P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467990>
80. **Transition in learning during COVID-19: Student nurse anxiety, stress, and resource support.** *Nurs. Forum* 2021; Fitzgerald A, Konrad S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484171>
81. **Analysis of nursing students' obsessive and coping behaviors during the COVID-19 pandemic.** *Perspect. Psychiatr. Care* 2021; Bahçecioğlu Turan G, Köse S, Aksoy M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484182>
82. **Response to "letter to the editor regarding the effect of isolation on athletes' mental health during the COVID-19 pandemic".** *Phys. Sportsmed.* 2021;1 Şenışık S, Denerel N, Köyağasıoğlu O, Tunç S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476217>
83. **Lockdown-related factors associated with the worsening of cardiovascular risk and anxiety or depression during the COVID-19 pandemic.** *Prev Med Rep* 2021; 21:101300 Bérard E, Huo Yung Kai S, Coley N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457196>

84. **Psychologic distress and sleep quality among adults in Turkey during the COVID-19 pandemic.** Prog. Neuropsychopharmacol. Biol. Psychiatry. 2021:110254Duran S, Geyiktepe Ö E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485962>
85. **The prevalence of anxiety and depression among healthcare workers during the COVID-19 pandemic: An umbrella review of meta-analyses.** Prog. Neuropsychopharmacol. Biol. Psychiatry 2021:110247Sahebi A, Nejati B, Moayed S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476692>
86. **COVID-19 Pandemic and Mental Health of the General Public: Is there a Tsunami of Mental Disorders?** Psychiatr. Prax. 2020; 47:452-456Riedel-Heller S, Richter D.
87. **Increased mood disorder symptoms, perceived stress, and alcohol use among college students during the COVID-19 pandemic.** Psychiatry Res 2021; 296:113706Charles NE, Strong SJ, Burns LC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482422>
88. **May confusion be a misleading initial clinical presentation of COVID-19 in individuals with mood disorders?** Psychiatry Res 2021; 297:113710Vorspan F, Amarsy R, Etain B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482576>
89. **Effect of SARS-CoV-2 antibody screening on participants' attitudes and behaviour: a study of industry workers in Split, Croatia.** Public Health 2020; 191:11-16Ljubić T, Banovac A, Buljan I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465515>
90. **Physical and Mental Health of Older People while Cocooning during the COVID-19 Pandemic.** QJM 2021; Bailey L, Ward M, DiCosimo A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33471128>
91. **Post-COVID syndrome and suicide risk.** QJM 2021; Sher L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486531>
92. **How have youth with Autism Spectrum Disorder managed quarantine derived from COVID-19 pandemic? An approach to families perspectives.** Res. Dev. Disabil. 2021; 110:103860Mumbardó-Adam C, Barnet-López S, Balboni G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486395>
93. **Parental well-being in times of Covid-19 in Germany.** Rev Econ Househ 2021:1-32Huebener M, Waights S, Spiess CK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469413>
94. **[Impact of confinement measures on the Covid-19 pandemic on alcohol risk consumption.].** Rev. Esp. Salud Publica 2021; 95Villanueva VJ, Motos P, Isorna M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468986>
95. **The Impact of COVID-19 on Sexual Health: A Preliminary Framework Based on a Qualitative Study With Clinical Sexologists.** Sex Med 2020; 9:100299Pascoal PM, Carvalho J, Raposo CF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482611>
96. **Sleep quality and mental health of medical workers during the coronavirus disease 2019 pandemic.** Sleep Biol. Rhythms 2021:1-8Zheng Y, Wang L, Feng L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456342>
97. **COVID Eyes: REM in COVID-19 Survivors.** Sleep Vigil 2021:1-3Goyal A, Kar A, Saxena K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458562>
98. **Psychological distress in North America during COVID-19: The role of pandemic-related stressors.** Soc. Sci. Med. 2021; 270:113687Zheng J, Morstead T, Sin N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465600>

99. **Anxiety among the Vietnamese Population during the COVID-19 Pandemic: Implications for Social Work Practice.** Soc Work Public Health 2021:1-8 Nam PT, Dung NH, Liem NK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459207>
100. **Investigation of COVID-19 Fear, Well-Being and Life Satisfaction in Turkish Society.** Soc Work Public Health 2021:1-14 Özmen S, Özkan O, Özer Ö, Yanardağ MZ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461428>
101. **Sexual health and COVID-19: protocol for a scoping review.** Syst Rev 2021; 10:37 Kumar N, Janmohamed K, Nyhan K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485393>
102. **Effect of government interventions to contain the COVID-19 pandemic on incidence of pulmonary embolism - A Danish nationwide register-based cohort study.** Thromb Res 2021; 199:97-100 Sindet-Pedersen C, Olesen JB, Blanche P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485095>
103. **Does Pandemic Anxiety Affect Urology Health Care Workers?** Urol. Int. 2021:1-7 Apfelbeck M, Staehler M, Rodler S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477161>
104. **Effects of the COVID-19 pandemic on perinatal mental health in Spain: Positive and negative outcomes.** Women Birth 2021; Chaves C, Marchena C, Palacios B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461897>

Meta-analyses - systematic reviews (20 articles)

1. **Effect of antiplatelet treatments on patients with COVID-19 infection: A systematic review and meta-analysis.** Am J Emerg Med 2021; 43:27-30 Wang Y, Ao G, Nasr B, Qi X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485124>
2. **A meta-analysis of comorbidities in COVID-19: Which diseases increase the susceptibility of SARS-CoV-2 infection?** Comput. Biol. Med. 2021; 130:104219 Singh MK, Mobeen A, Chandra A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486379>
3. **Incidence and Clinical Impacts of COVID-19 Infection in Patients with Hemodialysis: Systematic Review and Meta-Analysis of 396,062 Hemodialysis Patients.** Healthcare (Basel) 2021; 9 Chen CY, Shao SC, Chen YT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466527>
4. **D-dimer levels is associated with severe COVID-19 infections: A meta-analysis.** Int J Clin Pract 2021:e14031 Wu ZH, Cheng Q. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33474792>
5. **Red Blood Cell Distribution Width, Disease Severity, and Mortality in Hospitalized Patients with SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis.** J Clin Med 2021; 10 Zinellu A, Mangoni AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466770>

Mortality (29 articles)

1. **Mortality risk of COVID-19 in elderly males with comorbidities: a multi-country study.** Aging (Albany NY) 2020; 13:27-60 Li G, Liu Y, Jing X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472167>
2. **Electrocardiographic markers of increased risk of sudden cardiac death in patients with COVID-19 pneumonia.** Ann. Noninvasive Electrocardiol.

- 2021:e12824Alareedh M, Nafakhi H, Shaghee F, Nafakhi A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33463863>
3. **Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts.** Ann. Rheum. Dis. 2021; Wong AY, MacKenna B, Morton CE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478953>
 4. **Higher comorbidities and early death in hospitalized African-American patients with Covid-19.** BMC Infect. Dis. 2021; 21:78Gupta R, Agrawal R, Bukhari Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461499>
 5. **Clinical characteristics of 14 COVID-19 deaths in Tianmen, China: a single-center retrospective study.** BMC Infect. Dis. 2021; 21:88Hu J, Zhang Y, Wang W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472591>
 6. **The risk factors associated with COVID-19-Related death among patients with end-stage renal disease.** BMC Nephrol. 2021; 22:33Rastad H, Ejtahed HS, Shafiee G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468081>
 7. **Pre-hospital lowest recorded oxygen saturation independently predicts death in patients with COVID-19.** Br Paramed J 2020; 5:59-65Dillon K, Hook C, Coupland Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456398>
 8. **ICU Admission Levels of Endothelial Biomarkers as Predictors of Mortality in Critically Ill COVID-19 Patients.** Cells 2021; 10Vassiliou AG, Keskinidou C, Jahaj E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477776>
 9. **Telehealth in Palliative Care: Communication Strategies From the COVID-19 Pandemic.** Clin. J. Oncol. Nurs. 2021; 25:17-22Stockdill ML, Barnett MD, Taylor R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480883>
 10. **Clinical Characteristics of 47 Death Cases With COVID-19: A Retrospective Study at a Tertiary Center in Lahore.** Cureus 2020; 12:e12039Ussaid A, Riaz B, Rafai W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457138>
 11. **Automated processing of social media content for radiologists: applied deep learning to radiological content on twitter during COVID-19 pandemic.** Emerg Radiol 2021; Khurana S, Chopra R, Khurana B.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33459907>
 12. **Effects of chronic exposure to ambient air pollutants on COVID-19 morbidity and mortality - A lesson from OECD countries.** Environ. Res. 2021:110723Barnett-Iltzhaki Z, Levi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484722>
 13. **COVID-19 incidence and mortality in Lombardy, Italy: an ecological study on the role of air pollution, meteorological factors, demographic and socioeconomic variables.** Environ. Res. 2021:110777de Angelis E, Renzetti S, Volta M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485909>
 14. **Does death from Covid-19 arise from a multi-step process?** Eur. J. Epidemiol. 2021; Pearce N, Moirano G, Maule M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459897>
 15. **Effects of rapid recruitment and dissemination on Covid-19 mortality: the RECOVERY trial.** F1000Res 2020; 9:1017Knowlson C, Torgerson DJ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33447376>
 16. **Patterns of COVID-19 related excess mortality in the municipalities of Northern Italy during the first wave of the pandemic.** Health Place 2021; 67:102508Gibertoni D, Adja KYC, Golinelli D *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33476843>

17. **Is prognostic nutritional index a predictive marker for estimating all-cause in-hospital mortality in COVID-19 patients with cardiovascular risk factors?** Heart Lung 2021; 50:307-312 Çınar T, Hayıroğlu M, Çiçek V *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33482433>
18. **The mortality rate of COVID-19 was high in cancer patients: a retrospective single-center study.** Int. J. Clin. Oncol. 2021; Erdal GS, Polat O, Erdem GU *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33486624>
19. **Factors Affecting the Cases and Deaths of COVID-19 Victims.** Int J Environ Res Public Health 2021; 18Velasco JM, Tseng WC, Chang CL.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33466900>
20. **Procalcitonin Has Good Accuracy for Prognosis of Critical Condition and Mortality in COVID-19: A Diagnostic Test Accuracy Systematic Review and Meta-analysis.** Iran. J. Allergy Asthma Immunol. 2020; 19:557-569 Zare ME, Wang Y, Nasir Kansestani A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33463126>
21. **Prognostic Factors at Admission for In-Hospital Mortality from COVID-19 Infection in an Older Rural Population in Central Spain.** J Clin Med 2021; 10Maestre-Muñiz MM, Arias Á, Arias-González L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33467207>
22. **The Prognostic Value of Eosinophil Recovery in COVID-19: A Multicentre, Retrospective Cohort Study on Patients Hospitalised in Spanish Hospitals.** J Clin Med 2021; 10Mateos González M, Sierra Gonzalo E, Casado Lopez I *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33467585>
23. **Predictors of Mortality in a Multi-Racial Urban Cohort of Persons with Type 2 Diabetes and Novel Coronavirus 19.** J. Diabetes 2021; Myers AK, Kim TS, Zhu X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486896>
24. **Immune profiling reveals early disease trajectories associated with COVID-19 mortality: a sub-study from the ACTT-1 trial.** J Infect Dis 2021; Thiede JM, Gress AR, Libby SD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476387>
25. **A U-shaped association between baseline neutrophil count and COVID-19-related mortality: a retrospective cohort study.** J Med Virol 2021; Fu W, Chen C, Chen XL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33463721>
26. **Impact of the COVID-19 pandemic on the mortality of the elderly patient with a hip fracture.** Rev. Esp. Anesthesiol. Reanim. 2020; Biarnés-Suñé A, Solà-Enríquez B, González Posada M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461768>
27. **Autopsy findings after long-term treatment of COVID-19 patients with microbiological correlation.** Virchows Arch. 2021:1-12 Evert K, Dienemann T, Brochhausen C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33471172>
28. **Association between chronic kidney disease and COVID-19-related mortality in New York.** World J. Urol. 2021:1-7 Mohamed NE, Benn EKT, Astha V *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33481113>
29. **COVID-19 after liver transplant: Mortality is comparable with other patient groups.** Z. Gastroenterol. 2020; 58:1162-1164 Franke K.

Online – IT – Apps (47 articles)

1. **Smart technologies driven approaches to tackle COVID-19 pandemic: a review.** 3 Biotech 2021; 11:50 Khan H, Kushwah KK, Singh S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33457174>

2. **Recent biotechnological advances as potential intervention strategies against COVID-19.** 3 Biotech 2021; 11:41 Lobo-Galo N, Gálvez-Ruíz JC, Balderrama-Carmona AP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457170>
3. **Teleneuropsychology practice survey during COVID-19 within the United States.** Appl Neuropsychol Adult 2021; 1-11 Rochette AD, Rahman-Filipiak A, Spencer RJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33471555>
4. **A protocol for adding knowledge to Wikidata: aligning resources on human coronaviruses.** BMC Biol. 2021; 19:12 Waagmeester A, Willighagen EL, Su AI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482803>
5. **Using Baidu search values to monitor and predict the confirmed cases of COVID-19 in China: - evidence from Baidu index.** BMC Infect. Dis. 2021; 21:98 Tu B, Wei L, Jia Y, Qian J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478425>
6. **Quality and readability of web-based Arabic health information on COVID-19: an infodemiological study.** BMC Public Health 2021; 21:151 Halboub E, Al-Ak'hali MS, Al-Mekhlafi HM, Alhajj MN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461516>
7. **Bioinformatics and system biology approach to identify the influences of COVID-19 on cardiovascular and hypertensive comorbidities.** Brief. Bioinform. 2021; Nashiry A, Sarmin Sumi S, Islam S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458761>
8. **Tele-health and cancer care in the era of COVID-19: New opportunities in low and middle income countries (LMICs).** Cancer Treat Res Commun 2021; 27:100313 Grewal US, Shankar A, Saini D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465561>
9. **Medicine on Twitter: Boon or Bane?** Circ Arrhythm Electrophysiol 2021; 14:e009434 Kowey PR, Robinson VM, Thind M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33464944>
10. **Interprofessional Communication: Integrating Evidence to Enhance Systems During a Pandemic.** Clin. J. Oncol. Nurs. 2021; 25:56-60 Cazeau N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480871>
11. **Telehealth in Palliative Care: Communication Strategies From the COVID-19 Pandemic.** Clin. J. Oncol. Nurs. 2021; 25:17-22 Stockdill ML, Barnett MD, Taylor R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480883>
12. **Integrating Metamaterial Antenna Node and LiFi for Privacy Preserving Intelligent COVID-19 Hospital Patient Management.** Cognit. Comput. 2021:1-14 Garhwal A, Bunruangsas M, Arumona AE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456619>
13. **Telemedicine Practice in Saudi Arabia During the COVID-19 Pandemic.** Cureus 2020; 12:e12004 Kaliyadan F, M AAA, Al Ameer A, Al Alwan Q. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457115>
14. **Orthopedic Surgery and Telemedicine in Times of COVID-19 and Beyond: a Review.** Curr. Rev. Musculoskelet. Med. 2021; Moisan P, Barimani B, Antoniou J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33460020>
15. **Delivering telemedicine consultations for patients with Transient Ischemic Attack during the COVID-19 pandemic in a comprehensive tertiary stroke centre in the United Kingdom.** Eur. J. Neurol. 2021; D'Anna L, Ellis N, Bentley P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476421>
16. **Fortifying the diagnostic-frontiers with nanoscale technology amidst the COVID-19 catastrophe.** Expert Rev Mol Diagn 2021; Konwarh R, Cho WC.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33470125>
17. **Effects of rapid recruitment and dissemination on Covid-19 mortality: the RECOVERY trial.** E1000Res 2020; 9:1017Knowlson C, Torgerson DJ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33447376>
 18. **COVID-19 and supply with blood components, current status regarding introduction of telematics infrastructure, GSAV and ASV.** Hamostaseologie 2020; 40:694-696Sucker C, Kappert G, Koscielny J.
 19. **Physician Athletes Promoting Physical Fitness Through Social Media During the COVID-19 Pandemic.** Health Promot Pract 2021:1524839920988261Stanford FC, Salles A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467929>
 20. **China health technology and stringency containment measures during COVID-19 pandemic: A discussion of first and second wave of COVID-19.** Health Technol (Berl) 2021:1-6Abbas HSM, Xu X, Sun C.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33462559>
 21. **Application of telemedicine and eHealth technology for clinical services in response to COVID-19 pandemic.** Health Technol (Berl) 2021:1-8Bokolo AJ.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33469474>
 22. **Developing the eMedical Student (eMS)-A Pilot Project Integrating Medical Students into the Tele-ICU during the COVID-19 Pandemic and beyond.** Healthcare (Basel) 2021; 9Ho J, Susser P, Christian C *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33466781>
 23. **Telework and Social Services in Spain during the COVID-19 Pandemic.** Int J Environ Res Public Health 2021; 18Morilla-Luchena A, Muñoz-Moreno R, Chaves-Montero A, Vázquez-Aguado O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467723>
 24. **Medical Studies during the COVID-19 Pandemic: The Impact of Digital Learning on Medical Students' Burnout and Mental Health.** Int J Environ Res Public Health 2021; 18Zis P, Artemiadis A, Bargiotas P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33466459>
 25. **Real-World Direct-to-Patient Teledermatology in a Low-Income, Elderly Population.** J Am Acad Dermatol 2021; Cline A, Kim C, Deitz M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33476731>
 26. **Development and validation of a machine learning model predicting illness trajectory and hospital utilization of COVID-19 patients-a nationwide study.** J Am Med Inform Assoc 2021; Roimi M, Gutman R, Somer J *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33479727>
 27. **Increased usage of smartphones during COVID-19: Is that blue light causing skin damage?** J Cosmet Dermatol 2020; 19:2466-2467Jakhar D, Kaul S, Kaur I.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33460228>
 28. **A Review of Mobile Applications Available in the App and Google Play Stores Used During the COVID-19 Outbreak.** J Multidiscip Healthc 2021; 14:45-57Alanzi T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469298>
 29. **Providing Compassionate Care: The Role of Medical Students and Videoconference Technology in the COVID-19 Pandemic.** J Patient Exp 2020; 7:1002-1006Suresh D, Flatley K, McDonough M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33457538>
 30. **Assessment of COVID-19 Information Overload Among the General Public.** J Racial Ethn Health Disparities 2021:1-9Mohammed M, Sha'aban A, Jatau AI *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33469869>

31. **Digital Contact Tracing Based on a Graph Database Algorithm for Emergency Management During the COVID-19 Epidemic: Case Study.** JMIR Mhealth Uhealth 2021; 9:e26836Mao Z, Yao H, Zou Q *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33460389>
32. **Online Obstetrics and Gynecology Medical Students Clerkship During the Covid-19 Pandemic: a Pilot Study.** Med Sci Educ 2021;1-5Armon S, Benyamini Y, Grisaru-Granovsky S, Avitan T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457067>
33. **[Teledermatology during de COVID-19 pandemic in a public hospital].** Medicina (B. Aires) 2020; 80 Suppl 6:18-24Debernardi ME, Bordón MP, Campastri A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33481728>
34. **An empirical study on Twitter's use and crisis retweeting dynamics amid Covid-19.** Nat Hazards (Dordr) 2021;1-18Wang B, Liu B, Zhang Q.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33469243>
35. **[Telerehabilitation: from the virtual world to reality-Medicine in the twenty-first century : Video-assisted treatment in times of COVID-19].** Nervenarzt 2021; Meyding-Lamadé U, Bassa B, Tibitanzl P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33459797>
36. **Telemedicine during the Coronavirus Disease (COVID-19) Pandemic: A Multiple Sclerosis (MS) Outpatients Service Perspective.** Neurol. Int. 2021; 13:25-31Corea F, Ciotti S, Cometa A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477432>
37. **Patient and Provider Satisfaction With Telemedicine in Otolaryngology.** OTO Open 2021; 5:2473974x20981838Riley PE, Fischer JL, Nagy RE *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33474522>
38. **Promotion of unproved and potential dangerous measures in fighting COVID-19 pandemic: urgent need for vigilant appropriate public communication and generation of scientific evidence.** Pan Afr. Med. J. 2020; 37:29Kalabamu FS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33456653>
39. **Neurologists' perceptions of utilising tele-neurology to practice remotely during the COVID-19 pandemic.** Patient Educ. Couns. 2021; Courtney E, Blackburn D, Reuber M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478853>
40. **Opportunities to improve COVID-19 provider communication resources: A systematic review.** Patient Educ. Couns. 2021; Wittenberg E, Goldsmith JV, Chen C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33455825>
41. **Use of Artificial Intelligence to understand adults' thoughts and behaviours relating to COVID-19.** Perspect Public Health 2021;1757913920979332Flint SW, Piotrkowicz A, Watts K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472547>
42. **[Role of the information systems and e-health in the COVID-19 pandemic. A call to action.].** Rev. Esp. Salud Publica 2021; 95Martín Fernández A.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33473100>
43. **Environmental management strategy in response to COVID-19 in China: Based on text mining of government open information.** Sci Total Environ 2021; 769:145158Kang A, Ren L, Hua C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485207>
44. **Nurse navigators' telemonitoring for cancer patients with COVID-19: a French case study.** Support. Care Cancer 2021;1-8Ferrua M, Mathivon D, Duflot-Boukobza A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33462724>

45. **A big-data driven approach to analyzing and modeling human mobility trend under non-pharmaceutical interventions during COVID-19 pandemic.** Transp Res Part C Emerg Technol 2021; 124:102955Hu S, Xiong C, Yang M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456212>
46. **Virtual skills-training in urology: Teaching at the Technical University of Munich during the COVID-19-pandemic.** Urologe 2021; Kidess M, Schmid SC, Pollak S *et al.*
47. **Identifying factors that influenced wellbeing and learning effectiveness during the sudden transition into eLearning due to the COVID-19 lockdown.** Work 2021; Naddeo A, Califano R, Fiorillo I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459679>

Other – Miscellaneous (53 articles)

1. **Enabling Your Radiology Business to Thrive Strategic Lessons Learned During the Initial and Subsequent Surges of the Covid-19 Pandemic.** Acad Radiol 2021; Kruskal JB, Rosen MP, Hara AK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33455861>
2. **Anatomy in a Post-Covid-19 World: Tracing a New Trajectory.** Anat Sci Educ 2021; Jones DG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33463041>
3. **"More Attention than Usual": A Thematic Analysis of Dog Ownership Experiences in the UK during the First COVID-19 Lockdown.** Animals (Basel) 2021; 11Holland KE, Owczarczak-Garstecka SC, Anderson KL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477947>
4. **The food choices of us university students during COVID-19.** Appetite 2021:105130Powell PK, Lawler S, Durham J, Cullerton K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484787>
5. **Equitable recovery from COVID-19: bring global commitments to community level.** BMJ Glob Health 2021; 6Loewenson R, D'Ambruoso L, Duc DM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33455911>
6. **Social influence matters: We follow pandemic guidelines most when our close circle does.** Br. J. Psychol. 2021; Tunçgenç B, El Zein M, Sulik J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33474747>
7. **The effects of weather on the spread of COVID-19: evidence from Ghana.** Bull Natl Res Cent 2021; 45:20Aidoo EN, Adebajji AO, Awashie GE, Appiah SK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456305>
8. **COVID-19, Obesity, and Structural Racism: Understanding the Past and Identifying Solutions for the Future.** Cell Metab. 2021; Bleich SN, Ard JD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465335>
9. **COVID-19 as an occupational disease or work-related accident: Considerations regarding insurance cover and reporting obligation in the statutory accident insurance.** Clin. Plast. Surg. 2021; Nowak D, Ochmann U, Brandenburg S *et al.*
10. **Assessment of contact lens wearers' attitude toward contact lens wear and care during Coronavirus Disease 2019 (COVID-19) pandemic: A cross-sectional online survey.** Cont Lens Anterior Eye 2021; Bakkar MM, Alzghoul EA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461877>
11. **The Effect of Social Isolation during COVID-19 Pandemic on Nutrition and Exercise Behaviors of Nursing Students.** Ecol. Food Nutr. 2021:1-19Özden G,

- Parlar Kiliç S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33475005>
12. **COVID-19 incidence and mortality in Lombardy, Italy: an ecological study on the role of air pollution, meteorological factors, demographic and socioeconomic variables.** *Environ. Res.* 2021;110777de Angelis E, Renzetti S, Volta M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485909>
 13. **The Double Effect of COVID-19 Confinement Measures and Economic Recession on High-Risk Drug Users and Drug Services.** *Eur. Addict. Res.* 2021;1-3Costa Storti C, Bretteville-Jensen AL, De Grauwe P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477135>
 14. **Changes in the Food-Related Behaviour of Italian Consumers during the COVID-19 Pandemic.** *Foods* 2021; 10Fanelli RM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467727>
 15. **Mixed Method Study to Explore Ethical Dilemmas and Health Care Workers' Willingness to Work Amid COVID-19 Pandemic in Palestine.** *Front Med (Lausanne)* 2020; 7:576820Maraqa B, Nazzal Z, Zink T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469543>
 16. **The Coronavirus Pandemic as a Game-Changer: When NBA Players Forced America to Think. Again.** *Front. Psychol.* 2020; 11:600267Galily Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469437>
 17. **Reinventing health promotion for healthy default beverage laws in the face of COVID-19.** *Glob Health Promot* 2021;1757975920986696McGurk MD, Pirkle CM, Beckelman T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482708>
 18. **Getting to the Truth: Ethics, Trust, and Triage in the United States versus Europe during the Covid-19 Pandemic.** *Hastings Cent Rep* 2021; Orfali K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486774>
 19. **Direct from the COVID-19 crisis: research and innovation sparks in Brazil.** *Health Res. Policy Syst.* 2021; 19:10Rosa MFF, da Silva EN, Pacheco C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478499>
 20. **COVID-19 Echo Chambers: Examining the Impact of Conservative and Liberal News Sources on Risk Perception and Response.** *Health Secur* 2021; Lachlan KA, Hutter E, Gilbert C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33470883>
 21. **Perceptions of Romanian Physicians on Lockdowns for COVID-19 Prevention.** *Healthcare (Basel)* 2021; 9Dima A, Balaban DV, Jurcut C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477522>
 22. **Impact of COVID-19 pandemic on sustainability determinants: A global trend.** *Heliyon* 2021:e05912Abbas HSM, Xu X, Sun C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458434>
 23. **Mucor in a Viral Land: A Tale of Two Pathogens.** *Indian J Ophthalmol* 2021; 69:244-252Sen M, Lahane S, Lahane TP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33463566>
 24. **Controlling COVID-19 Outbreaks with Financial Incentives.** *Int J Environ Res Public Health* 2021; 18Lee C, Kwak S, Kim J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467714>
 25. **Safety and Health Measures for COVID-19 Transition Period in the Hotel Industry in Spain.** *Int J Environ Res Public Health* 2021; 18Robina-Ramírez R, Medina-Merodio JA, Moreno-Luna L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467614>
 26. **Looking for the right balance between human and economic costs during COVID-19 outbreak.** *Int. J. Qual. Health Care* 2021; Seghieri C, La Regina M,

- Tanzini M, Tartaglia R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33470405>
27. **Food for thought; the importance of Nutritional wellbeing during COVID-19.** *Ir. J. Psychol. Med.* 2021;1-18Burke-Furey L, McNicholas F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33455607>
 28. **Present cum future of SARS-CoV-2 virus and its associated control of virus-laden air pollutants leading to potential environmental threat - A Review.** *J Environ Chem Eng* 2021;104973Mukherjee S, Boral S, Siddiqi H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33462561>
 29. **The impacts of human migration and city lockdowns on specific air pollutants during the COVID-19 outbreak: A spatial perspective.** *J. Environ. Manage.* 2020; 282:111907Zeng J, Bao R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465715>
 30. **COVID-19 Surveillance and Competition in Sport: Utilizing Sport Science to Protect Athletes and Staff during and after the Pandemic.** *J Funct Morphol Kinesiol* 2020; 5Hagen J, Stone JD, Hornsby WG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467284>
 31. **Elite Athletes and COVID-19 Lockdown: Future Health Concerns for an Entire Sector.** *J Funct Morphol Kinesiol* 2020; 5Paoli A, Musumeci G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467246>
 32. **Coronavirus Outbreak in Italy: Physiological Benefits of Home-Based Exercise During Pandemic.** *J Funct Morphol Kinesiol* 2020; 5Ravalli S, Musumeci G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467247>
 33. **NCSBN's Environmental Scan COVID-19 and Its Impact on Nursing and Regulation.** *J Nurs Regul* 2021; 11:S1-s36. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33473323>
 34. **The COVID-19 pandemic and the 2020 US presidential election.** *J Popul Econ* 2021;1-29Baccini L, Brodeur A, Weymouth S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469244>
 35. **Why protect civil liberties during a pandemic?** *J. Public Health Policy* 2021;1-6Levine P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33462403>
 36. **Socioeconomic and Racial Segregation and COVID-19: Concentrated Disadvantage and Black Concentration in Association with COVID-19 Deaths in the USA.** *J Racial Ethn Health Disparities* 2021;1-9Khanijahani A, Tomassoni L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469872>
 37. **Structural Racism and COVID-19 in the USA: a County-Level Empirical Analysis.** *J Racial Ethn Health Disparities* 2021;1-11Tan SB, deSouza P, Raifman M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469868>
 38. **Structural Inequalities Established the Architecture for COVID-19 Pandemic Among Native Americans in Arizona: a Geographically Weighted Regression Perspective.** *J Racial Ethn Health Disparities* 2021;1-11Yellow Horse AJ, Yang TC, Huyser KR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469867>
 39. **Does COVID-19 affect metro use in Taipei?** *J Transp Geogr* 2021; 91:102954Chang HH, Lee B, Yang FA, Liou YY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456211>
 40. **Daylight is critical to preserve 5-methoxytryptophol levels in suspected and confirmed COVID-19 patients.** *Med. Hypotheses* 2021; 147:110504Şehirli A, Sayiner S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485026>
 41. **The COVID-19 response: the health impacts of austerity measures.** *Med. J. Aust.* 2021; Kavanagh SA, LaMontagne AD, Brennan-Olsen S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486785>

42. **COVID-19 Pandemic Is a Call to Search for Alternative Protein Sources as Food and Feed: A Review of Possibilities.** Nutrients 2021; 13Rzymiski P, Kulus M, Jankowski M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466241>
43. **Green giant - a tiny chloroplast genome with mighty power to produce high-value proteins: history and phylogeny.** Plant Biotechnol J 2021; Daniell H, Jin S, Zhu XG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484606>
44. **A call to action: Improving urban green spaces to reduce health inequalities exacerbated by COVID-19.** Prev. Med. 2021;106425Geary R, Wheeler B, Lovell R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33460630>
45. **The joint dynamics of investor beliefs and trading during the COVID-19 crash.** Proc Natl Acad Sci U S A 2021; 118Giglio S, Maggiori M, Stroebel J, Utkus S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468667>
46. **[Update on the risk of corticosterone therapy in combination with abiraterone acetate during the COVID-19 pandemic].** Prog Urol 2020; Rozet F, Mongiat-Artus P, Ploussard G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468416>
47. **Reopening elite sport during the COVID-19 pandemic: Experiences from a controlled return to elite football in Denmark.** Scand. J. Med. Sci. Sports 2021; Pedersen L, Lindberg J, Lind RR, Rasmussen H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480037>
48. **Environmental management strategy in response to COVID-19 in China: Based on text mining of government open information.** Sci Total Environ 2021; 769:145158Kang A, Ren L, Hua C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485207>
49. **Industry News October 2020.** Ther. Deliv. 2021; Harris E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33455454>
50. **Transl Med UniSa** 2020; 23:19Ciacci C, Piazza O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457316>
51. **COVID-19 pandemic crisis and food safety: Implications and inactivation strategies.** Trends Food Sci Technol 2021; 109:25-36Han S, Roy PK, Hossain MI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456205>
52. **Bats, pangolins, minks and other animals - villains or victims of SARS-CoV-2?** Vet. Res. Commun. 2021; 45:1-19do Vale B, Lopes AP, Fontes MDC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33464439>
53. **Can occupational therapy manpower be replaced with social robots in a singing group during COVID-19?** Work 2021; Liao YH, Tzu-Yuan L, Wu CC, Shih YN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459684>

Pathology (8 articles)

1. **Anatomical and Pathological Observation and Analysis of SARS and COVID-19: Microthrombosis Is the Main Cause of Death.** Biol. Proced. Online 2021; 23:4Chen W, Pan JY. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472576>
2. **The neuropathological impact of COVID-19: a review.** Bull Natl Res Cent 2021; 45:19Ibrahim Fouad G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456304>
3. **Microthrombi As A Major Cause of Cardiac Injury in COVID-19: A Pathologic Study.** Circulation 2021; Pellegrini D, Kawakami R, Guagliumi G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480806>
4. **Epidemiology and pathobiology of SARS-CoV-2 (COVID-19) in comparison with SARS, MERS: An updated overview of current knowledge and future**

- perspectives.** Clin Epidemiol Glob Health 2021; 10:100694Ganesh B, Rajakumar T, Malathi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33462564>
5. **Impact of COVID-19 pandemic on functioning of cytopathology laboratory: Experience and perspective from an academic centre in New York.** Cytopathology 2021; Virk RK, Wood T, Tiscornia-Wasserman PG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33463817>
 6. **Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis: JACC Review Topic of the Week.** J Am Coll Cardiol 2021; 77:314-325Kawakami R, Sakamoto A, Kawai K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478655>
 7. **Analysis of the persistence time of the SARS-CoV-2 virus in the cadaver and the risk of passing infection to autopsy staff.** Med. Leg. J. 2021:25817220980601Aquila I, Ricci P, Bonetta CF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33475037>
 8. **Autopsy findings after long-term treatment of COVID-19 patients with microbiological correlation.** Virchows Arch. 2021:1-12Evert K, Dienemann T, Brochhausen C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33471172>

Protection (39 articles)

1. **Smart technologies driven approaches to tackle COVID-19 pandemic: a review.** 3 Biotech 2021; 11:50Khan H, Kushwah KK, Singh S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457174>
2. **Cupric Oxide Coating That Rapidly Reduces Infection by SARS-CoV-2 via Solids.** ACS Appl Mater Interfaces 2021; Hosseini M, Chin AWH, Behzadinasab S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480246>
3. **Should neurosurgeons continue to work in the absence of personal protective equipment during the COVID-19 era?** Acta Neurochir. (Wien.) 2021:1-6Eijkholt M, Hulsbergen A, Muskens I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469692>
4. **Face shields for prevention of SARS-CoV-2 in community - need of the hour.** Adv Respir Med 2021; Mittal S, Mohan A, Madan K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33471352>
5. **The FEES box: A novel barrier to contain particles during aerosol-generating procedures.** Am. J. Otolaryngol. 2021; 42:102888Ganann MG, Kitila M, Patel R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33460980>
6. **Survival of silver diamine fluoride among patients treated in community dental clinics: a naturalistic study.** BMC Oral Health 2021; 21:35Raskin SE, Tranby EP, Ludwig S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472613>
7. **Frontline healthcare workers' experiences with personal protective equipment during the COVID-19 pandemic in the UK: a rapid qualitative appraisal.** BMJ Open 2021; 11:e046199Hoernke K, Djellouli N, Andrews L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472794>
8. **Repeated vaporised hydrogen peroxide disinfection of 3M 1860 N95 mask respirators does not degrade quantitative fit performance.** Br J Anaesth 2020; Moschella P, Liao W, Litwin A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485628>
9. **Airborne Transmission of SARS-CoV-2: What We Know.** Clin Infect Dis 2021; Samet JM, Prather K, Benjamin G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?>

term=33458756

10. **Review of hygiene adaptations among UK doctors in controlling the spread of SARS-CoV-2 infection.** Clin Med (Lond) 2021; 21:e20-e25Husain SA, Husain SA, Khan OU *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33479079>
11. **Self-reported symptoms of mask-associated dry eye: A survey study of 3,605 people.** Cont Lens Anterior Eye 2021; Boccardo L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485805>
12. **Implementing Hypertension Management Interventions in Immigrant Communities in the U.S.: a Narrative Review of Recent Developments and Suggestions for Programmatic Efforts.** Curr. Hypertens. Rep. 2021; 23:5Ali SH, Islam NS, Commodore-Mensah Y, Yi SS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33483867>
13. **Aquagenic Acrokeratoderma Due to Frequent Handwashing during the COVID-19 Pandemic Outbreak.** Dermatol Ther 2021; Karagün E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484064>
14. **Risk of contagion of SARS-CoV-2 among otorhinolaryngologists in Spain during the "Two waves".** Eur Arch Otorhinolaryngol 2021:1-7Martin-Villares C, Bernal-Sprekelsen M, Molina-Ramirez CP, Bartolome-Benito M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33464400>
15. **The dilemma of COVID-19 in dental practice concerning the role of saliva in transmission: a brief review of current evidence.** Eur Oral Res 2020; 54:92-100Hamedani S, Farshidfar N, Ziaei A, Pakravan H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33474554>
16. **Review of the use of nasal and oral antiseptics during a global pandemic.** Future Microbiol. 2021; Stathis C, Victoria N, Loomis K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33464122>
17. **Personal protective equipment (PPE) guidance during a global pandemic: A statistical analysis of National perceived confidence, knowledge and educational deficits amongst UK-based doctors.** Int J Clin Pract 2021:e14029Al-Hity S, Bhamra N, Kumar R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465833>
18. **Hand Hygiene Knowledge, Perception, and Practices among Domestic Visitors to the Prophet's Mosque in Al Madinah City Amid the COVID-19 Pandemic: A Cross-Sectional Study.** Int J Environ Res Public Health 2021; 18Mahdi HA, Assaggaf HM, Alfelali M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466858>
19. **COVID-19, Fake News, and Vaccines: Should Regulation Be Implemented?** Int J Environ Res Public Health 2021; 18Marco-Franco JE, Pita-Barros P, Vivas-Orts D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467179>
20. **The Utilization of Protective Face Masks among Polish Healthcare Workers during COVID-19 Pandemic: Do We Pass the Exam?** Int J Environ Res Public Health 2021; 18Reszke R, Matusiak Ł, Krajewski PK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478170>
21. **Deposition features of inhaled viral droplets may lead to rapid secondary transmission of COVID-19.** J Aerosol Sci 2021; 154:105745Shang Y, Tao Y, Dong J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456070>
22. **Aerosolized SARS-CoV-2 exposure assessment: dispersion modeling with AERMOD.** J Environ Health Sci Eng 2021:1-9Rezaali M, Fouladi-Fard R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456782>

23. **Municipal solid waste management during COVID-19 pandemic: a comparison between the current activities and guidelines.** J Environ Health Sci Eng 2021;1-7Torkashvand J, Jonidi Jafari A, Godini K *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33456781>
24. **The use of personal protective equipment (PPE) by police during a public health crisis: An experimental test of public perception.** J Exp Criminol 2021;1-23Simpson R, Sandrin R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456429>
25. **Prevalence of SARS-CoV-2 contamination on food plant surfaces as determined by environmental monitoring.** J. Food Prot. 2021; Ming Z, Han S, Deng K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33460439>
26. **Containment of Procedure-Associated Aerosols by an Extractor Tent: effect on nebulised drug particle dispersal.** J Hosp Infect 2021; Fennelly M, Keane J, Dolan L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484782>
27. **Experience of comprehensive interventions in reducing occupational exposure to COVID-19.** J Infect Public Health 2020; 14:201-205Liu H, Wang Y, He HY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486376>
28. **Factors influencing the filtration performance of homemade face masks.** J. Occup. Environ. Hyg. 2021;1-11Hao W, Xu G, Wang Y.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33476218>
29. **Mask fatigue.** J. Pak. Med. Assoc. 2020; 70:2484Kalra S, Chaudhary S, Kantroo V, Ahuja J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33475571>
30. **Understanding How Race, Ethnicity, and Gender Shape Mask-Wearing Adherence During the COVID-19 Pandemic: Evidence from the COVID Impact Survey.** J Racial Ethn Health Disparities 2021;1-8Hearne BN, Niño MD.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33469866>
31. **Panendoscopy and COVID-19: Positioning could reduce risk of contamination.** Laryngo- Rhino- Otologie 2021; 100:6-7Walther LE.
32. **Analysis of the persistence time of the SARS-CoV-2 virus in the cadaver and the risk of passing infection to autopsy staff.** Med. Leg. J. 2021;25817220980601Aquila I, Ricci P, Bonetta CF *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33475037>
33. **Effect of Wearing a Face Mask on fMRI BOLD Contrast.** Neuroimage 2021;117752Law CSW, Lan PS, Glover GH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33460795>
34. **Aerosolisation in endonasal endoscopic pituitary surgery.** Pituitary 2021;1-8Dhillon RS, Nguyen LV, Rowin WA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469830>
35. **Polymers with antiviral properties: A brief review.** Polim. Med. 2020; 50:79-82Zmonarski S, Stojanowski J, Zmonarska J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481361>
36. **Mask Up: Academic-Community-Government Partnerships to Advance Public Health During COVID-19.** Popul Health Manag 2021; Joseph JJ, Glover A, Olayiwola JN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467989>
37. **The hygiene hypothesis, the COVID pandemic, and consequences for the human microbiome.** Proc Natl Acad Sci U S A 2021; 118Finlay BB, Amato KR, Azad M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472859>
38. **Factors associated with mask wearing among psychiatric inpatients during the COVID-19 pandemic.** Schizophr Res 2021; 228:235-236Jung HR, Park C, Kim M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476952>

39. **Maximum incubation period for COVID-19 infection: do we need to rethink the 14-day quarantine policy?** Travel Med Infect Dis 2021; 40:101976Bikbov B, Bikbov A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476809>

Pulmonary disease (7 articles)

1. **New twist to an old problem: COVID-19 and idiopathic pulmonary fibrosis.** Adv Respir Med 2021; Upadhya P, Chary R, Chawla G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33471349>
2. **COVID-19 in Pulmonary Artery Hypertension (PAH) Patients: Observations from a Large PAH Center in New York City.** Diagnostics (Basel) 2021; 11Sulica R, Cefali F, Motschwiller C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467533>
3. **Is it a bulla or a pneumatocele?** Eur J Cardiothorac Surg 2021; Hamad AM, El-Saka HA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480415>
4. **Pulmonary Hypertension in COVID-19 Pneumoniae: It Is Not Always as It Seems.** Eur J Case Rep Intern Med 2020; 7:002160Pasqualetto MC, Sorbo MD, Vitiello M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457379>
5. **Preadmission use of inhaled corticosteroids and risk of fatal or severe COVID-19: A meta-analysis.** J. Asthma 2021:1-4Kow CS, Hasan SS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461348>
6. **Lung transplantation during the outbreak of Coronavirus Disease 2019 in China.** J. Thorac. Cardiovasc. Surg. 2020; Wu B, Huang M, Jiao G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461803>
7. **Epigenetic Underpinnings of Inflammation: Connecting the dots between Pulmonary Diseases, Lung Cancer and COVID-19.** Semin. Cancer Biol. 2021; Ahmad S, Manzoor S, Siddiqui S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484868>

Renal disease (8 articles)

1. **The risk factors associated with COVID-19-Related death among patients with end-stage renal disease.** BMC Nephrol. 2021; 22:33Rastad H, Ejtahed HS, Shafiee G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468081>
2. **COVID-19 Infection in Former Living Kidney Donors.** Clin. Transplant. 2021:e14230Doshi MD, Tsapepas D, Prashar R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484065>
3. **Incidence and Clinical Impacts of COVID-19 Infection in Patients with Hemodialysis: Systematic Review and Meta-Analysis of 396,062 Hemodialysis Patients.** Healthcare (Basel) 2021; 9Chen CY, Shao SC, Chen YT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466527>
4. **Risks of AKI and Major Adverse Clinical Outcomes in Patients with Severe Acute Respiratory Syndrome or Coronavirus Disease 2019.** J Am Soc Nephrol 2021; Teoh JY, Yip TC, Lui GC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33483314>
5. **Proteinuria in COVID-19: prevalence, characterization and prognostic role.** J Nephrol 2021:1-10Huart J, Bouqueneau A, Lutteri L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484426>
6. **Two episodes of SARS-CoV-2 infection in a patient on chronic hemodialysis. A note of caution.** Kidney Int 2021; Torreggiani M, Ebikili B, Bianchi S, Piccoli GB.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=33485912>

7. **Anti-HLA and anti-SARS-CoV2 Antibodies in Kidney Transplant Recipient with COVID-19.** Transpl Int 2021; Gandolfini I, Zanelli P, Palmisano A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33481306>
8. **Association between chronic kidney disease and COVID-19-related mortality in New York.** World J. Urol. 2021:1-7 Mohamed NE, Benn EKT, Astha V *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33481113>

Reviews (28 articles)

1. **Mechanistic modeling of the SARS-CoV-2 disease map.** BioData Min. 2021; 14:5 Rian K, Esteban-Medina M, Hidalgo MR *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33478554>
2. **Review of pharmacologic and immunologic agents in the management of COVID-19.** Biosaf Health 2021; Ungogo MA, Mohammed M, Umar BN *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33458647>
3. **The neuropathological impact of COVID-19: a review.** Bull Natl Res Cent 2021; 45:19 Ibrahim Fouad G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456304>
4. **Epidemiology and pathobiology of SARS-CoV-2 (COVID-19) in comparison with SARS, MERS: An updated overview of current knowledge and future perspectives.** Clin Epidemiol Glob Health 2021; 10:100694 Ganesh B, Rajakumar T, Malathi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33462564>
5. **Review of hygiene adaptations among UK doctors in controlling the spread of SARS-CoV-2 infection.** Clin Med (Lond) 2021; 21:e20-e25 Husain SA, Husain SA, Khan OU *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33479079>
6. **Defining the role of asymptomatic and pre-symptomatic SARS-CoV-2 transmission - a living systematic review.** Clin Microbiol Infect 2021; Qiu X, Nergiz AI, Maraolo AE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484843>
7. **Prophylaxis for COVID-19: a systematic review.** Clin Microbiol Infect 2021; Smit M, Marinosci A, Agoritsas T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476807>
8. **A Review of Venous Thromboembolism in COVID-19: In a Clinical Perspective.** Clin. Respir. J. 2021; Ozsu S, Gunay E, Konstantinides SV.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33484090>
9. **An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery.** Curr. Top. Med. Chem. 2021; Sabbah DA, Hajjo R, Bardaweel SK, Zhong HA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33463470>
10. **Maculopapular skin eruptions associated with Covid-19: a systematic review.** Dermatol Ther 2021:e14788 Shams S, Rathore SS, Anvekar P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33481314>
11. **A review of potential suggested drugs for coronavirus disease (COVID-19) treatment.** Eur. J. Pharmacol. 2021:173890 Tarighi P, Eftekhari S, Chizari M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33482181>
12. **Confronting the threat of SARS-CoV-2: Realities, challenges and therapeutic strategies (Review).** Exp. Ther. Med. 2021; 21:155 Wang R, Luo X, Liu F, Luo S.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33456522>
13. **What Will Be the Impact of the Covid-19 Quarantine on Psychological Distress? Considerations Based on a Systematic Review of Pandemic**

- Outbreaks.** Healthcare (Basel) 2021; 9Cavicchioli M, Ferrucci R, Guidetti M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477981>
14. **Mucor in a Viral Land: A Tale of Two Pathogens.** Indian J Ophthalmol 2021; 69:244-252Sen M, Lahane S, Lahane TP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33463566>
 15. **Immunology, immunopathogenesis and immunotherapeutics of COVID-19; an overview.** Int Immunopharmacol 2021; 93:107364Mohamed Khosroshahi L, Rokni M, Mokhtari T, Noorbakhsh F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486333>
 16. **Extracorporeal membrane oxygenation versus mechanical ventilation alone in adults with severe acute respiratory distress syndrome: a systematic review and meta-analysis.** Int J Clin Pract 2021:e14046Zhu Y, Zhang M, Zhang R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486824>
 17. **Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis: JACC Review Topic of the Week.** J Am Coll Cardiol 2021; 77:314-325Kawakami R, Sakamoto A, Kawai K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478655>
 18. **Present cum future of SARS-CoV-2 virus and its associated control of virus-laden air pollutants leading to potential environmental threat - A Review.** J Environ Chem Eng 2021:104973Mukherjee S, Boral S, Siddiqi H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33462561>
 19. **A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for current COVID-19 (SARS-CoV-2) pandemic.** J Med Virol 2021; Kheirabadi D, Haddad F, Mousavi-Roknabadi RS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33463727>
 20. **Evidence of Coronavirus (CoV) Pathogenesis and Emerging Pathogen SARS-CoV-2 in the Nervous System: A Review on Neurological Impairments and Manifestations.** J. Mol. Neurosci. 2021:1-18Jha NK, Ojha S, Jha SK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33464535>
 21. **From Hydroxychloroquine to Ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?** J Travel Med 2021; Rakedzon S, Neuberger A, Domb AJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480414>
 22. **Skin manifestations of COVID-19: A worldwide review.** JAAD Int 2021; 2:119-133Tan SW, Tam YC, Oh CC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33479703>
 23. **Neuropathologic findings of patients with COVID-19: a systematic review.** Neurol Sci 2021; Pajo AT, Espiritu AI, Apor A, Jamora RDG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33483885>
 24. **Opportunities to improve COVID-19 provider communication resources: A systematic review.** Patient Educ. Couns. 2021; Wittenberg E, Goldsmith JV, Chen C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33455825>
 25. **Takotsubo Syndrome a Rare Entity in COVID-19: a Systemic Review-Focus on Biomarkers, Imaging, Treatment, and Outcome.** SN Compr Clin Med 2021:1-11Sharma K, Desai HD, Patoliya JV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458567>
 26. **Urology during COVID-19 Pandemic Crisis: A Systematic Review.** Surg J (N Y) 2021; 7:e3-e10Thapa BB, Shrestha D, Bista S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469564>
 27. **Sexual health and COVID-19: protocol for a scoping review.** Syst Rev 2021; 10:37Kumar N, Janmohamed K, Nyhan K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485393>

28. **Can we Turn off the "Covid-Biting-Tail" Inflammation?** Transl Med UniSa 2020; 23:39-41 Giudice V, Filippelli A, Selleri C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457321>

Risk factors (51 articles)

1. **Mortality risk of COVID-19 in elderly males with comorbidities: a multi-country study.** Aging (Albany NY) 2020; 13:27-60 Li G, Liu Y, Jing X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472167>
2. **Electrocardiographic markers of increased risk of sudden cardiac death in patients with COVID-19 pneumonia.** Ann. Noninvasive Electrocardiol. 2021:e12824 Alareedh M, Nafakhi H, Shaghee F, Nafakhi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33463863>
3. **Correspondence on 'Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients'.** Ann. Rheum. Dis. 2021; Kermani TA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478954>
4. **Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts.** Ann. Rheum. Dis. 2021; Wong AY, MacKenna B, Morton CE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478953>
5. **Predictors for development of critical illness amongst older adults with COVID-19: Beyond age to age-associated factors.** Arch. Gerontol. Geriatr. 2020; 94:104331 Lim JP, Low KYH, Lin NJJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476755>
6. **Association of Overlapped and Un-overlapped Comorbidities with COVID-19 Severity and Treatment Outcomes: A Retrospective Cohort Study from Nine Provinces in China.** Biomed. Environ. Sci. 2020; 33:893-905 Ma Y, Zhu DS, Chen RB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472729>
7. **Higher comorbidities and early death in hospitalized African-American patients with Covid-19.** BMC Infect. Dis. 2021; 21:78 Gupta R, Agrawal R, Bukhari Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461499>
8. **Clinical course and challenging management of early COVID-19 infection after heart transplantation: case report of two patients.** BMC Infect. Dis. 2021; 21:89 Tchana-Sato V, Ancion A, Tridetti J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472599>
9. **Predictive value of the neutrophil to lymphocyte ratio for disease deterioration and serious adverse outcomes in patients with COVID-19: a prospective cohort study.** BMC Infect. Dis. 2021; 21:80 Zeng ZY, Feng SD, Chen GP, Wu JN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461497>
10. **The risk factors associated with COVID-19-Related death among patients with end-stage renal disease.** BMC Nephrol. 2021; 22:33 Rastad H, Ejtahed HS, Shafiee G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468081>
11. **Pre-hospital lowest recorded oxygen saturation independently predicts death in patients with COVID-19.** Br Paramed J 2020; 5:59-65 Dillon K, Hook C, Coupland Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456398>
12. **ICU Admission Levels of Endothelial Biomarkers as Predictors of Mortality in Critically Ill COVID-19 Patients.** Cells 2021; 10 Vassiliou AG, Keskinidou C, Jahaj E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477776>

13. **Utility of visual coronary artery calcification on non-cardiac gated thoracic CT in predicting clinical severity and outcome in COVID-19.** Clin Imaging. 2021; 74:123-130 Nair AV, Kumar D, Yadav SK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485116>
14. **A meta-analysis of comorbidities in COVID-19: Which diseases increase the susceptibility of SARS-CoV-2 infection?** Comput. Biol. Med. 2021; 130:104219 Singh MK, Mobeen A, Chandra A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486379>
15. **Predictors of clinical deterioration in non-severe patients with COVID-19: a retrospective cohort study.** Curr. Med. Res. Opin. 2021:1 Zhang Y, Chen M, Zhou L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459077>
16. **Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population.** Dig. Liver Dis. 2020; Maconi G, Bosetti C, De Monti A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33483259>
17. **Effects of chronic exposure to ambient air pollutants on COVID-19 morbidity and mortality - A lesson from OECD countries.** Environ. Res. 2021:110723 Barnett-Iltzhaki Z, Levi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484722>
18. **COVID-19 incidence and mortality in Lombardy, Italy: an ecological study on the role of air pollution, meteorological factors, demographic and socioeconomic variables.** Environ. Res. 2021:110777 de Angelis E, Renzetti S, Volta M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485909>
19. **Demographic predictors of hospitalization and mortality in US children with COVID-19.** Eur. J. Pediatr. 2021:1-5 Moreira A, Chorath K, Rajasekaran K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33474580>
20. **Health Inequalities and Ethnic Vulnerabilities During COVID-19 in the UK: A Reflection on the PHE Reports.** Fem Leg Stud 2021:1-12 Keys C, Nanayakkara G, Onyejekwe C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469247>
21. **Diabetes Might Augment the Severity of COVID-19: A Current Prospects.** Front Cardiovasc Med 2020; 7:613255 Sur J, Sharma J, Sharma D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469551>
22. **Association Between Clinical Characteristics and Short-Term Outcomes in Adult Male COVID-19 Patients With Mild Clinical Symptoms: A Single-Center Observational Study.** Front Med (Lausanne) 2020; 7:571396 Yan B, Song L, Guo J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469542>
23. **Age-associated difference in circulating ACE2, the gateway for SARS-COV-2, in humans: results from the InCHIANTI study.** Geroscience 2021:1-9 AlGhatrif M, Tanaka T, Moore AZ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33462706>
24. **Patterns of COVID-19 related excess mortality in the municipalities of Northern Italy during the first wave of the pandemic.** Health Place 2021; 67:102508 Gibertoni D, Adja KYC, Golinelli D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476843>
25. **Is prognostic nutritional index a predictive marker for estimating all-cause in-hospital mortality in COVID-19 patients with cardiovascular risk factors?** Heart Lung 2021; 50:307-312 Çınar T, Hayıroğlu M, Çiçek V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482433>
26. **The mortality rate of COVID-19 was high in cancer patients: a retrospective single-center study.** Int. J. Clin. Oncol. 2021; Erdal GS, Polat O, Erdem GU *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486624>

27. **Vulnerable Workers and COVID-19: Insights from a Survey of Members of the International Commission for Occupational Health.** Int J Environ Res Public Health 2021; 18:Tamin J, Samuel O, Suraya A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466436>
28. **Risk Assessment for COVID-19 Pandemic in Taiwan.** Int J Infect Dis 2021; Jian SW, Kao CT, Chang YC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486014>
29. **Risk factors for illness severity in patients with COVID-19 pneumonia: a prospective cohort study.** Int. J. Med. Sci. 2021; 18:921-928Zhang N, Zhang H, Tang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456349>
30. **Procalcitonin Has Good Accuracy for Prognosis of Critical Condition and Mortality in COVID-19: A Diagnostic Test Accuracy Systematic Review and Meta-analysis.** Iran. J. Allergy Asthma Immunol. 2020; 19:557-569Zare ME, Wang Y, Nasir Kansestani A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33463126>
31. **Broader Insights into Understanding Tumor Necrosis Factor and Neurodegenerative Disease Pathogenesis Infer New Therapeutic Approaches.** J. Alzheimers Dis. 2021; Clark IA, Vissel B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459706>
32. **Preadmission use of inhaled corticosteroids and risk of fatal or severe COVID-19: A meta-analysis.** J. Asthma 2021;1-4Kow CS, Hasan SS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461348>
33. **Prognostic Implications of Chronic Heart Failure and Utility of NT-proBNP Levels in Heart Failure Patients with SARS-CoV-2 Infection.** J Clin Med 2021; 10:Belarte-Tornero LC, Valdivielso-Moré S, Vicente Elcano M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477268>
34. **When Does the Cytokine Storm Begin in COVID-19 Patients? A Quick Score to Recognize It.** J Clin Med 2021; 10:Cappanera S, Palumbo M, Kwan SH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467466>
35. **Prognostic Factors at Admission for In-Hospital Mortality from COVID-19 Infection in an Older Rural Population in Central Spain.** J Clin Med 2021; 10:Maestre-Muñiz MM, Arias Á, Arias-González L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467207>
36. **Evaluation of procalcitonin as a contribution to antimicrobial stewardship in SARS-CoV-2 infection: a retrospective cohort study.** J Hosp Infect 2021; Williams EJ, Mair L, de Silva TI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484783>
37. **Immune profiling reveals early disease trajectories associated with COVID-19 mortality: a sub-study from the ACTT-1 trial.** J Infect Dis 2021; Thiede JM, Gress AR, Libby SD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476387>
38. **Genome-wide DNA methylation profiling of peripheral blood reveals an epigenetic signature associated with severe COVID-19.** J. Leukoc. Biol. 2021; Corley MJ, Pang APS, Dody K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33464637>
39. **A U-shaped association between baseline neutrophil count and COVID-19-related mortality: a retrospective cohort study.** J Med Virol 2021; Fu W, Chen C, Chen XL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33463721>
40. **Impact of a Long-Term Air Pollution Exposure on the Case Fatality Rate of COVID-19 Patients - A Multi-City Study.** J Med Virol 2021; Hou CK, Qin YF, Wang G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33470428>

41. **Clinical Outcomes of Critically Ill Patients with COVID-19 by Race.** J Racial Ethn Health Disparities 2021:1-5Marmarchi F, Liu M, Rangaraju S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33469873>
42. **Mitochondrial Functionality in Inflammatory Pathology-Modulatory Role of Physical Activity.** Life (Basel) 2021; 11Casuso RA, Huertas JR.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33467642>
43. **Statistical analysis of COVID-19 infection caused by environmental factors: Evidence from Pakistan.** Life Sci 2021:119093Fawad M, Mubarik S, Malik SS, Ren J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476630>
44. **[Risk stratification nomogram for COVID-19 patients with interstitial pneumonia in the emergency department : A retrospective multicenter study].** Med Klin Intensivmed Notfmed 2021:1-9Pfeifer N, Zaboli A, Ciccariello L *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33481077>
45. **SARS-CoV-2 and Obesity: "CoVesity"-a Pandemic Within a Pandemic.** Obes. Surg. 2021:1-10Zakka K, Chidambaram S, Mansour S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33479921>
46. **An increase in CD62L(dim) neutrophils precedes the development of pulmonary embolisms in COVID-19 patients.** Scand. J. Immunol. 2021:e13023Spijkerman R, Jorritsma NK, Bongers SH *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33482019>
47. **People with dyssomnia showed increased vulnerability to CoVID-19 pandemic: a questionnaire-based study exploring the patterns and predictors of sleep quality using the latent class analysis technique in Indian population.** Sleep Med. 2021; 79:29-39Radhakrishnan A, Govindaraj R, Sasidharan A *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33485259>
48. **Altered Cholesterol and Lipid Synthesis Mediates Hyperinflammation in COVID-19.** Trends Endocrinol. Metab. 2021; Sohrabi Y, Reinecke H, Godfrey R.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33455862>
49. **Expression of SARS-CoV-2 Host Cell Entry Factors in Immune System Components of Healthy Individuals and Its Relevance for COVID-19 Immunopathology.** Viral Immunol 2021; Kumar A, Kumar S, Narayan RK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33481684>
50. **Investigating the relationship between occupation and SARS-CoV2.** Work 2021; Sarailoo M, Matin S, Vosoughi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459683>
51. **Association between chronic kidney disease and COVID-19-related mortality in New York.** World J. Urol. 2021:1-7Mohamed NE, Benn EKT, Astha V *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33481113>

Safety (19 articles)

1. **Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications.** Acta Myol. 2020; 39:289-301Dalakas MC.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33458584>
2. **Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts.** Ann. Rheum. Dis. 2021; Wong AY, MacKenna B, Morton CE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478953>

3. **Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain?** Best Pract. Res. Clin. Rheumatol. 2021;101658Egeli BH, Sparks JA, Kim AHJ, Liew JW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33483287>
4. **Unilateral axillary Adenopathy in the setting of COVID-19 vaccine.** Clin Imaging 2021; 75:12-15Mehta N, Sales RM, Babagbemi K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486146>
5. **Coagulation Inhibitors in COVID-19 Leading to Compressive Airway Hematoma.** Cureus 2021; 13:e12580Mohamed A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457144>
6. **Hydroxychloroquine and COVID-19: a Rheumatologist's Take on the Lessons Learned.** Curr. Allergy Asthma Rep. 2021; 21:5Udupa A, Leverenz D, Balevic SJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33475900>
7. **COVID-19, Angiotensin-Converting Enzyme 2 and Renin-Angiotensin System Inhibition: Implications for Practice.** Curr. Hypertens. Rev. 2021; Katsi V, Pavlidis G, Charalambous G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33475077>
8. **Exacerbation of psoriasis following hydroxychloroquine in a patient with suspected COVID-19.** Dermatol Ther 2021:e14806Öncü INS, Güler D, Gürel G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486832>
9. **The development of dermatologic diseases in patients recovered from COVID-19.** Dermatol Ther 2021; Temiz SA, Kutlu Ö. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484016>
10. **Is it safe to use remdesivir in combination with a combined p-glycoprotein and CYP3A4 inhibitor?** Eur J Hosp Pharm 2021; Bahçecioğlu Ö F, Gök S, Durmuş M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472816>
11. **The Efficacy and Safety of Hydroxychloroquine in Patients with COVID-19: A Multicenter National Retrospective Cohort.** Infect Dis Ther 2021; Abdulrahman A, AlSayed I, AlMadhi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484407>
12. **Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?** Int. J. Hematol. 2021:1-7Iba T, Connors JM, Spyropoulos AC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33471294>
13. **Preadmission use of inhaled corticosteroids and risk of fatal or severe COVID-19: A meta-analysis.** J. Asthma 2021:1-4Kow CS, Hasan SS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461348>
14. **Prediction of adverse drug reactions using drug convolutional neural networks.** J. Bioinform. Comput. Biol. 2021:2050046Mantripragada AS, Teja SP, Katasani RR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472571>
15. **Increased usage of smartphones during COVID-19: Is that blue light causing skin damage?** J Cosmet Dermatol 2020; 19:2466-2467Jakhar D, Kaul S, Kaur I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33460228>
16. **Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19.** JACC Clin Electrophysiol 2021; 7:16-25O'Connell TF, Bradley CJ, Abbas AE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478708>
17. **Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies.** Leuk. Lymphoma 2021:1-9Ferrari S, Caprioli C, Weber A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461387>

18. **Chloroquine may induce endothelial injury through lysosomal dysfunction and oxidative stress.** Toxicol. Appl. Pharmacol. 2021;115412Gregório PC, da Cunha RS, Biagini G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484708>
19. **Cardiotoxic Potential of Hydroxychloroquine, Chloroquine and Azithromycin in Adult Human Primary Cardiomyocytes.** Toxicol. Sci. 2021; Jordaan P, Dumotier B, Traebert M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33483756>

Treatment options (88 articles)

1. **Recent biotechnological advances as potential intervention strategies against COVID-19.** 3 Biotech 2021; 11:41Lobo-Galo N, Gálvez-Ruíz JC, Balderrama-Carmona AP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457170>
2. **Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered via Lipid Nanoparticles.** ACS Nano 2021; Elia U, Ramishetti S, Rosenfeld R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480671>
3. **Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications.** Acta Myol. 2020; 39:289-301Dalakas MC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458584>
4. **A review of Ciclesonide in COVID-19. Still a long way to go.** Adv Respir Med 2021; Deokar K, Agarwal M, Dutt N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33471354>
5. **Fighting the storm: could novel anti-TNF α and anti-IL-6 C. sativa cultivars tame cytokine storm in COVID-19?** Aging (Albany NY) 2021; 13Kovalchuk A, Wang B, Li D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465050>
6. **Developing statewide remdesivir use criteria.** Am. J. Health Syst. Pharm. 2021; Fox ER, Shah M, Vinik R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33483744>
7. **Protease inhibitor GC376 for COVID-19: Lessons learned from feline infectious peritonitis.** Ann Med Surg (Lond) 2021; 61:122-125Sharun K, Tiwari R, Dhama K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456770>
8. **Diarylureas: Repositioning from Antitumor to Antimicrobials or Multi-Target Agents against New Pandemics.** Antibiotics (Basel) 2021; 10Catalano A, Iacopetta D, Pellegrino M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477901>
9. **Pharmacoinformatics approach based identification of potential Nsp15 endoribonuclease modulators for SARS-CoV-2 inhibition.** Arch. Biochem. Biophys. 2021:108771Savale RU, Bhowmick S, Osman SM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485847>
10. **Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain?** Best Pract. Res. Clin. Rheumatol. 2021:101658Egeli BH, Sparks JA, Kim AHJ, Liew JW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33483287>
11. **Biochemical features and mutations of key proteins in SARS-CoV-2 and their impacts on RNA therapeutics.** Biochem. Pharmacol. 2021:114424Zeng L, Li D, Tong W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482149>
12. **Human endeavor for anti-SARS-CoV-2 pharmacotherapy: A major strategy to fight the pandemic.** Biomed. Pharmacother. 2021; 137:111232Wang R, Stephen P, Tao Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486202>
13. **Review of pharmacologic and immunologic agents in the management of COVID-19.** Biosaf Health 2021; Ungogo MA, Mohammed M, Umar BN *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458647>
14. **Allergen fragrance molecules: a potential relief for COVID-19.** BMC Complement Med Ther 2021; 21:41 Aydın AD, Altinel F, Erdoğan H, Son Ç D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478471>
 15. **A pilot trial of human amniotic fluid for the treatment of COVID-19.** BMC Res. Notes 2021; 14:32 Selzman CH, Tonna JE, Pierce J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482902>
 16. **Research Evaluation Alongside Clinical Treatment in COVID-19 (REACT COVID-19): an observational and biobanking study.** BMJ Open 2021; 11:e043012 Burke H, Freeman A, Dushianthan A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33483446>
 17. **Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation: protocol for a randomised, controlled, open-label intervention, multicentre trial.** BMJ Open 2021; 11:e043345 Rieder M, Schubach F, Schmoor C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33455938>
 18. **The NICE COVID-19 rapid guideline on haematopoietic stem cell transplantation: development, implementation and impact.** Br. J. Haematol. 2021; Orchard K, Dignan FL, Lee J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33474730>
 19. **Early mortality benefit with COVID-19 convalescent plasma: a matched control study.** Br. J. Haematol. 2021; Shenoy AG, Hettinger AZ, Fernandez SJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482025>
 20. **Ligand-based approach for predicting drug targets and for virtual screening against COVID-19.** Brief. Bioinform. 2021; Yang Y, Zhu Z, Wang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461215>
 21. **Synthetic Siglec-9 Agonists Inhibit Neutrophil Activation Associated with COVID-19.** ChemRxiv 2020; Delaveris C, Wilk A, Riley N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469569>
 22. **Small Molecules to Destabilize the ACE2-RBD Complex: A Molecular Dynamics Study for Potential COVID-19 Therapeutics.** ChemRxiv 2020; Razizadeh M, Nikfar M, Liu Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469570>
 23. **Convalescent Plasma: Education and Administration Implications.** Clin. J. Oncol. Nurs. 2021; 25:28-32 Martin JC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480877>
 24. **Prophylaxis for COVID-19: a systematic review.** Clin Microbiol Infect 2021; Smit M, Marinosci A, Agoritsas T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476807>
 25. **Anti-phospholipids antibodies and immune complexes in COVID-19 patients: a putative role in disease course for anti-annexin-V antibodies.** Clin Rheumatol 2021; 1-7 Cristiano A, Fortunati V, Cherubini F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33464429>
 26. **Coagulation Inhibitors in COVID-19 Leading to Compressive Airway Hematoma.** Cureus 2021; 13:e12580 Mohamed A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457144>
 27. **Hydroxychloroquine and COVID-19: a Rheumatologist's Take on the Lessons Learned.** Curr. Allergy Asthma Rep. 2021; 21:5 Udupa A, Leverenz D, Balevic SJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33475900>
 28. **Natural agents modulating ACE-2: A review of compounds with potential against SARS-CoV-2 infections.** Curr. Pharm. Des. 2021; Junior AG, Tolouei SEL,

- Dos Reis Lívero FA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459225>
29. **Therapeutic agents against COVID-19 with clinical evidence.** Curr. Pharm. Des. 2021; Tian C, Xiang M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459226>
30. **Exacerbation of psoriasis following hydroxychloroquine in a patient with suspected COVID-19.** Dermatol Ther 2021:e14806Öncü INS, Güler D, Gürel G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486832>
31. **The development of dermatologic diseases in patients recovered from COVID-19.** Dermatol Ther 2021; Temiz SA, Kutlu Ö. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484016>
32. **Treatment of Crimean-Congo Haemorrhagic Fever by Favipiravir in a Patient with Novel Coronavirus Co-Infection.** Eur J Case Rep Intern Med 2020; 7:002042Dülger AC, Yakarışık M, Uzun YE, Şahin AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457366>
33. **Is it safe to use remdesivir in combination with a combined p-glycoprotein and CYP3A4 inhibitor?** Eur J Hosp Pharm 2021; Bahçecioğlu Ö F, Gök S, Durmuş M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472816>
34. **The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2.** Eur. J. Med. Chem. 2021; 213:113157Shagufta, Ahmad I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486200>
35. **A review of potential suggested drugs for coronavirus disease (COVID-19) treatment.** Eur. J. Pharmacol. 2021:173890Tarighi P, Eftekhari S, Chizari M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482181>
36. **The European tiered approach for virucidal efficacy testing - rationale for rapidly selecting disinfectants against emerging and re-emerging viral diseases.** Euro Surveill 2021; 26Eggers M, Schwebke I, Suchomel M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478622>
37. **Confronting the threat of SARS-CoV-2: Realities, challenges and therapeutic strategies (Review).** Exp. Ther. Med. 2021; 21:155Wang R, Luo X, Liu F, Luo S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456522>
38. **SARS-CoV-2 RNA dependent RNA polymerase as a therapeutic target for COVID-19.** Expert Opin. Ther. Pat. 2021; Vicenti I, Zazzi M, Saladini F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33475441>
39. **SARS-CoV-2 meta-interactome suggests disease-specific, autoimmune pathophysiologies and therapeutic targets.** F1000Res 2020; 9:992Bellucci G, Ballerini C, Mechelli R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456761>
40. **Combating COVID-19 With Mesenchymal Stem/Stromal Cell Therapy: Promise and Challenges.** Front Cell Dev Biol 2020; 8:627414Wang SH, Shetty AK, Jin K, Chunhua Zhao R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469541>
41. **Single-Cell RNA Sequencing of Tocilizumab-Treated Peripheral Blood Mononuclear Cells as an in vitro Model of Inflammation.** Front Genet 2020; 11:610682Zarinsefat A, Hartoularos G, Rychkov D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469465>
42. **Transcriptome network analyses in human coronavirus infections suggest a rational use of immunomodulatory drugs for COVID19 therapy.** Genomics 2021; Wong HS, Guo CL, Lin GH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482326>
43. **Framing access to medicines during COVID-19: A qualitative content analysis of Gilead's Remdesivir.** Glob Public Health 2021:1-13Flynn MB, Silva EO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33460356>

44. **The Efficacy and Safety of Hydroxychloroquine in Patients with COVID-19: A Multicenter National Retrospective Cohort.** *Infect Dis Ther* 2021; Abdulrahman A, AlSayed I, AlMadhi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484407>
45. **In silico exploration of novel protease inhibitors against coronavirus 2019 (COVID-19).** *Inform Med Unlocked* 2021; 23:100516Aghaee E, Ghodrati M, Ghasemi JB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457495>
46. **Ozone therapy for the treatment of COVID-19 pneumonia: A scoping review.** *Int Immunopharmacol* 2020; 92:107307Izadi M, Cegolon L, Javanbakht M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476982>
47. **Immunology, immunopathogenesis and immunotherapeutics of COVID-19; an overview.** *Int Immunopharmacol* 2021; 93:107364Mohamed Khosroshahi L, Rokni M, Mokhtari T, Noorbakhsh F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486333>
48. **Pharmacological strategies to prevent SARS-CoV-2 infection and to treat the early phases of COVID-19 disease.** *Int J Infect Dis* 2021; Scarabel L, Guardascione M, Dal Bo M, Toffoli G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476760>
49. **Prediction of adverse drug reactions using drug convolutional neural networks.** *J. Bioinform. Comput. Biol.* 2021:2050046Mantripragada AS, Teja SP, Katasani RR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472571>
50. **An in silico analysis of Ibuprofen enantiomers in high concentrations of sodium chloride with SARS-CoV-2 main protease.** *J Biomol Struct Dyn* 2021:1-12Clemente CM, Freiburger MI, Ravetti S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459192>
51. **In silico study indicates antimalarials as direct inhibitors of SARS-CoV-2-RNA dependent RNA polymerase.** *J Biomol Struct Dyn* 2021:1-18Doharey PK, Singh V, Gedda MR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33475021>
52. **In silico evaluation of lapachol derivatives binding to the Nsp9 of SARS-CoV-2.** *J Biomol Struct Dyn* 2021:1-15Junior NN, Santos IA, Meireles BA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478342>
53. **Withanolides from Withania somnifera as an immunity booster and their therapeutic options against COVID-19.** *J Biomol Struct Dyn* 2021:1-14Khanal P, Chikhale R, Dey YN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459174>
54. **Dissecting the novel mechanism of Reduning injection in treating Coronavirus Disease 2019 (COVID-19) based on network pharmacology and experimental verification.** *J. Ethnopharmacol.* 2021:113871Jia S, Luo H, Liu X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485971>
55. **Convalescent Plasma: Alternative or Promising Therapy?** *J Glob Antimicrob Resist* 2021; Mina FB, Billah M, Rahman S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476835>
56. **Targeting SARS-CoV-2 Viral Proteases as a Therapeutic Strategy to Treat COVID-19.** *J Med Virol* 2021; Anirudhan V, Lee H, Cheng H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33475167>
57. **Zinc treatment of outpatient COVID-19: A retrospective review of 28 consecutive patients.** *J Med Virol* 2021; Finzi E, Harrington A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33475170>
58. **A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for current COVID-19 (SARS-CoV-2) pandemic.** *J Med Virol* 2021; Kheirabadi D, Haddad F, Mousavi-Roknabadi RS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33463727>

59. **ACE-2-Derived Biomimetic Peptides for the Inhibition of Spike Protein of SARS-CoV-2.** *J. Proteome Res.* 2021; Panda SK, Sen Gupta PS, Biswal S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472369>
60. **From Hydroxychloroquine to Ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?** *J Travel Med* 2021; Rakedzon S, Neuberger A, Domb AJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480414>
61. **Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19.** *JACC Clin Electrophysiol* 2021; 7:16-25 O'Connell TF, Bradley CJ, Abbas AE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478708>
62. **Effective virus-neutralizing activities in antisera from the first wave of severe COVID-19 survivors.** *JCI Insight* 2021; Han Y, Liu P, Qiu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476301>
63. **Treatment of Severe COVID-19 with Convalescent Plasma in Bronx, NYC.** *JCI Insight* 2021; Yoon HA, Bartash R, Gendlina I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476300>
64. **Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies.** *Leuk. Lymphoma* 2021:1-9 Ferrari S, Caprioli C, Weber A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461387>
65. **Antibodies to watch in 2021.** *MAbs* 2021; 13:1860476 Kaplon H, Reichert JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33459118>
66. **Engineering a Reliable and Convenient SARS-CoV-2 Replicon System for Analysis of Viral RNA Synthesis and Screening of Antiviral Inhibitors.** *mBio* 2021; 12 Luo Y, Yu F, Zhou M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468688>
67. **Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses In Vitro.** *mBio* 2021; 12 Stone NE, Jaramillo SA, Jones AN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468703>
68. **What sunspots are whispering about covid-19?** *Med. Hypotheses* 2021; 147:110487 Morchiladze MM, Silagadze TK, Silagadze ZK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33465563>
69. **Fecal microbiota transplantation for COVID-19; a potential emerging treatment strategy.** *Med. Hypotheses* 2020; 147:110476 Nejadghaderi SA, Nazemalhosseini-Mojarad E, Asadzadeh Aghdaei H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482620>
70. **Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19.** *Med. Hypotheses* 2021; 147:110486 Vitiello A, La Porta R, Ferrara F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33460992>
71. **[Convalescent plasma as a therapy for severe COVID-19 pneumonia].** *Medicina (B. Aires)* 2020; 80 Suppl 6:9-17 Valentini R, Fernández J, Riveros D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481727>
72. **Could targeting immunometabolism be a way to control the burden of COVID-19 infection?** *Microbes Infect* 2021:104780 Berber E, Sumbria D, Rouse BT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482357>
73. **COVID-19 Transmission, Current Treatment, and Future Therapeutic Strategies.** *Mol. Pharm.* 2021; Salian VS, Wright JA, Vedell PT *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=33464914>
74. **COVID-19 in ocrelizumab-treated people with multiple sclerosis.** Mult Scler Relat Disord 2020; 49:102725 Hughes R, Whitley L, Fitovski K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482590>
 75. **Effectiveness of In-Hospital Cholecalciferol Use on Clinical Outcomes in Comorbid COVID-19 Patients: A Hypothesis-Generating Study.** Nutrients 2021; 13:Giannini S, Passeri G, Tripepi G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466642>
 76. **Use of tocilizumab in a patient with severe COVID-19 in a Teaching Hospital in Ghana: a case report.** Pan Afr. Med. J. 2020; 37:30 Hardy YO, Hutton-Mensah KA, Amenuke DAY, Amoah-Dankwah J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456654>
 77. **COVID-19: Analysis of Drug Repositioning Practice.** Pharm Chem J 2021; 1-8 Savosina PI, Druzhilovskii DS, Poroikov VV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456092>
 78. **COVID-19-The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection.** Pharmaceuticals (Basel) 2021; 14:Kotfis K, Lechowicz K, Drożdżal S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477294>
 79. **17 β -estradiol reduces SARS-CoV-2 infection in vitro.** Physiol Rep 2021; 9:e14707 Lemes RMR, Costa AJ, Bartolomeo CS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33463909>
 80. **[Update on the risk of corticosterone therapy in combination with abiraterone acetate during the COVID-19 pandemic].** Prog Urol 2020; Rozet F, Mongiat-Artus P, Ploussard G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468416>
 81. **Surfactant therapy for COVID-19 related ARDS: a retrospective case-control pilot study.** Respir Res 2021; 22:20 Piva S, DiBlasi RM, Slee AE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461535>
 82. **Re-reading ACT, BCG, and Low COVID-19 in Africa.** SN Compr Clin Med 2021; 1-5 Kangbai JB, Babawo LS, Kaitibi D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458569>
 83. **Chloroquine may induce endothelial injury through lysosomal dysfunction and oxidative stress.** Toxicol. Appl. Pharmacol. 2021; 115412 Gregório PC, da Cunha RS, Biagini G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33484708>
 84. **Cardiotoxic Potential of Hydroxychloroquine, Chloroquine and Azithromycin in Adult Human Primary Cardiomyocytes.** Toxicol. Sci. 2021; Jordaan P, Dumotier B, Traebert M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33483756>
 85. **Covid-19 Convalescent Plasma Donor Characteristics, Product Disposition and Comparison With Standard Apheresis Donors.** Transfusion 2021; Lasky B, Goodhue Meyer E, Steele WR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458811>
 86. **The Intersection of Photopheresis and COVID-19 Vaccination.** Transplant Cell Ther 2021; Booth GS, Savani BN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33462569>
 87. **Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial.** Trials 2021; 22:70 Diago-Sempere E, Bueno JL, Sancho-López A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472681>

88. **Evaluation of the efficacy and safety of inhaled magnesium sulphate in combination with standard treatment in patients with moderate or severe COVID-19: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2021; 22:60Pourdowlat G, Mousavinasab SR, Farzanegan B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461602>

Trials (11 articles)

1. **SARS-CoV-2 vaccines in advanced clinical trials: where do we stand.** *Adv Drug Deliv Rev* 2021; Chakraborty S, Mallajosyula V, Tato CM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482248>
2. **Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation: protocol for a randomised, controlled, open-label intervention, multicentre trial.** *BMJ Open* 2021; 11:e043345Rieder M, Schubach F, Schmoor C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33455938>
3. **REACT study protocol: resilience after the COVID-19 threat (REACT) in adolescents.** *BMJ Open* 2021; 11:e042824Smith AJ, Moreno-López L, Davidson E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472787>
4. **Early mortality benefit with COVID-19 convalescent plasma: a matched control study.** *Br. J. Haematol.* 2021; Shenoy AG, Hettinger AZ, Fernandez SJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482025>
5. **Short-term cardiac outcome in survivors of COVID-19: a systematic study after hospital discharge.** *Clin Res Cardiol* 2021;1-10Sechi LA, Colussi G, Bulfone L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481096>
6. **Effects of rapid recruitment and dissemination on Covid-19 mortality: the RECOVERY trial.** *F1000Res* 2020; 9:1017Knowlson C, Torgerson DJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33447376>
7. **[Differential clinic in children infected by SARS-CoV-2, traceability of contacts and cost-effectiveness of diagnostic tests: Cross-sectional observational study].** *An Pediatr (Barc)* 2020; Fiel-Ozores A, González-Durán ML, Novoa-Carballal R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485824>
8. **COVID-19 and Clinical Trials: Current Challenges and Future Directions.** *Rev. Recent Clin. Trials* 2021; Singh V, Garg S, Klimek M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480349>
9. **Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial.** *Trials* 2021; 22:70Diago-Sempere E, Bueno JL, Sancho-López A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472681>
10. **Evaluation of the efficacy and safety of inhaled magnesium sulphate in combination with standard treatment in patients with moderate or severe COVID-19: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2021; 22:60Pourdowlat G, Mousavinasab SR, Farzanegan B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461602>
11. **Managing clinical trials during COVID-19: experience from a clinical research facility.** *Trials* 2021; 22:62Shiely F, Foley J, Stone A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461595>

Vaccines (34 articles)

1. **Designing a next generation multi-epitope based peptide vaccine candidate against SARS-CoV-2 using computational approaches.** 3 Biotech 2021; 11:47 Saha R, Ghosh P, Burra V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457172>
2. **[COVID-19 Vaccine: From Theory to Practice].** Acta Med Port 2021; Oliveira Pinto B, Silva L, Baptista Leite R, Pedrosa V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33468299>
3. **SARS-CoV-2 vaccines in advanced clinical trials: where do we stand.** Adv Drug Deliv Rev 2021; Chakraborty S, Mallajosyula V, Tato CM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482248>
4. **Equity in Covid-19 vaccine development and deployment.** Am J Obstet Gynecol 2021; Modi N, Ayres DECD, Bancalari E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33460584>
5. **Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine.** Angew. Chem. Int. Ed. Engl. 2021; Jangra S, De Vrieze J, Choi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33464672>
6. **A domain-based vaccine construct against SARS-CoV-2, the causative agent of COVID-19 pandemic: development of self-amplifying mRNA and peptide vaccines.** Bioimpacts 2021; 11:65-84 Pourseif MM, Parvizpour S, Jafari B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469510>
7. **Unilateral axillary Adenopathy in the setting of COVID-19 vaccine.** Clin Imaging 2021; 75:12-15 Mehta N, Sales RM, Babagbemi K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486146>
8. **COVID-19 Vaccines: Preparing for Vaccination in the Context of Clinical Oncology Care.** Clin. J. Oncol. Nurs. 2021; 25:76-84 Carr E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33480870>
9. **A plea for equitable global access to COVID-19 diagnostics, vaccination and therapy: the NeuroCOVID-19 task Force of the european Academy of neurology.** Eur. J. Neurol. 2021; Sellner J, Jenkins TM, von Oertzen TJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33460486>
10. **SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.** Gut 2021; Siegel CA, Melmed GY, McGovern DP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472895>
11. **A Tale of Two Crises: Addressing Covid-19 Vaccine Hesitancy as Promoting Racial Justice.** HEC Forum 2021:1-12 Bunch L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33464452>
12. **Absence of association between 2019-20 influenza vaccination and COVID-19: Results of the European I-MOVE-COVID-19 primary care project, March-August 2020.** Influenza Other Respir Viruses 2021; Kissling E, Hooiveld M, Brytting M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33481344>
13. **COVID-19, Fake News, and Vaccines: Should Regulation Be Implemented?** Int J Environ Res Public Health 2021; 18 Marco-Franco JE, Pita-Barros P, Vivas-Orts D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33467179>
14. **Value of Immunizations during the COVID-19 Emergency.** Int J Environ Res Public Health 2021; 18 Stefanati A, d'Anchera E, De Motoli F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477591>

15. **Pharmacological strategies to prevent SARS-CoV-2 infection and to treat the early phases of COVID-19 disease.** Int J Infect Dis 2021; Scarabel L, Guardascione M, Dal Bo M, Toffoli G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33476760>
16. **An Evidence-Based Guide to SARS-CoV-2 Vaccination of Patients on Immunotherapies in Dermatology.** J Am Acad Dermatol 2021; Gresham LM, Marzario B, Dutz J, Kirchhof MG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482251>
17. **COVID-19 Vaccination: An Overview and Education Tool for Nuclear Medical Technologists.** J. Nucl. Med. Technol. 2021; Barnswell LH, 3rd, Crosthwaite MH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33483330>
18. **Doctor - Should I get the COVID-19 vaccine? Infection and Immunization in Individuals with Neuromuscular Disorders.** Muscle Nerve 2021; živković SA, Gruener G, Narayanaswami P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33471383>
19. **At least 156 reasons to prioritise COVID-19 vaccination in patients receiving in-centre haemodialysis.** Nephrol Dial Transplant 2021; Combe C, Kirsch AH, Alfano G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33475137>
20. **[A summary of characteristics of the first wave of new type coronavirus epidemic and potential association with tuberculosis vaccination].** Orv. Hetil. 2021; 162:123-134Emődy-Kiss B, Pataki Á, Deli G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33486464>
21. **Implementing nationwide measles supplemental immunization activities in Ethiopia in the context of COVID-19: process and lessons learnt.** Pan Afr. Med. J. 2020; 37:36Nigus M, Zelalem M, Abraham K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456660>
22. **Re-reading ACT, BCG, and Low COVID-19 in Africa.** SN Compr Clin Med 2021:1-5Kangbai JB, Babawo LS, Kaitibi D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33458569>
23. **Associations of COVID-19 risk perception with vaccine hesitancy over time for Italian residents.** Soc. Sci. Med. 2021; 272:113688Caserotti M, Girardi P, Rubaltelli E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33485215>
24. **The Intersection of Photopheresis and COVID-19 Vaccination.** Transplant Cell Ther 2021; Booth GS, Savani BN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33462569>
25. **The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization.** Vaccine 2021; Kohli M, Maschio M, Becker D, Weinstein MC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33483216>
26. **Short term impact of the COVID-19 pandemic on incidence of vaccine preventable diseases and participation in routine infant vaccinations in the Netherlands in the period March-September 2020.** Vaccine 2021; Middeldorp M, van Lier A, van der Maas N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478793>
27. **Predictors of intention to vaccinate against COVID-19: Results of a nationwide survey.** Vaccine 2021; Ruiz JB, Bell RA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461833>
28. **Vaccination patterns of the northeast Ohio Amish revisited.** Vaccine 2021; Scott EM, Stein R, Brown MF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478791>

29. **Immuno-informatics approach for B-cell and T-cell epitope based peptide vaccine design against novel COVID-19 virus.** *Vaccine* 2021; Singh J, Malik D, Raina A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33478787>
30. **Acceptance of the COVID-19 vaccine based on the health belief model: A population-based survey in Hong Kong.** *Vaccine* 2021; Wong MCS, Wong ELY, Huang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461834>
31. **Change of Willingness to Accept COVID-19 Vaccine and Reasons of Vaccine Hesitancy of Working People at Different Waves of Local Epidemic in Hong Kong, China: Repeated Cross-Sectional Surveys.** *Vaccines (Basel)* 2021; 9Wang K, Wong EL, Ho KF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477725>
32. **Willingness to Receive COVID-19 Vaccination in Japan.** *Vaccines (Basel)* 2021; 9Yoda T, Katsuyama H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466675>
33. **Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies.** *Viruses* 2021; 13Finkelstein MT, Mermelstein AG, Parker Miller E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477902>
34. **Domains and Functions of Spike Protein in Sars-Cov-2 in the Context of Vaccine Design.** *Viruses* 2021; 13Xia X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33466921>

Women – pregnancy (20 articles)

1. **Gestation and COVID-19: clinical and microbiological observational study (Gesta-COVID19).** *BMC Pregnancy Childbirth* 2021; 21:78Suy A, Garcia-Ruiz I, Carbonell M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33482757>
2. **Home was not a safe haven: women's experiences of intimate partner violence during the COVID-19 lockdown in Nigeria.** *BMC Womens Health* 2021; 21:32Fawole OI, Okedare OO, Reed E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33472627>
3. **Combined hormonal contraception and COVID-19.** *Eur. J. Contracept. Reprod. Health Care* 2021;1-9Lete I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33475429>
4. **DGGG and other professional societies - Update October 2020: Recommendations on SARS-CoV-2/COVID-19 in pregnancy, childbirth and puerperium.** *Geburtshilfe Frauenheilkd.* 2020; 80:1182-1190Hagenbeck C, Hecher K, Pecks U *et al.*
5. **The Effects of Fear and Knowledge of COVID-19 on Preventive Practice Among Pregnant Women Who Attend Antenatal Care in Northwest Ethiopia, 2020: Institution-Based Cross-Sectional Study.** *Int J Womens Health* 2021; 13:95-100TG WM, Kassie BA, Asratie MH, Abate AT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469387>
6. **The Profile of the Obstetric Patients with SARS-CoV-2 Infection According to Country of Origin of the Publication: A Systematic Review of the Literature.** *J Clin Med* 2021; 10Cuñarro-López Y, Pintado-Recarte P, Cueto-Hernández I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477946>
7. **The Gender of COVID-19 Experts in Newspaper Articles: a Descriptive Cross-Sectional Study.** *J Gen Intern Med* 2021;1-6Fletcher S, Joe MB, Hernandez S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33469777>
8. **Impact of mitigation measures against the COVID 19 pandemic on the perinatal results of the reference maternity hospital in Uruguay.** *J Matern Fetal*

- Neonatal Med 2021;1-3Brionzo L, Tomasso G, Viroga S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33455516>
9. **Case series of 20 pregnant women with 2019 novel coronavirus disease in Wuhan, China.** J. Obstet. Gynaecol. Res. 2021; Guo Y, Yuan J, Wang M *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33462908>
 10. **A Nurses' Personal Labor and Postpartum Experience During COVID-19.** J Patient Exp 2020; 7:817-819Shackleford JL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457499>
 11. **A considerable asymptomatic proportion and thromboembolism risk of pregnant women with COVID-19 infection in Wuhan, China.** J. Perinat. Med. 2020; Wang Y, Liang X, Wang H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33470960>
 12. **A case study of the first pregnant woman with COVID-19 in Bukavu, eastern Democratic Republic of the Congo.** Matern Health Neonatol Perinatol 2021; 7:6Birindwa EK, Mulumeoderhwa GM, Nyakio O *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33472696>
 13. **Online Obstetrics and Gynecology Medical Students Clerkship During the Covid-19 Pandemic: a Pilot Study.** Med Sci Educ 2021;1-5Armon S, Benyamini Y, Grisaru-Granovsky S, Avitan T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33457067>
 14. **Viral pathogenesis of SARS-CoV-2 infection and male reproductive health.** Open Biol 2021; 11:200347Roychoudhury S, Das A, Jha NK *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33465325>
 15. **Restoring and maintaining robust maternity services in the COVID-19 era: a public health dilemma in Zimbabwe.** Pan Afr. Med. J. 2020; 37:32Murewanhema G, Nyakanda MI, Madziyire MG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=33456656>
 16. **Patient attitudes towards prenatal diagnostic testing during antenatal care in an urban population.** Prenat. Diagn. 2021; Igel CM, Rabin-Havt S, Estrada Trejo F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33470437>
 17. **The impact of the COVID-19 pandemic on maternal and perinatal health: a scoping review.** Reprod Health 2021; 18:10Kotlar B, Gerson E, Petrillo S *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=33461593>
 18. **A Rare Coincidence-a Second Trimester Ectopic Pregnancy Following Early Medical Abortion: a Case Report.** SN Compr Clin Med 2021;1-4McCarthy CM, Hayes-Ryan D, Harrity C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33462565>
 19. **Neuroinvasion and Encephalitis Following Intranasal Inoculation of SARS-CoV-2 in K18-hACE2 Mice.** Viruses 2021; 13Kumari P, Rothan HA, Natekar JP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33477869>
 20. **Effects of the COVID-19 pandemic on perinatal mental health in Spain: Positive and negative outcomes.** Women Birth 2021; Chaves C, Marchena C, Palacios B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=33461897>

to subscribe click [here](#)

mailing address is:
lansberg@gmail.com

© P.J. Lansberg